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The global epidemic of tuberculosis (TB) is mainly due to the development of resistance against 
current therapies. One way to overcome this challenge is to discover new therapeutics based on 
novel scaffolds and acting on novel targets. A library of Mannich bases of 1-alkyl/alkenyl indoles 
were synthesized and screened for activity on Mycobacterium bovis BCG. The structural features 
contributing to activity were identified in a preliminary SAR study. Six compounds were identified as 
promising hits based on their activities (MIC50 < 10 µM) on M. bovis BCG which was further 
confirmed on the H37Rv strain of human M. tuberculosis. These compounds were characterized by 
the presence of basic azepin-1-ylmethyl, 4-methylpiperidin-1-ylmethyl and 1,4-dioxapiperidin-1-
ylmethyl side chains at position 3 of the indole scaffold. Other substituents were n-octyl at position 1 
and 4F/6-OMe on the aromatic portion of the indole ring. A greater than 10-fold selective activity 
against M. tuberculosis as compared to mammalian Vero cells was found for 5 of the 6 promising 
compounds. The compounds had moderate aqueous solubilities that fall within the range of 25-75 
µM. The likelihood of generating a reactive iminoquinonemethide intermediate was assessed by an 
in vitro NMR method using cysteamine as a representative nucleophile. The results based on one 
representative compound suggested that this was not a likely phenomenon. The compounds were 
found to interact with phospholipid vesicles suggesting that membrane perturbation may have a role 





Chapter 1. Introduction 
1.1. Overview of tuberculosis 
Tuberculosis (TB) is a widespread, infectious disease caused by various strains of mycobacteria. In 
humans, it affects many organs, particularly the lungs. The main causative organism of human 
tuberculosis is Mycobacterium tuberculosis (M. tuberculosis). Infections by M. tuberculosis are either 
latent or active.[1,2] In healthy immunocompetent persons, the infection is contained by host 
defenses and manifests itself as asymptomatic and non-contagious latent TB. Patients with latent TB 
may eventually progress to the contagious active stage under conditions of poor nutrition or 
weakened immunity. Although no more than 10% of patients with latent TB will make this transition 
in their lifetimes, this still amounts to approximately 1.5 million deaths annually. Among infectious 
diseases, active TB is ranked 2nd only to HIV-AIDs in terms of mortality.[3] 
With the aim of reducing the global burden of TB, the World Health Organization (WHO) has set 
timelines to reduce the prevalence and mortality of this infection.[4,5] The goal is to end the global TB 
epidemic, starting with a 95% reduction in mortalities and 90% reduction in incidence based on 
current figures, by 2035. There are three main challenges that must be addressed if these goals are 
to be realized. These are drug resistance to current anti-TB drugs, co-infection with HIV, and low 
patient compliance to drug treatment.[5] 
The development of drug resistant forms of M. tuberculosis is a major cause for the rapid spread of 
TB. Two types of resistant states are recognized by the WHO: (i) Multidrug resistant TB (MDR-TB) 
and (ii) Extensively drug resistant TB (XDR-TB). The standard drugs for non-resistant TB are isoniazid, 
rifampicin, pyrazinamide and ethambutol. Patients with MDR-TB do not respond to isoniazid and 
rifampicin and require treatment with 2nd line anti-TB drugs which are aminoglycosides, quinolone 
antibiotics, cycloserine and capreomycin. An estimated 9% of patients with MDR-TB harbor strains of 
M. tuberculosis which are extensively drug-resistant. These patients do not respond to isoniazid and 
rifampicin or to the 2nd line drugs. In 2007, only 9% of total TB cases were MDR-TB with 1% classified 
as XDR-TB. In 2013, levels have surged to 24% and 9% for MDR-TB  and XDR-TB respectively.[5] The 
unrelenting increase in drug resistant cases is aggravated by the lack of effective treatments and 
protocols for TB control. 
The lethal synergy of TB and HIV accelerates the progress of both diseases and contributes to their 
morbidity and mortality.[6] Activation rates of latent to active TB are 20 to 30 fold higher in patients 
with HIV-AIDS, making TB the leading cause of death in these patients.[7,8] The WHO estimated that 
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13% of new TB cases in 2014 were linked to HIV-AIDS and 24% of TB deaths were recorded in 
patients with concurrent HIV-AIDS infection.[5] 
The treatment of TB requires patients to adhere to a strict daily regimen of 4 drugs taken over 6 
months. If the patient exhibits MDR-TB, the treatment period is extended to 18-24 months and 
requires 4 to 6 drugs, including an injectable 2nd line drug. The high pill burden, inconvenience linked 
to the long treatment period and associated side effects result in poor patient compliance which in 
turn lead to a vicious cycle of treatment failure, relapse of infection and emergence of genetic drug 
resistance.[9] These problems are amplified in patients with HIV-AIDS because of pharmacokinetic 
and pharmacodynamic incompatabilities between drugs for TB and HIV-AIDS. Shortening the 
treatment period can only be achieved if an agent is able to eliminate non-replicating M. 
tuberculosis. Unlike replicating mycobacteria, non-replicating organisms are metabolically less active 
and hence, less susceptible to anti-TB drugs. They reside in structures called foamy macrophages 
which are thought to provide a secure environment for the organism, allowing it to avoid the body’s 
immune system and hence persist in the body.[9] These persistent mycobacteria (“persisters”) 
contribute to phenotypic drug resistance, which unlike genetic drug resistance, is non-inheritable 
and reversible.[9] 
 
Figure 1. Structures of selected clinical drugs for TB 
The foregoing discussion highlights the critical need for new anti-TB drugs to revive the shrinking 
armamentarium of clinical drugs that have been rendered less effective by the emergence of genetic 
and phenotypic resistance. In the past decade, academic institutes and pharmaceutical companies 
have made major investments in TB drug discovery and development. Two major approaches 
(target-based and cell-based approaches) are currently employed.[10-12] Both approaches have their 
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strengths and weaknesses. A target-based approach involves the application of molecular and 
chemical knowledge to investigate a specific molecular hypothesis. It involves high throughput 
screening against the specific target protein, following which the clinical relevance of the target to 
disease pathogenesis must be validated. The main failing of this approach is that frequently, in vitro 
activity against a mycobacterial target protein or enzyme fails to translate to in vivo activity. The 
alternative approach of cell-based (phenotypic) screening involves the testing of chemical entities on 
mycobacteria without foreknowledge of the molecular target(s). Novel compounds acting on new 
targets or pathways may be uncovered and it is significant that all currently used antibiotics were 
discovered by cell based phenotypic screening, thus underscoring the value of this approach.[13]  
Target identification is still required and should preferably be completed quickly so as not to hinder 
progression to lead optimization. Notwithstanding its good track record, in vitro growth conditions 
employed in phenotypic screening do not always mimic actual disease settings. For example, reliable 
assays to evaluate activity against latent bacteria are still lacking.[13] 
Experts from the Japanese Global Health Innovative Technology Fund and the TB Alliance have 
proposed guidelines for the progression of hit and lead compounds for TB.[2] A validated hit should 
have a minimum inhibitory concentration (MIC50) against the M. tuberculosis laboratory strain H37Rv 
of < 10 µM under replicating growth conditions. It should exhibit a 10-fold or greater difference 
between cytotoxicity against mammalian cells (preferably Vero cells which are kidney epithelial cells 
from the African green monkey) and M. tuberculosis H37Rv. Evidence of a preliminary structure 
activity relationship (SAR) should be available. Hits should be derived from tractable chemotypes 
that do not have reactive or unstable moieties. They should also be amendable to structural 
variation by chemical or biochemical synthesis and pass basic drug-like filters to eliminate 
promiscuous hits that lack target specificity.[2] 
Criteria for early anti-TB lead compounds are (i) MIC50 against M. tuberculosis H37Rv of < 1 µM 
under replicating conditions and MIC50 < 10 µM under non-replicating anaerobic conditions; (ii) in 
vitro activity against M. tuberculosis strains that are resistant to a single TB drug (isoniazid or 
rifampicin)  preferably acting by a novel mode of action; (iii) evidence of in vitro bactericidal activity; 
(iv) oral bioavailability in rodents; (v) oral efficacy in a mouse acute infection model and (vi) safety of 
lead compound should be demonstrated in hERG and other cell health assays.[2] 
In view of the challenges to current anti-TB therapy, the last decade has seen a renewed focus on 
the discovery and development of anti-TB drugs. Even then, only 2 drugs (bedaquiline and 
delamanid) have been approved for the treatment of MDR-TB.[5] According to the recent Global 
Tuberculosis Report published by WHO,[4] seven compounds have entered preclinical trials and ten 
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anti-TB drug candidates are currently in Phase I to III (Figure 2). However, urgent research in new 
anti-TB drugs is necessary if the goal of ending the global TB epidemic is to be achieved once and for 
all. 
  OBR: Optimized Background Regimen 
Figure 2. New anti-TB candidates in different phases of development as of August 2015[4] 
1.2. Mycobacterial cell wall 
Bacteria are traditionally classified as Gram positive or Gram negative depending on the ability of 
their cell walls to take up the Gram stain. Briefly, the cell wall of a Gram positive organism comprises 
an inner plasma membrane surrounded by a thick layer of peptidoglycan molecules which provides 
structural rigidity to the wall. In contrast, the cell wall of Gram negative bacteria contains a thin 
sheet of peptidoglycan contained within the periplasmic space surrounding the plasma membrane. 
An outer layer surrounds the peptidoglycan sheets and occasionally, the entire structure is enclosed 
within a carbohydrate capsule. Interspersed within the inner and outer layers are 
lipopolysaccharides, lipoproteins and porins (channels). 
Mycobacteria are unusual in that although they are classified as Gram positive, their cell walls differ 
significantly from the prototypical Gram positive cell wall. The mycobacterial cell wall has a distinct 
and unique architecture that sets it apart from other bacterial cell walls. Figure 3 depicts the main 
components of the mycobacterial cell wall. The cell wall comprises outer and inner layers.[14] The 
inner layer is composed of mycolic acids anchored to arabinogalactan which is in turn linked to 
peptidoglycan. This arrangement is often referred to as a mycolyl-arabinogalactan-peptidoglycan 




The outer layer is composed of an assortment of proteins, covalently bound mycolic acids and a vast 
array of “free” lipids such as sulfolipids, glycolipids and phthiocerol dimycoserosates.[15] Interpersed 
within this outer layer are cell wall proteins such as lipoarabinomannan LAM, lipomannan LM and 
phosphotidyl-inositol mannosides PIMs. These outer proteins and lipids make up the soluble 
components of the cell wall and are widely considered to be the signaling and effector molecules 
deployed by the mycobacteria when interacting with the immune system.[16] 
When the cell wall is disrupted (for example, by organic solvents), the outer layer is solubilized and 
the MAPc remains as the insoluble residue. For this reason, the insoluble core is widely considered 
to be essential for the viability of the mycobacteria and many drugs intercept mycobacteria by 
targeting the MAPc. For example ethambutol inhibits the polymerization step of arabinoglycan 
synthesis and isoniazid is activated by KatG catalase (a mycobacterial enzyme) and thus inhibits 
mycolic acid synthesis. 
 
Figure 3. Diagram of the basic components of the mycobacterial cell wall[14]  
(AG: arabinoglycan; PG: peptidoglycan)   
Differences in the lipid composition of bacterial and mammalian plasma membranes should also be 
highlighted. Bacterial membranes of both Gram positive and Gram negative organisms are 
negatively charged because their membranes are enriched with negatively charged phospholipids 
(phosphatidylglycerol and cardiolipin).[17] Membranes of Gram negative bacteria also contain 
zwitterionic phospholipids (such as phosphatidylethanolamines) which are uncommon in Gram 
positive organisms.[18] In contrast, mammalian membranes abound in zwitterionic phospholipids, 




1.3. The cell membrane as an antibacterial target 
The discovery of naturally occurring antimicrobial peptides (AMPs) in all classes of organisms 
(vertebrate animals including humans, invertebrate animals, plants, microbes) has called attention 
to the potential of the cell membrane as a viable antibacterial target.[20] AMPs are cationic 
amphiphilic peptides with broad spectrum microbicidal activity that is associated with 
permeabilization of cell membranes. The cationic state of these entities ensures accumulation at the 
polyanionic microbial cell surfaces and their lipophilicity provides the driving force for dissolution in 
the lipid rich membrane matrix. AMPs have a highly favorable selectivity profiles and cause limited 
cytolytic or cytotoxic activity against host cells. While resistance to some AMPs has emerged, the 
general consensus is that this class of compounds has lower resistance liability. This is because 
resistance would involve considerable changes to the membrane and its components, and such 
modifications would be inimical to the survival of the organism.[21]  Unfortunately, the development 
of AMPs into therapeutic agents has been hindered by various factors, namely their liability to 
hydrolysis by proteases, challenging synthesis and incompatability with parenteral or oral 
administration. Taken together, AMPs validate the significance of the cell membrane as a target for 
antibiotics. There are additional factors that weigh in favor of this approach. First, an intact cell 
membrane is absolutely essential for a viable organism, regardless of its metabolic status. It ensures 
selective permeability for cellular homeostasis and efficient metabolic energy transduction. Second, 
1/3rd of cellular proteins are concentrated within the membrane and as such, it is the site for crucial 
processes such as active transport of nutrients/ wastes and cell-cell communication in biofilms. The 
polarized state of the membrane ensures optimal energy generation and transduction by membrane 
embedded enzymes of the respiratory chain. An agent that disrupts the membrane would thus 
affect a host of targets, many of which are mandatory to the survival of the organism. Third, as a 
consequence of the preceding points, the ability of bacteria to acquire resistance to membrane 
targeting agents is limited. As mentioned earlier, bacterial resistance may be due to genetic 
mutations or physiological adaptations to adverse growth conditions. For the latter, the organism is 
not genetically modified and may revert to type when favorable conditions return. These organisms 
(“persisters”) are slow-growing or non-growing, not readily removed by the immune system and 
unaffected by current antibiotics. In tuberculosis, persistent organisms thrive within granulomatous 
structures, and account for the prolonged treatment period that is characteristic of tuberculosis 
therapy. In spite of their dormant states, persisters still require some form of cellular energy and 
redox homeostasis to maintain viability. Hence their survival depends on an intact, functional 
membrane and like their metabolically more active counterparts, would succumb to membrane 
disrupting agents. There is indeed collateral evidence to support this notion. Reutericyclin (isolated 
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from lactobacilli),[22] the cationic porphyrin XF-73,[23] the peptide mimetic CSA-13,[24] the quinolone 
HT61[25] and the iminophenazine clofazimine[26] – all of which possess membrane depolarizing 
properties - have been cited to affect dormant bacteria (Figure 4). More recently, the antimicrobial 
efficacies of cationic xanthones (I and II) structurally related to -mangostin[19,28] and cationic 
benzophenone-based teramides (III and IV)[27] against methicillin resistant Staphylococcus aureus 
(MRSA) were attributed to selective membrane perturbation (Figure 4). 
 
Figure 4. Chemical structures of membrane active anti-infectives  
1.4. Challenges to the development of membrane-active antibacterial agents 
Membrane targeting agents are under-explored as chemotherapeutics primarily due to concerns 
over their potential to disrupt mammalian membranes. The red blood cell (RBC) hemolysis assay 
provides a simple approach for identifying selective candidates that preferentially disrupt bacterial 
membranes as compared to mammalian membranes and should be done early to identify selective 
analogs. However, design strategies for selective toxicities would have to be established for each 
scaffold by appropriate structure-activity relationship (SAR) studies as deductions made for one 
scaffold may not apply to another scaffold. 
Another challenge relates to physicochemical issues posed by membrane targeting agents as 
features required for membrane perturbation (cationic amphiphilicity) would be at odds with those 
that promote lead-like or drug-like properties.[26] Agents designed to target mycobacteria would 
have to contend with the lipid-rich mycobacterial cell wall. As such, they would have to be even 
more lipophilic and likely to exceed the threshold limits normally set for drug-like entities. Targeting 
bacterial membranes is viewed as an underexploited mechanism for eradicating persisters but 
ironically, there is some difficulty in identifying compounds that are active against persisters because 
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the usual measure of antibacterial potency (minimum inhibitory concentration) does not apply to 
non-growing bacteria.[26] Other parameters like minimum stationary-cidal/dormicidal concentrations 
will have to be employed.  
1.5. Mannich Bases of 1-substituted indoles as lead antimycobacterial agents 
The classical Mannich reaction is a one-pot, three-component reaction involving a substrate with an 
activated H atom, an aldehyde and an amine (Figure 5). The reaction results in the introduction of an 
aminoalkyl side chain to the substrate at the position of the activated H.  
 
Figure 5. General depiction of the Mannich reaction where X-H is the substrate with an activated H, 
R1-CHO is the aldehyde (usually R1 = H: formaldehdye) and R2-NH is the amine component.  
When formaldehyde is used as the aldehyde component, the reaction results in aminomethylation 
and the resulting product is widely referred to as a Mannich base, in recognition of the newly 
introduced basic functionality.  The Mannich base is a popular motif in medicinal chemistry for many 
reasons. Foremost is the structural diversity introduced by the Mannich reaction. The wide choice of 
substrates with activated H atoms (ie nucleophilic centres) and the plethora of amine bases that are 
available result in a wide range of Mannich bases that cover a broad spectrum of lipophilicities. 
Second, Mannich bases are usually, if not always, extensively protonated at physiological pH due to 
the basicity of the amino function. Thus their presence serve to modulate the physicochemical 
profile of the final molecule by offsetting excessive lipophilicity with the polarity of the positive 
centre. The latter may also participate in electrostatic interactions with complementary anionic 
centres on the target protein. This may be the reason for the varied biological properties associated 
with Mannich bases.[29] In the context of membrane targeting of mycobacterium, the positive charge 
imparted by Mannich bases would reinforced their attraction for the predominantly negatively 
charged phospholipids of the mycobacterial membranes in contrast to the neutral phospholipids of 
mammalian membranes. 
Screening of a small in-house library of 3-N,N-disubstituted aminomethy-1-alkylindoles at a single 
concentration (10 µM) on M. smegmatis (a bovine species of mycobacteria) revealed the presence 
of antimycobacterial activity for several members. Compounds that reduced mycobacterial growth 




indole (114, Figure 6) was selected for further exploration. A major factor influencing the decision to 
follow up on 114 was its solubility profile. Although 114 and other shortlisted compounds were 
highly lipophilic (cLogP values 7-8), 114 was more soluble than the other compounds.  
 
Figure 6. Structure and solubility characteristic of 114  
Further investigations showed that the 114 was equally effective in curtailing the growth of M. 
smegmatis in glycerol-containing (7H9) and non-glycerol containing (MHB) media (Table 1). This was 
a significant finding because the breakdown of glycerol to pyruvic acid in mycobacteria involves the 
formation of a cytotoxic intermediate methylglyoxal.[30] The anti-TB activities of some lead 
compounds were found to be glycerol dependent,[30]  indicating that the observed in vitro activity 
was driven by methylglyoxal rather than the compound per se. The absence of media dependency in 
the antimycobacterial activity of 114 indicates that it is a bona fide hit, acting independently of the 
glycerol content of the media.  
Table 1. Summary of the antimycobacterial activity of 114 
 
MIC 7H9a (µM) MIC MHBb (µM) MBCc (µM) LCCd (µM) 
M. smegmatis M. bovis BCG M. smegmatis M. smegmatis M. bovis BCG M. smegmatis 
MIC50 MIC90 MIC50 MIC90 MIC50 MIC90 MBC90 MBC99 MBC90 MBC99 LCC90 LCC99 
114 4 8 4 8 6 12 6 12 <6 12 12 12 
a,bMIC: Minimum inhibitory concentration. MIC50 and MIC90 are concentrations required to reduce bacterial 
growth by 50% and 90% respectively. MIC values were obtained in 7H9 broth (contains glycerol) and Mueller-
Hinton Broth (MHB, does not contain glycerol) to determine if there is media-dependency. The similar MIC 
values obtained on the two media confirm that the antimycobacterial activity of 114 is not affected by glycerol 
content. cMBC: Minimal bactericidal concentration: MBC90 and MBC99 are concentrations required to reduce 
bacterial colonies to 105 colony forming units (CFU)/mL and 104 CFU/mL respectively. dLCC: Loebel-cidal 
concentration: Concentration required to kill bacteria in a nutrient-deprived, oxygen-rich (“Loebel” model) 
condition. LCC90 and LCC99 have the same meanings as MBC90 and MBC99. Loebel conditions mimic one of the 
conditions (absence of nutrients) that promotes growth of non-replicating mycobacteria (“persisters”) 
114 arrested proliferation of M. bovis BCG (bovine strain of mycobacteria that is cross infective in 
humans) and the H37Rv strain of M. tuberculosis (Table 1). It was also bactericidal on M. smegmatis 
and M. bovis BCG. Furthermore, its bactericidal activity extended to nutrient-deprived (‘Loebel’ 
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model) M. smegmatis which mimicked conditions that promote viability of non-replicating 
mycobacteria. 
Based on the criteria set by the TB Alliance and the Global Health Innovative Technology Fund for 
the progression of hit and lead anti-TB compounds (2), 114 meets the threshold requirement for 
potency (MIC50 < 10 µM) against M. tuberculosis H37Rv. It is bactericidal at concentrations 
comparable to those required to arrest proliferation and there was no indication of media 
dependency in its antimycobacterial activity.  However, total endorsement of 114 as a validated hit 
would require more investigations, namely evidence of selective cytotoxicity, demonstration of a 
dynamic SAR and some indication that it intercepts a specific target in the bacterium. With regard to 
the latter, it is noted that 114 is an amphiphilic molecule with a lipophilic geranyl side chain and a 
charged/polar centre embedded in the strongly basic piperidinyl side chain. These are features of 
membrane disrupting agents and it is highly conceivable that the antimycobacterial activity of 114 
involves the targeting of the cellular membrane. 
1.6. Hypothesis 
In view of the preceding considerations, the investigations described in this thesis are posited on the 
notion that the membrane disrupting properties of amphiphilic Mannich bases of 1-alkyl/alkenyl 
substituted indoles, as represented by 114, contribute to antimycobacterial activity. To examine this 
hypothesis, it would be necessary to (i) establish the importance of amphiphilicity for the 
antimycobacterial activity of 114, (ii) provide evidence of a dynamic SAR which is a necessary step 
towards the design of 114 analogs with improved potencies and physicochemical properties; (iii) 
determine the selective toxicities of 114 and its promising analogs and (iv) provide preliminary 
evidence that the antimycobacterial activities of this scaffold involves the disruption of cellular 





Chapter 2. Design and synthesis of target compounds 
2.1. Compound design 
The indole ring of 114 is substituted at positions 1, 3 and 5. The branched and partially unsaturated 
10-carbon geranyl side chain is attached to the indole nitrogen and is a significant contributor to the 
lipophilicity of 114. The substituents at positions 3 and 5 are piperidin-1-ylmethyl and fluoro 
respectively. The basic character of the piperidine ring (pKa  9) ensures that the piperidinylmethyl 
side chain is extensively protonated (> 90%) at pH 7.4. 
Establishing SAR is a key objective of this thesis and serves a 2-fold purpose. First, to assess the 
importance of features that impart amphipathicity to 114 (namely, the geranyl and the charged 
piperidinylmethyl side chains) and second, to identify structural modifications that would enhance 
the antimycobacterial activity of 114, without incurring further losses in solubility. To this end, the 
following series of compounds (Series A-G) are synthesized. 
Series A: Removal of the substituent at position 1, 3 or 5 of 114 resulted in analogs (A-1, A-2, A-3) 
that are substituted at only two of the three positions (Figure 7). These modifications report on the 
relative importance of the omitted functionality and thus address the objective of correlating 
amphipathicity to activity.    
 
Figure 7. Structures of compounds in Series A 
Five other series (Series B-F) have diverse substituents at positions 1, 3 and 5. As mentioned earlier, 
114 is highly lipophilic and excessive lipophilicity hinders key pharmacokinetic processes and 
predisposes to toxicity.[31] On the other hand, if 114 acts by disrupting membranes, lipophilicity 
would be a necessary and essential attribute for activity. Thus a lipophilic “sweet-spot” must be 
identified in order to balance the contrasting requirements of potency and drug-likeness. The 
modifications in series B-E were undertaken with this end in mind. 
Series B: In this series, the geranyl side chain is replaced by but-1-ynyl, n-butyl, n-octyl and several 
N-substituted aminocarbonylmethyl side chains (Table 2). The presence of an amide moiety in B-4 to 
B-7 reduced lipophilicity by 103 to 104 times. In the same way, replacing n-butyl to but-1-ynyl 
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lowered lipophilicity by nearly 10 fold. On the other hand, insertion of n-octyl in place of geranyl had 
minimal effects on lipophilicity. 
Table 2. Structures and estimated lipophilicities (cLogP) of Series B compounds 
 
NO. R1 cLogPb NO. R1 cLogPb NO. R1 cLogPb 
114a  7.54 B-3
a  7.51 B-6  
3.31 




B-2a  5.40 B-5  
3.37    
              aSynthesized by previous researchers. bChemDraw Ultra Version 12.0.21076. 
Series C: Mannich bases other than piperidinylmethyl are explored in Series C. The basic 
piperidinering of 114 is replaced by: 
(a) N,N-dialkylamino with homologous extension of the alkyl side chains (methyl, ethyl and n-butyl);  
(b) Less basic heterocyclic rings - morpholine (C-4), thiomorpholine (C-5) and thiomorpholine-S,S-
dioxide (C-6). The less basic nature of these structures would decreases the proportion of 
protonated species at pH 7.4 but estimated LogD7.4 values of these compounds indicated that 
lipophilicity was only reduced for the polar thiomorpholine dioxide analog C-6 (LogD7.4 5.12). It was 
maintained for the morpholine C-5 and increased for thiomorpholine C-6 due to the hydrophobic 
nature of sulfur; 
(c) Substituted piperidine rings represented by 4-methylpiperidine (C-7) and the bicyclic 1,4-dioxa-8-
azaspiro[4,5]decane (C-8). Interestingly, C-8 was at least 10x less lipophilic than 114 while retaining 
the same level of basicity; 
(d) The more lipophilic seven-membered azepine ring in C-9;  
(e) A slew of secondary amines with the following substituents: a solitary N-alkyl analog C-10 (N-
isopropyl), carbocyclic rings (cyclopropyl C-11, cyclopentyl C-12, cycoheptyl C-13, adamantyl C-14 
and C-15); an N-phenyl analog C-16 [N-(4-piperidin-1-yl)aniline], cyclohexylmethyl C-17 and  
arylmethyl analogs (benzyl C-18, pyrimidin-2-ylmethyl C-19);  
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(f) A non-basic piperidinylcarbonyl side chain in C-20. 
Table 3. Structures and selected physicochemical parameters of Series C compounds 
 








7.41 4.56 9.7 C-13  
8.47 5.56 10.1 
C-3a 
 
9.52 7.30 9.0 C-14 
 
8.54 5.79 10.4 
C-4a 
 
6.26 5.45 6.6 C-15 
 
8.54 6.45 9.8 
C-5a  6.82 6.74 6.9




5.30 5.12 5.2 C-17 
 
8.53 5.58 10.0 
C-7  8.06 5.90 9.1
 C-18a 
 
7.04 5.80 8.8 
C-8 
 
6.08 4.62 9.1 C-19 
 
4.59 5.26 7.54 
C-9 
 
8.10 5.98 9.0 C-20 
 
6.34 6.89 -0.8 
C-10  6.72 4.14 9.8 114
a 
 
7.54 5.40 9.01 
C-11  6.47 4.86 8.5      
 aSynthesized by previous researchers. bChemDraw Ultra Version 12.0.21076. cACD V11.0 
Series D: This series explores substitution of the indole ring. The investigation is limited to isosteric 
replacement of the original 5-F in 114 with other halogens (5-Cl, 5-Br) and introduction of two non-
halogen groups – a representative electron withdrawing group 4-nitro and a prototypical electron 
donating group 5-methoxy. Fluoro attached to an aromatic ring is electroneutral (p 0.06). Also 
included in this series are the regioisomers of 114 in which the fluoro is attached to other positions 
on the benzenoid portion of indole. As seen from Table 4, lipophilicity was largely unchanged in the 




Table 4. Structures and estimated lipophilicities (cLogP) of Series D compounds 
 
NO. R3 cLogPb NO. R3 cLogPb NO. R3 cLogPb 
114a 5F 7.54 D-3 4F 7.54 D-6 4-NO2 7.75 
D-1a 5-Cl 8.11 D-4 6F 7.54 D-7 5-OMe 7.42 
D-2a 5-Br 8.26 D-5 7F 7.54    
              aSynthesized by previous researchers; bChemDraw Ultra Version 12.0.21076. 
Series E looks at the replacement of the indole ring with other isosteric scaffolds. This is the 
commonly deployed medicinal chemistry strategy of scaffold hopping.[31] Two scaffolds were 
investigated – 7-azaindole and indazole – and 9 analogs were prepared. Of these, only two (E-1, E-2) 
are Mannich bases and thus comparable to 114. The other compounds (indazoles) are amides and 
thus are not amphipathic.  
Figure 8. Structures and lipophilicities (cLogP) of Series E compounds. 
Series F was designed after Series A-E were evaluated for antimycobacterial activity. The results 
identified substituents at positions 1, 3 and 5 that were associated with better or equivalent activity 
compared to 114. They are n-octyl at position 1, fluoro and methoxy at position 5 and the following 
Mannich bases at position 3: 4-methylpiperidin-1-ylmethyl, 1,4-dioxapiperidin-1-ylmethyl and 
azepin-1-ylmethyl. 1-Adamantylaminomethyl was included in Series F because this moiety is a 
common motif in several TB leads – SQ109[33] and GW623128[34] (Figure 9) although in Series C, the 
1- and 2-adamantylaminomethyl analogs C-14 and C-15 were inactive. 1,4-Dioxa-8-azaspiro[4,5]-




Figure 9. Structures of SQ109, GW623128 and BTZ043 
Table 5.  Structures and lipophilicities (cLogP, LogD7.4) of Series F compounds 
 
NO. R3 R2 cLogPb LogD7.4c pKac NO. R3 R2 cLogPb LogD7.4c pKac 
F-1a 4F  7.51 5.09 8.9 F-21 4-OMe  
5.92 3.29 9.2 
F-2a 5F  7.51 4.82 9.1 F-22 5-OMe  
5.92 4.32 9.3 
F-3 6F  7.51 4.93 9.2 F-23
a 6-OMe 
 
5.92 4.01 9.3 
F-4 7F  7.51 6.42 9.1 F-24 7-OMe  
5.92 4.05 9.3 
F-5 4-OMe  7.39 4.06 9.1 F-25
a 4F  8.07 5.66 8.9 
F-6 5-OMe  7.39 5.07 9.3 F-26 5F  8.07 5.42 9.0 
F-7 6-OMe  7.39 4.76 9.3 F-27 6F  8.07 5.53 9.1 
F-8 7-OMe  7.39 4.80 9.2 F-28 7F  8.07 7.01 9.0 
F-9a 4F  8.03 5.59 9.0 F-29 4-OMe  7.94 4.66 9.0 
F-10 5F  8.03 5.33 9.0 F-30 5-OMe  7.94 5.68 9.1 
F-11 6F  8.03 5.43 9.2 F-31
a 6-OMe  7.94 5.37 9.2 
F-12 7F  8.03 6.92 9.1 F-32 7-OMe  7.94 5.41 9.1 
F-13 4-OMe  7.90 4.56 9.1 F-33
a 4F 
 
8.51 5.56 10.2 
F-14 5-OMe  7.90 5.57 9.3 F-34
a 5F 
 
8.51 5.23 10.4 
F-15a 6-OMe  7.90 5.26 9.3 F-35 6F  
8.51 5.35 10.5 
F-16 7-OMe  7.90 5.30 9.3 F-36 7F  
8.51 6.82 10.4 
F-17a 4F 
 
6.05 4.30 9.0 F-37 4-OMe 
 
8.39 4.67 10.4 
F-18 5F 
 
6.05 4.06 9.2 F-38 5-OMe 
 
8.39 5.53 10.5 
F-19 6F 
 
6.05 4.17 9.2 F-39 6-OMe 
 
8.39 5.23 10.6 
F-20 7F 
 
6.05 5.65 9.2 F-40 7-OMe 
 
8.39 5.25 10.5 
aSynthesized by previous researchers; bChemDraw Ultra Version 12.0.21076.cACD V11.0 
In terms of lipophilicity, for the same R2 substituent, the fluoro analogs were more lipophilic than the methoxy 
analogs (Table 5). Lipophilicities of fluoro regioisomers were largely unchanged and the same was true of 
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methoxy regioisomers.  Of the different basic ring structures at R2, the most lipophilic was adamantylamino, 
followed by azepinyl and 1-methylpiperidinyl, then piperidinyl and lastly dioxapiperidinyl. 
Series G explored the effect of varying alkyl side chains at position 1 of a representative compound 
F-25 which was chosen because it was found to be among the more potent compounds on M. 
tuberculosis. The original n-octyl side chain of F-25 was modified to ethyl (G-2), n-butyl (G-3) and n-
decyl (G-4). 
Table 6. Structures and lipophilicities (cLogP) of series F compounds 
 
No R1 cLogPa 
G-1 H 4.03 
G-2 C2H5 4.90 
G-3 C4H7-n 5.96 
F-25 C8H17-n 8.07 
G-4 C10H21-n 9.13 
                                                                                    aChemDraw Ultra Version 12.0.21076. 
2.2. Chemical considerations 
Series A-F compounds were synthesized by two general reaction sequences. Insertion of the N-
substituent (R1, position 1) was achieved by a nucleophilic displacement reaction carried out in the 
presence of sodium hydride (Scheme 1, step i). Deprotonation of the indole, 7-azaindole or indazole 
N-H under these conditions yielded the nucleophilic anion intermediate which then displaced the 
halogen in the alkyl /alkenyl halide (geranylbromide, 1-bromooctane, 1-bromobutane, 4-bromobut-






The 2nd general step involved the Mannich reaction which introduces the substituted aminomethyl 
side chain to position 3 of the N-substituted indole, indazole or 7-azaindole (Step ii, Scheme 1). 
Mechanistically, this reaction involves the condensation of the primary or secondary amine with 
formaldehyde to form an electrophilic iminium cation which is then attacked by the electron rich 
carbon at position 3 of the heteroaromatic ring. 
Compounds B-4 to B-7 are substituted at position 1 with an N-substituted aminocarbonylmethyl side 
chain. The synthesis of this side chain is outlined in Scheme 2. First, bromoacetic acid was converted 
to the amide by 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) coupling with the relevant 
primary amine. The resulting N-substituted bromoacetamide was then reacted with 5-fluoroindole in 
the presence of NaH.  The piperidinylmethyl side chain was then introduced at position 3 by the 




Scheme 3 outlines the synthesis of C-20 which has an aminocarbonyl side chain at position 3.  The 
aminocarbonyl side chain was introduced by a Vilsmeier-Haack reaction in which the indole was 
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reacted with dimethylformamide (DMF) and phosphorus oxychloride to give a carbaldehyde. The 
carbaldehye was then oxidized to an indole-3-carboxylic acid with potassium permanganate, and 
converted to an amide in an EDC coupling reaction with piperidine. In the last step, the geranyl side 
chain was attached to the indole nitrogen as described earlier. 
Scheme 3.  
 
The indazoles of Series E were also substituted at position 3 with an aminocarbonyl side chain.  
Unlike C-20, the indazole ring had to be synthesized de novo and this was achieved by a sequence of 
reactions starting with alkaline hydrolysis of substituted isatin, reaction with sodium nitrite to give a 
diazonium salt and reduction of the latter with tin chloride to give an aryl hydrazide. Cyclization of 
the latter under acidic conditions afforded indazole-3-carboxylic acid. The carboxylic acid was 
converted to an amide by EDC coupling with an appropriate primary amine. Scheme 4 shows the 
reaction sequences resulting in a representative indazole E-9. 





Chapter 3. Antimycobacterial activities of Series A-G on M. bovis BCG: Establishment of Structure-
Activity Relationships (SAR) 
The synthesized compounds were evaluated for antimycobacterial activity on M. bovis BCG by 
research personnel in Dr Thomas Dick’s Laboratory in the Department of Microbiology, Yong Loo Lin 
School of Medicine. The plate dilution method was employed and bacterial growth was monitored 
over 5 days before quantification by absorbance (600 nm). MIC50 and MIC90 values were obtained 
from at least 2 separate determinations. In the following sections, SAR from each series is discussed. 
3.1. Series A   
The importance of the substituents at positions 1, 3 and 5 of 114 was explored in Series A. The 
results showed that the loss of either the geranyl (R1) or piperidinylmethyl side chain (R2) completely 
abolished antimycobacterial activity (MIC50 > 50 µM). On the other hand, omission of 5-fluoro (A-3) 
had minimal impact on activity. Thus, a compelling case can be made for the role of amphiphilicity 
on the antimycobacterial activity of 114, since this property depends on the presence of both the 
lipophilic geranyl side chain and the polar piperidinylmethyl side chain. 
Table 7. MIC50 and MIC90 values of Series A compounds on M. bovis BCG 
 
No. R1 R2 R3 
MIC (µM) 
MIC50 MIC90 
114a   5F 4 8 
A-1 H  5F > 50 > 50 
A-2  H 5F > 50 > 50 
A-3a   H 3 6 
            aSynthesized by previous researchers 
3.2. Series B 
Having shown that the geranyl side chain was essential to the activity of 114, investigations were 
carried out to identify other side chains that were comparable or superior to it in terms of 
antimycobacterial activity. As seen from Table 8, only the n-octyl sidechain was a suitable 
alternative. The MIC50 of the n-octyl bearing analog B-3 (5 µM) was comparable to that of 114. On 
the other hand, the butynyl analog B-2 and n-butyl analog B-2 were essentially inactive, as were B-4 
to B-7 which had polar aminocarbonyl moieties embedded in the R1 side chain. These results clearly 
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endorsed the requirement for a lipophilic R1 side chain for activity. 114 and B-3 had comparable 
lipophilicities (evaluated by cLogP) and antimycobacterial activities while analogs with shorter or 
more polar side chains were inactive. 
Table 8. Antimycobacterial activities of Series B analogs modified at R1 on M. bovis BCG 
 
NO. R1 cLogP 
MIC (µM) 
NO. cLogP R1 
MIC (µM) 
MIC50 MIC90 MIC50 MIC90 
114a  7.54 6 10 B-4 4.31  
> 50 > 50 
B-1  4.39 > 50 > 50 B-5 3.37  
> 50 > 50 
B-2a  5.40 > 50 > 50 B-6 3.31 
 
> 50 > 50 
B-3a  7.51 5 10 B-7 3.78  
> 50 > 50 
                           aSynthesized by previous researcher 
3.3. Series C 
Analogs (C-1 to C-19) bearing different Mannich bases at R2 (position 3) were explored in Series C.  
Estimated pKa values (ACD Labs, Ver 12) indicated that these were moderate to strong bases and 
would be predominantly protonated (> 50%) at pH 7.4. C-6 is an exception and it will be mentioned 
later. Because of their protonated states, lipophilicities would be more accurately reflected by 
LogD7.4 values. These were also estimated (ACD Labs, Ver 12) and found to cover a broad range from 
4.14 to 8.24.  A quick regression of LogD7.4 versus MIC50 of the Mannich bases showed no correlation 
between these two parameters. Thus, thiomorpholine C-5 and adamantyl C-15 have comparable 
lipophilicities (LogD7.4 6.7 and 6.5) but contrasting antimycobacterial activities (MIC50 14 µM for C-5 
and > 50 µM for C-15). Another example is seen in the N,N-dialkylamines C-1, C-2 and C-3. 
Homologous extension of the alkyl side chains increased lipophilicity but had minimal effects on 
activity (MIC50 12-14 µM). Clearly, unlike the R1 substituent at position 1 which must necessarily be 
lipophilic (as seen from Series B), greater structural leeway is permitted at the cationic side chain, as 
long as a lipophilic side chain is retained at position 1 (geranyl for Series C).  
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Key SAR deductions from series C are as follows: 
(i) C-20 bearing an amide side chain at R2 was inactive, a finding that was in keeping with A-2 (Table 
8). Thus, a positively charged centre at position 3 is mandatory for antimycobacterial activity. 
(ii)There are indications that a tertiary amino group is preferred to a secondary amino group. 
Analogs C-1 to C-9 have tertiary amino groups and except for C-6 (MIC50 > 50 µM), have activities 
that fall within a narrow 3-fold range (4-14 µM). The inactivity of C-6 may be attributed to the 
sulfonyl group. The strong electron withdrawing sulfonyl reduces the pKa of the ring N, so that it is 
largely uncharged at pH 7.4. Furthermore, the polarized nature of the sulfonyl group would result in 
a concentration of negative charge at the distal end of the side chain, a feature that may be 
detrimental to activity. Analogs C-10 to C-19 have secondary amino groups in the R2 side chain. Of 
these, 6 out of 10 were inactive (MIC50 > 50 µM). Inactive analogs had either very short (C-10, C-11) 
or excessively bulky/elongated N-substituents (C-13 to C-16). The activity advantage of the tertiary 
amino group is well illustrated by the activities of C-9 and C-13. C-13 with the bulky N-cycloheptyl 
substituent (a secondary amine) was inactive but when the basic N was embedded in the cycloheptyl 
ring (yielding a tertiary amine), the resulting analog C-9 regained activity. Lipophilicity considerations 
were not relevant here as both C-9 and C-13 had comparable lipophilicities. Notwithstanding, the 
most active secondary amine analog (C-17, MIC50 3 µM) was as active as the most potent tertiary 
amine analogs (C-8, C-9). The secondary amino N of C-17 was substituted with N-cyclohexylmethyl 
and interestingly, replacing it with an aromatic ring as in N-benzyl (C-18, MIC50 14 µM) and N-





Table 9. Antimycobacterial activities (M. bovis BCG) and selected physicochemical parameters of 
Series C compounds 
 
NO. R2 cLogP LogD7.4 pKa 
MIC (µM) 
NO. R2 cLogP LogD7.4 pKa 
MIC (µM) 
MIC50 MIC90 MIC50 MIC90 
C-1a 
 
6.35 4.39 8.8 14 20 C-12  7.36 4.57 10.0
 8 14 
C-2a 
 
7.41 4.56 9.7 12 25 C-13  
8.47 5.56 10.12 > 50 > 50 
C-3a 
 
9.52 7.30 9.0 12 25 C-14 
 
8.54 5.79 10.4 > 50 > 50 
C-4a 
 
6.26 5.45 6.6 14 25 C-15 
 
8.54 6.45 9.8 > 50 > 50 
C-5a  6.82 6.74 6.9
 14 25 C-16  8.30 8.24 8.12
 > 50 > 50 
C-6 
 
5.30 5.12 5.2 > 50 > 50 C-17 
 
8.53 5.58 10.0 3 4 
C-7  
8.06 5.90 9.1 5 6 C-18a 
 
7.04 5.80 8.8 14 25 
C-8 
 
6.08 4.62 9.1 4 6 C-19 
 
4.59 5.26 7.54 7 12 
C-9 
 
8.10 5.98 9.0 4 4 C-20 
 
6.34 6.89 -0.8 > 50 > 50 
C-10  6.72 4.14 9.8 > 50 > 50 114
a 
 
7.54 5.40 9.0 6 10 
C-11  6.47 4.86 8.5 > 50 > 50        
aSynthesized by previous researchers. 
In summary, SAR from series C underscores the importance of a positively charged amino group at 
position 3. The amino group should preferentially be tertiary and incorporated in a ring. A secondary 
amino group is acceptable when attached to a carbocyclic ring via a methylene linker (as in C-17). 
Taken together, there are arguably less stringent requirements for the R2 side chain at position 3. 





3.4. Series D 
Series D investigates the substitution on the benzenoid ring of indole, which as observed in Series A, 
was less critical for activity. The activities of the Series D compounds provide further confirmation 
(Table 10). Replacing F with its more lipophilic isosteres (Cl, Br) or electron withdrawing 
(NO2)/electron donating (OCH3) groups had minimal effects on activity. 
Table 10. Anti-mycobacterial activities (M. bovis BCG) and cLogP values of Series D compounds 
 
NO. R3 cLogP 
MIC (µM) 
NO. R3 cLogP 
MIC (µM) 
MIC50 MIC90 MIC50 MIC90 
114a 5F 7.54 4 8 D-4 6F 7.54 8 17.5 
D-1a 5-Cl 8.11 7 10 D-5 7F 7.54 11 18 
D-2a 5-Br 8.26 8 10 D-6 4-NO2 7.75 4.5 20 
D-3 4F 7.54 4 9 D-7 5-OMe 7.42 9 12 
                                            aSynthesized by previous researchers. 
3.5. Series E 
None of the series E compounds possessed antimycobacterial activity (MIC50 > 50 µM). Of these 
compounds, the 7-azaindole E-1 and indazole E-2 closely resembled 114 in retaining geranyl at 
position 1 and piperidinylmethyl at position 3 (Figure 9).  Azaindole is a more polar scaffold than 
indazole due to the presence of the protonable azomethine nitrogen at position 7 (pKa 4.5). In 
contrast the azomethine N in indazole is a weaker base (pKa 1.3), thus resulting in a more lipophilic 
scaffold. Notwithstanding these differences, both E-1 and E-2 were inactive which may imply some 
role for the indole ring that is not linked to lipophilicity. The other indazoles (E-3, E-4, E-5, E-6, E-7, E-
8 and E-9) have amide bearing side chains at position 3 and several did not have geranyl at position 
1. Thus, their poor activities (MIC50 > 50 µM) may be attributed to the absence of amphiphilicity 




Figure 10. Structures of compounds in which the indole ring of 114 has been was replaced by other 
N-containing scaffolds. The MIC50 of all Series E compounds exceeded 50 µM when screened on M. 
bovis BCG. 
3.6. Series F 
The series F compounds incorporated features at positions 1, 3 and 5 that were deemed comparable 
or superior to those present in 114. Thus, n-octyl (comparable to geranyl) was introduced at position 
1 and the most promising Mannich bases from Series C (4-methylpiperidin-1-ylmethyl, azepin-1-
ylmethyl, 1,4-dioxapiperidin-1-ylmethyl) were introduced at position 3. 1-Adamantylaminomethyl 
was also included in spite of its poor activity (C-14) for reasons mentioned earlier (Section 2.1). 
Fluoro was retained at the benzenoid portion of indole because of its metabolic stability and low 
lipophilicity ( 0.14). Lipophilicity considerations also prompted the selection of the more polar 
methoxy group ( -0.02). 
Table 11. Selected physicochemical parameters and antimycobacterial activities (M. bovis BCG) of 
Series F compounds 
 
NO. R3 R2 cLogP LogD7.4 pKa 




F-1a 4F  7.51 5.09 8.9 6 10 16.9±0.7 2.8 
F-2a 5F  7.51 4.82 9.1 6 11 22.7±0.7 3.8 
F-3 6F  7.51 4.93 9.2 6 11 18.6±2.8 3.4 
F-4 7F  7.51 6.42 9.1 20 41 24.5±1.8 3.3 
F-5 4-OMe  7.39 4.06 9.1 16 34.5 9.2±1.4 1.2 
F-6 5-OMe  7.39 5.07 9.3 5 7.5 16.1±0.3 3.2 
F-7 6-OMe  7.39 4.76 9.3 7 13 19.2±2.2 2.7 
F-8 7-OMe  7.39 4.80 9.2 10 18 15.9±1.8 2.5 
33 
 
F-9a 4F  8.03 5.59 9.0 1 3 15.6±1.2 7.8 
F-10 5F  8.03 5.33 9.0 5 7 19.9±1.9 5.0 
F-11 6F  8.03 5.43 9.2 5 8 20.7±3.8 5.2 
F-12 7F  8.03 6.92 9.1 5 7 23.3±1.8 5.8 
F-13 4-OMe  7.90 4.56 9.1 12 18 11.1±2.7 0.9 
F-14 5-OMe  7.90 5.57 9.3 4 6.5 14.9±1.5 3.7 
F-15a 6-OMe  7.90 5.26 9.3 1 3 15.7±1.3 7.9 
F-16 7-OMe  7.90 5.30 9.3 3 6 18.7±2.0 4.7 
F-17a 4F 
 
6.05 4.30 9.0 1 3 21.8±1.2 7.3 
F-18 5F 
 
6.05 4.06 9.0 5 7 19.8±1.2 6.6 
F-19 6F 
 
6.05 4.17 9.2 3 6 23.5±3.4 9.4 
F-20 7F 
 
6.05 5.65 9.2 3 6 / / 
F-21 4-OMe 
 
5.92 3.29 9.2 5 8 13.0±1.9 2.6 
F-22 5-OMe 
 
5.92 4.32 9.3 5 9 16.2±0.6 3.2 
F-23a 6-OMe 
 
5.92 4.01 9.3 0.5 1.5 15.7 10.5 
F-24 7-OMe 
 
5.92 4.05 9.3 36 49 / / 
F-25a 4F 
 
8.07 5.66 8.9 1.5 3 19.2±1.0 9.6 
F-26 5F 
 
8.07 5.42 9.0 5 7 21.1 ±2.0 5.3 
F-27 6F 
 
8.07 5.53 9.1 5 7 15.2±1.8 3.8 
F-28 7F 
 
8.07 7.01 9.0 4 7 23.4±0.4 5.2 
F-29 4-OMe 
 
7.94 4.66 9.0 5 6 8.6±1.0 1.7 
F-30 5-OMe 
 
7.94 5.68 9.1 5 6 17.3±2.1 4.3 
F-31a 6-OMe 
 
7.94 5.37 9.1 3 6 9.3±1.0 2.3 
F-32 7-OMe 
 
7.94 5.41 9.1 7 12 20.4±2.6 3.4 
F-33a 4F 
 
8.51 5.56 10.2 1.5 3 13.0±0.5 8.4 
F-34a 5F 
 
8.51 5.23 10.4 2.5 6.5 14.9±0.5 6.0 
F-35 6F 
 
8.51 5.35 10.5 3 4 13.3±1.2 5.3 
F-36 7F 
 
8.51 6.82 10.4 3 4 15.6±2.0 5.2 
F-37 4-OMe 
 
8.39 4.67 10.4 6 11 10.4±1.8 2.3 
F-38 5-OMe 
 
8.39 5.53 10.5 3 4 11.1±1.8 4.4 
F-39 6-OMe 
 
8.39 5.23 10.6 4 7 13.2±0.8 4.4 
F-40 7-OMe 
 
8.39 5.25 10.5 3 11 11.3±1.4 3.8 
        aSynthesized by previous researchers; bSelectivity Index: IC50 Hep G2/MIC50 M. bovis BCG. 
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In all, forty series F analogs were investigated for antimycobacterial activity (Table 11). SAR 
deductions gleaned from this series are highlighted in the following paragraphs. 
First, among the fluoro regioisomers, the 4-F analog enjoyed an activity advantage. This is seen in 
four of the five Mannich bases (F-9, F-17, F-25, F-33) which were among the most potent analogs 
identified in this investigation (MIC50 of 1-1.5 µM). The exception was the piperidin-1-ylmethyl 
analog E-1 whose activity was equivalent to that of the other regioisomers. Earlier, mention was 
made of the poorer activity of the 7-F regioisomer D-5. This was again observed in F-4 (the n-octyl 
analog of D-5) but not in the other 7-F regioisomers.  In general, there were minimal differences in 
the activities of the 5-F, 6-F and 7-F regioisomers.   
 
Figure 11. Structures of compounds F-9, F-17, F-25 and F-33 and MIC50 on M. bovis BCG 
Second, the methoxy regioisomers yielded a very different profile from the fluoro regioisomers. 
Here, there was no apparent “favored regioisomer” but it was not difficult to single out those 
regioisomers with poorer activity. These were the 4-OMe and/or 7-OMe analogs. In two of the five 
Mannich base side chains, the 4 and 7 regioisomers had the lowest activities (R2 = piperidin-1-yl and 
4-methylpiperidin-1-yl). In the remaining R2 side chains, either the 4-OMe or 7-OMe analog was the 
least active. There were no marked differences in the activities of the 5-OMe and 6-OMe 
regioisomers, although the most active methoxy analog was the 6-OMe bearing F-23 (MIC50 0.5 µM). 
 
Figure 12. Structure of F-23 
Third, a comparison of the most potent analogs from the F and OMe families revealed that they 
were broadly comparable when R2 = piperidin-1-ylmethyl, 4-methylpiperidin-1-ylmethyl and 1,4-
dioxapiperidin-1-ylmethyl. For the remaining Mannich bases (azepinylmethyl, adamantylamino 
methyl) at R2, the fluoro analog was modestly more potent than its methoxy counterpart (F-25 > F-
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31; F-33 > F-38). Special mention should be made of the good activities of the N-(1-
adamantylamino)methyl analogs (F-33 to F-40) which was not anticipated in view of the dismal 
activity of a related analog C-14. It would seem that the rebound in activity is linked to the 
replacement of geranyl (C-14) by n-octyl (F-33 to F-40), for reasons that are not entirely clear. 
Lastly, selective cytotoxicity was evaluated by comparing MIC50 values with growth inhibitory IC50 
values obtained from human liver cancer cells (Hep G2) which served as a proxy for normal human 
cells. Ideally, the compounds should be at least 10x more potent against mycobacteria compared to 
Hep G2 (ie selectivity index SI ≥ 10). To obtain an objective gauge of selectivity trends across the 
series, SI values were averaged for compounds with the same R2 and R3 groups (Table 12). 
Table 12. Average selectivity indices of series F compounds with similar R2 and R3 group 
 
R2 aR3 Average SI R2 aR3 Average SI 
 F 3.3  OCH3 2.4 













                            aIncludes R3 at positions 4, 5, 6 and 7. 
The average SI values indicate that for the same R2, the fluoro analogs are associated with better 
selectivities than the methoxy analogs. The R2 side chain associated with the highest selectivity 
(regardless of R3) is 1,4-dioxapiperidin-1-ylmethyl and it is heartening to note that the more potent 
compounds in series F (F-17, F-23) are also from this subset. 
3. 7. Series G 
Series G comprises analogs of F-25 with varying alkyl groups at position 1 (Table 13). The results 
indicate that a minimum side chain length (C4, n-butyl) was required for activity. Extension to C8 (n-
octyl) resulted in an improvement but further lengthening to C10 (n-decyl) caused a decline, 
notwithstanding the increase in cLogP values. Earlier, the importance of a lipophilic side chain at 
position 1 was emphasized in series B. The present findings reiterate this requirement but also 
reveal an optimal lipophilicity range for activity. At present, this appears to be associated with the C8 
n-octyl side chain. 
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Table 13. Lipophilicities (cLogP) and antimycobacterial activities (M. bovis BCG) and of series G 
compounds 
      
No R1 cLogP MIC50 (µM) 
G-1 H 4.03 > 50 
G-2 C2H5 4.90 > 50 
G-3 C4H7-n 5.96 9.7 
F-25 C8H17-n 8.07 1.5 
G-4 C10H21-n 9.13 9.7 
3.8. Summary  
This chapter has provided valuable insight into the structural requirements for antimycobacterial 
activity in Mannich bases of 1-substituted indoles. Foremost is the confirmation that amphiphilicity 
is a mandatory requirement for activity. Amphiphilicity requires the concurrent presence of a 
lipophilic side chain at position 1 and a positively charged entity at position 3 of the indole ring.   
From the results, the optimal lipophilic side chain is provided by n-octyl, followed by geranyl. 
Extension to n-decyl increases lipophilicity but not antimycobacterial activity, as shown by Table 13. 
Various Mannich bases may be introduced at position 3 to satisfy the requirement for the positively 
charged entity. There is a preference for tertiary amino groups at this position but secondary amines 
are acceptable if the N-substituents are not excessively bulky, elongated or too small. Thus, 
structural requirements at this position are less prescriptive and unlike position 1, not entirely 
dictated by lipophilicity. Substitution at the benzenoid portion of the indole ring is not critical for 
activity but serves a predominantly modulatory role. Fluoro and methoxy groups were found to be 
acceptable substituents. Contrasting regioisomeric preferences were observed for these groups, 
namely a preference for position 4 among the fluoro regioisomers, and positions 5 or 6 for the 
methoxy regioisomers. Interestingly, selective toxicity is influenced by substitution on the benzenoid 
portion of the indole ring for the same groups at positions 1 (R1) and 3 (R2). Between fluoro and 
methoxy, fluoro substitution resulted in a more favorable cytotoxicity profile. As for the indole 
scaffold, attempts to replace the indole ring of the hit compound 114 with either 7-azaindole or 
indazole failed to improve activity, suggesting some role for the scaffold which has yet to be 
explored. Finally, the structural modifications undertaken in this chapter have succeeded in 
identifying 6 analogs (F-9, F-15, F-17, F-19, F-23, F-25) with potent and good selective activity against 









Chapter 4. Characterization of promising hit compounds, F-9, F-15, F-17, F-19, F-23 and F-25 
The hypothesis of this thesis is that membrane perturbation by amphiphilic Mannich bases of 1-
alkyl/alkenyl substituted indoles contribute to their antimycobacterial activity. Thus far, 
investigations have confirmed the importance of cationic amphiphilicity for the antimycobacterial 
activity of 114 as well as other structurally related analogs. Evidence of a dynamic SAR has been 
adduced and analogs of 114 with selective and low micomolar activities against M. bovis BCG were 
identified. This chapter describes the antimycobacterial activity of the short listed compounds F-9, F-
15, F-17, F-19, F-23 and F-25 on a laboratory strain H37Rv of human M. tuberculosis, additional 
evidence of selective toxicity and their compliance to drug-like properties. To determine if the short 
listed candidates induce membrane perturbation, investigations are initiated on 1,2-dimyristoyl-sn-
glycero-3-phosphoglycerol(DMPG) phospholipid bilayers (liposomes) to detect interactions with lipid 
bilayers. 
4.1. Activity against M. tuberculosis H37RV and Vero cells 
F-9, F-15, F-17, F-19, F-23 and F-25 were tested against the H37Rv strain of M. tuberculosis. Their 
selective activities against mycobacteria, previously tested on Hep G2 cells, were further tested on 
another mammalian cell line (kidney epithelial cells of the Green African monkey - Vero E6). Unlike 
Hep G2, Vero cells are non-malignant. A 10-fold or more difference between cytotoxicity against 
Vero cells and the MIC against M. tuberculosis H37Rv was cited as one of 3 checkpoint criteria for a 
validated tuberculosis hit.[2] 
All the target compounds inhibited growth of M. tuberculosis H37Rv with MIC50 ≤ 5 µM. The most 
promising compounds were the 6-methoxy substituted analogs F-15 and F-23 (MIC50 1.2-1.5 µM). 
The 4-fluoro analogs (F-9, F-17, F-19, F-25) were marginally less potent (MIC50 2.3-5.3 µM). 
The selective toxicities of the test compounds were re-evaluated based on their activities on M. 
tuberculosis and Vero cells. It is heartening to note that the selective toxicities (IC50 Vero/MIC50 Mtb) of 
five compounds, F-9, F-15, F-19, F-23 and F-25, were at least 10-fold or more under these conditions. 
Specifically, compound F-23 which shows the best M. tuberculosis H37Rv activity (MIC50 Mtb 1.2 µM 
and MIC90 Mtb 2.0 µM, respectively) has lowest toxicity on Vero cells with IC50 46.1 µM and SI value 
38.4. The 4-F analogs were less selective, a finding that is at odds with the conclusions reached in 
section 3.5, where fluoro analogs were deemed to have a more favored selective toxicity profile 
than methoxy analogs. These opposing findings highlight the importance of confirming selectivities 
on more than one mammalian cell line although selective indices of the target compounds based on 
either Hep G2 or Vero cells, were broadly comparable in terms of ranking. 
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Table 14. Antimycobacterial and cytotoxicity activities of F-9, F-15, F-17, F-19, F-23 and F-25 
 















MIC50 MIC90 MIC50 MIC90 
F-9 4F  1 3 3.0 6 15.6±0.2 5.2 35.2±0.3 11.7 
F-15 6-OMe  1 3 1.5 4 15.7±0.4 10.5 32.2±4.8 21.5 
F-17 4F 
 
1 3 5.3 12 21.8±0.3 4.1 38.9±2.1 7.3 
F-19 6F 
 
3 5 2.7 6 23.5±3.4 8.7 47.5±2.3 17.6 
F-23 6-OMe 
 
0.5 1.5 1.2 2 15.7±0.5 13.1 46.1±3.3 38.4 
F-25 4F 
 
1.5 3 2.3 6 19.2±0.3 8.3 29.2±1.1 12.7 
aSelectivity index: IC50 Hep G2/MIC50 M. tuberculosis; bIC50 Vero cells/MIC50 M. tuberculosis 
4.2. Assessment of drug-like properties based on Lipinski’s rule of five and Veber’s Rules 
Investigators have developed “filters” to identify “drug-like” features. These filters are simple 
guidelines derived from various sources and they define threshold values for critical properties that 
will affect oral bioavailability. Most of these guidelines involve counting of certain features such as 
number of H bond donors, H bond acceptors, rotatable bonds or they may be calculated by software 
(cLogP, polar surface area).The best known guidelines for “drug-likeness” are the Lipinski’s rule of 
five[36] and those proposed by Veber and coworkers.[37] It may be argued that it is premature to apply 
these guidelines to the current list of target compounds as there is no evidence as yet, of clinical 
efficacy. Notwithstanding, in the generic hit selection criteria for infectious diseases proposed by the 
Japanese Global Health Innovation Technology Fund,[2] it was stated that “A hit should have a 
tractable chemotype: it should have no highly reactive or unstable moieties in the pharmacophore 
and be amendable to structural variation by chemical (or biochemical) synthesis. Hits should pass 
basic drug-like filters, such as pan-assay interference filters (PAINS) to eliminate promiscuous hits 
that lack target specificity. Conformity to the “rule of five” is preferred.[2] To this end, the target 
compounds were evaluated for compliance to the “rule of 5” (namely, molecular weight < 500 
40 
 
daltons, cLogP < 5 and no more than 5 and 10 hydrogen bond donors and acceptors respectively) 
and Veber’s rules ( 10 rotatable bonds, and polar surface area of   140 Å2). 
















358.54 8.03 0 2 8.17 9 
F -15 
 
370.54 7.13 0 2 17.4 10 
F-17 
 
402.55 6.05 0 4 6.63 9 
F-19 
 
402.55 6.05 0 4 26.63 9 
F-23 
 
414.58 5.92 0 5 35.86 10 
F-25 
 
358.54 7.51 0 2 8.17 9 
    aObtained from ChemDraw Ultra 10.0; bFrom sum of OH and NH groups; cFrom sum of O and N atoms; dFrom     
ACD Labs/Phys ChemVer 12; eAny single bond, not in a ring, attached to a non-terminal heavy atom.[31] 
As seen from table 15, the target compounds failed to comply with only one of the 4 criteria stated 
in the rule of five, namely cLogP. However, it is not mandatory that all 4 rules be met in order to 
have a high possibility of oral bioavailability. Up to 2 rules may be broken. In the case of the 
guidelines set by Veber and co-workers, all the compounds were compliant although the limit set for 
rotatable bond count was nearly surpassed. The n-octyl side chain present in the target compounds 
is mainly responsible for the high cLogP and rotatable bond count, but as seen in series G (section 
3.6), shortening the alkyl side chain at position 1 is not an option. 
Taken together, the target compounds adhered to the broad guidelines set for drug-like character. 
However, these are just predictive methods for rapid property profiling and while useful, should not 




4.3. Generation of reactive electrophilic species 
3-Methylindoles are known to generate iminoquinonemethides which are electrophilic species that 
can react with biological nucleophiles like thiol groups of cysteine and glutathione, and amino 
groups of lysine and DNA bases.[38] Baell and Holloway have flagged out 3-alkylindoles as likely “Pan 
Assay Interference Compounds” (PAINS), albeit with an enrichment value of 42% which is not as high 
as those found in other PAINS.[39] The enrichment value measures the number of compounds from a 
particular class that are positive on unrelated assays (2-6) as compared to the number from the 
same class that hit none of the assays. 
Although the target compounds F-9, F-15, F-17, F-19, F-23 and F-25 are not 3-methylindoles and do 
not strictly have the features stated by Baell and Holloway,[38] electrophilic species may be generated 
by the mechanism outlined in Figure 14.  
 
Figure 14. Proposed mechanism by which the tertiary heterocyclic amino ring is lost to generate an 
iminoquinonemethide intermediate. 
This mechanism proposes that protonation of the basic amino nitrogen in the side chain at position 3 
will enhance the leaving group ability of the amine. An electrophilic carbocation will result, the 
formation of which is favored by electron donation fromthe indole N. The iminoquinonemethidethus 
formed is a “soft” electrophile and will have an affinity for “soft” nucleophiles like thiol-containing 
compounds (cysteine, glutathione) or amino groups found in lysine and histidine. This sequence of 
events may occur without enzymatic intervention if the electrophile is readily formed and not 
rapidly quenched. 
To explore the likelihood of  iminoquinonemethide formation in the target compounds, the 
reactivity of F-25 to the thiol group of cysteaminewas investigated by a 1H NMR method.[40] Briefly, 
the method involves monitoring the chemical shift of the methyleneprotonsat position 3 (site of the 
electrophilic carbocation) of F-25. If reaction with the thiol of cysteamine occurs, the chemical shift 
and appearance of the methylene protons will be altered. On the other hand, if no reaction has 




Figure 15. Structures of analogs (F-25, F-26 and F-27) investigated for reactivity with cysteamine 
As seen from Figure 16, the methyleneprotons of F-25 were detected as a singlet at 3.13 ppm in the 
1H NMR spectrum (deuterated DMSO as solvent). On addition of acid (deuteratedacetic acid, 1%), a 
downfield shift to 3.69 ppm, with no change in shape or integration, was observed. The downfield 
shift is anticipated as the protonation of the azepinyl nitrogen would enhance electron withdrawing 
effect of the N. Cysteamine was then added and the spectrum was recorded at time intervals of 5 
min (immediately), 30 min, 24 h and 48 h respectively. If a quinonemethideis generated, it will react 
with the nucleophilicthiol of cysteamine and cause a change in the position and appearance of the 
methylene singlet. As can be seen from Figure 14, no change in the chemical shift of the methylene 
protons (3.49 ppm) was observed on addition of cysteamine, even after longer time intervals.  
The experiment was repeated with the 5-fluoro (F-26) and 6-fluoro (F-27) analogs of F-25. The 
methyleneprotonsof F-26 and F-27 were detected as singlets at 3.76 ppm and 3.79 ppm respectively. 
On acidification, downfield shifts to 3.86 ppm (F-26) and 3.88 ppm (F-27) were observed. When 
cysteamine was added, slight shifts to 3.71 ppm (F-26) and 3.70 ppm (F-27) were noted but these 
remained unchanged over time. There was no broadening of the peaks as would be expected if a 
reaction with cysteamine had occurred. The NMR spectra of F-26 and F-27 are presented in Figures 
17 and 18.  
Thus, F-25, F-26 and F-27 did not generate reactive iminoquinonemethides under the in vitro 
conditions employed. While this does not negate their ability to form reactive intermediates in vivo, 







Figure 16. 1H spectra of F-25 under different conditions: (a) In deuterated DMSO; (b) In deuterated DMSO and 
1% deuterated acetic acid with spectrum collected immediately ( 5 min); (c) As in (b) but in the presence of 
cysteamine; For (d), (e) and (f), the conditions described in (c) apply except that the exposure times to 





Figure 17. 1H spectra of F-26 under different conditions: (a) In deuterated DMSO; (b) In deuterated DMSO and 
1% deuterated acetic acid with spectrum collected immediately ( 5 min); (c) As in (b) but in the presence of 
cysteamine; For (d), (e) and (f), the conditions described in (c) apply except that the exposure times to 




Figure 18. 1H spectra of F-27 under different conditions: (a) In deuterated DMSO; (b) In deuterated DMSO and 
1% deuterated acetic acid with spectrum collected immediately ( 5 min); (c) As in (b) but in the presence of 
cysteamine; For (d), (e) and (f), the conditions described in (c) apply except that the exposure times to 
cysteamine were 30 min, 24 h and 48 h respectively.  
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4.4. Determination of aqueous solubility 
In section 1.5, it was mentioned that 114, the forerunner of the target compounds (F-9, F-15, F-17, F-
23, F-25), was selected because its aqueous solubility exceeded that of the other shortlisted 
compounds. One of the objectives of this investigation was to identify analogs that were more 
potent than 114 while retaining or improving on its solubility .Having shown that the target 
compounds were more mycobactericidal than 114 (on M. bovis BCG), the next step would be to 
assess their aqueous solubilities. 
To this end, the turbimetric method was employed for solubility determination.[41] This method 
employs light scattering to determine the concentration at which a solute precipitates out of a 
solution to form a suspension. Briefly, incremental additions of the test compound (in DMSO) are 
made to a known volume of aqueous buffer (pH 7.4). Absorbance at 670 nm is monitored after each 
addition and a rise in absorbance signals precipitation and hence, the solubility limit of the test 
compound. The method is convenient but suffers some limitations. First, it does not provide a 
specific solubility value but a solubility range for the test compound. Second, the determinations 
must be repeated many times (at least 3 times) to confirm the solubility range as the changes in 
absorbance are small.  
Figure 19 shows representative plots of absorbance with concentration of test compound. The 
solubility limit (range) is indicated by the inflection in the plot and these are listed in Table 16.  
As seen from Table 16, most of the target compounds had solubilities that were comparable to 114, 
except for F-25 which was more soluble.  
 













F-9 7.9 25-50 23.2 (4.9) F-23 5.9 25-50 31.3 (1.1) 
F-15 7.4 25-50 44.9 (6.6) F-25 7.9 50-75 35.9 (6.9) 
F-17 6.1 25-50 NDd 114 7.5 25-50 27.6 (3.7) 
aEstimated on ChemDraw Ultra Version 12.0.21076; bDeterminations were carried out as described in 
reference 33, with modifications. cDeterminations were determined after 24 h of agitation at 25 oC (room 
temperature). They carried out by Dr Chen Xiao of the Drug Development Unit, NUS, following methods 





Figure 19. Determination of solubility by the turbimetric method: Representativeplots of absorbance 
(670nm) (Y-axis) versus concentrations of test compounds (X-axis). 
In order to obtain a more accurate assessment of solubility, some of the compounds were submitted 
to the Drug Development Unit of NUS for solubility determinations by the more precise filtration 
method. This method involves agitating a suspension of the test compound for 24 h at 25 °C, 
followed by filtration.[34, 42] The concentration of the test compound in the filtrate was determined 
by HPLC or LCMS to give its kinetic solubility of the compound. The results which are listed in Table 
16 were within the estimated solubility range estimated by turbimetry. F-15 and F-25 were more 
soluble than 114, while F-9 and F-23 were comparable to it. 
4.5. Preliminary investigations on the interactionof F-25 with phospholipid vesicles 
The SAR described in Chapter 3 has confirmed the importance of amphiphilicity for 
antimycobacterial activity in this class of compounds. To determine if this requirement is linked to 
the disruption of cellular membranes, experiments were designed to examine their interactions with 
phospholipid vesicles (liposomes). Liposomes are vesicles in which an aqueous volume is enclosed by 
a membrane composed of lipid molecules, usually phospholipids. They form spontaneously when 
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lipids are dispersed in aqueous media, giving rise to a population of vesicles of different sizes (nm to 
µm).The liposomal membrane forms a bilayer which is in principal identical to the lipid portion of 
natural cell membranes.[43] For this reason, liposomal bilayers are widely employed as proxies to 
study interactions of biologically active compounds with cell membranes.[29,44-45] 
In this investigation, 1,2-dimyristolyl-sn-glycero-3-phosphatidylglycerol (DMPG) vesicles containing 
the test compound were prepared and the interaction was monitored by differential scanning 
calorimetry (DSC). DMPG has a net negative charge and is thus a close mimic of the bacterial 
membrane which is intrinsically rich in negatively charged lipids. DMPG vesicles were employed to 
examine the interaction of the anti-TB drug rifabutin with bacterial membranes.[46] 
DSC is a sensitive method for studying compound- phospholipid interactions. Interactions result in a 
reduction in thephase transition temperature Can of the lipid bilayer. Tm is the temperature at 
which the phospholipid bilayer changes from an ordered gel state to a disordered fluid state. 
Changes in Tm may be accompanied by concurrent broadening of the transition endotherm and a 
reduction in the molar enthalpy (heat required for gel-fluid transition). Useful deductions can be 
made about the localization of the compound in the phospholipid bilayers based on the changes in 
these parameters.[47] 
Figure 20 shows the thermogram of DMPG vesicles prepared in Tris buffer (Ph 7.4). A broad phase 
transition peak was observed and the Tm peak was split into two (21.22 °C and 23.34 °C). Others 
have made similar observations which were attributed to the low ionic strength of the DMPG 
liposomal suspension.[48,49] Figure 19 also shows the thermograms of DPPC vesicles containing the 
Series G compounds at a fixed compound to lipid ratio of 1:10. These compounds are analogs of F-25 
and have varying alkyl side chains at position 1. As noted in Section 3.6, antimycobacterial activity 
was affected by chain length and was optimal for the n-octyl side chain (F-25). It can be seen that the 
progressive lengthening of the alkyl side chain caused a downshift in Tm and flattening of the 
melting endotherm with significant reduction in enthalpy. Thus, G-1 which has an unsubstituted 
indole N had minimal effects on the DMPG melting endotherm whereas F-25 which has an n-octyl 
side chain depressed the melting endotherm (loss of the bifurcated transition, flattening of 
endotherm, reduction in molar enthalpy). Thus, interaction with DMPG vesicles is strongly 
influenced by the alkyl chain length which is also an important determinant of antimycobacterial 
activity. The correlation between both antimycobacterial activity and phospholipid interaction with 
alkyl chain length hints at a link between membrane disruption and bacterial cell death. 
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Mention should be made of the n-decyl analog G-4 which like the n-octyl bearing F-25 strongly 
depressed the melting endotherm. However, in terms of MIC50 on M. bovis BCG, G-4 (MIC50 9.7 µM) 
is less potent than F-25 (MIC50 1.5 µM). Therefore the ability of G-4 to perturb DMPG vesicles did not 
translate to a level of antimycobacterial potency that is comparable or exceeds that of F-25. One 
possible explanation is that the highly lipophilic character of G4 promotes aggregate formation 
which hampers access across the mycobacterial cell wall. This phenomenon which has been 
reported by others[50-52] may be less problematic in DMPG vesicles, whose composition is 
considerably less complex than the cell wall. Aggregate formation may be investigated by a dynamic 
light scattering method[53] and future work should focus on investigating the aggregation potential of 
series G compounds. 
 
Figure 20. Melting endotherms of DMPG vesicles in the presence of Series G compounds and F-25. 
Compound to Lipid ratio was maintained at 1:10. 
The propensity of the other compounds (F-9, F-15, F-17, F-19, F-23) to interact with DMPG vesicles 
was also investigated. Figure 21 shows that these compounds modified the transition endotherm of 
DMPG vesicles in a similar manner as F-25, namely a downward shift in Tm, broadening of the 
melting endotherm and a marked reduction in molar enthalpy. The lowering of Tm is indicative of 
destabilization of the phospholipid assembly at the lipid/water interface which may be induced by 
changes in the hydration of the head groups, thus altering the packing density at the head group 
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region of the phospholipid. A possible scenario is that the positive charge on the test compound 
competes with the polar head groups (glycerol) for water molecules or interacts directly with the 
negatively charged phosphate residues (located within the head group region) and displaces water 
molecules in the process. The broadening of the endotherm with significant loss in molar enthalpy 
signifies partitioning of the test compound within the acyl chain region of the phospholipid. 
Together, this would signify that disruption of the phospholipid assembly by the test compound 
involves a specific orientation in which the positively charged side chain is positioned at the region of 
the head group while the lipophilic n-octyl side chain is directed towards the hydrophobic core of 
the phospholipid.  
 
Figure 21. Melting endotherms of DMPG vesicles in the presence of six promising hits 
If disruption of bacterial membranes is an important facet of the antimycobacterial activity of the 
test compounds, it would then be necessary to demonstrate that membrane disruption is directed 
preferentially against bacterial and not mammalian membranes. To address this concern, a 
hemolytic assay was carried out in which test compound was incubated with human erythrocytes for 
24 h in an isotonic phosphate buffer of Ph 7.4. Hemolysis was indicated by hemoglobin release 
measured at 570 nm and compound-induced hemolysis was expressed as a % of that caused by the 
positive control (Triton X, 0.01%) which was set to 100%. The concentration required to induce 50% 
of the hemolysis observed in Triton-X treated cells (HC50) was determined from the % hemolysis 
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versus concentration curve. F-15, F-23 and F-25 induced concentration-dependent hemolysis with 
HC50 values estimated at 59 µM, 41 µM and 22 µM. Analogs of F-25 without substitution at the 
indole N (G-1) and with an N-ethyl substituent at the indole N (G2) did not induce hemolysis over the 
entire concentration range, which is in keeping with their mimimal effects on the gel-fluid transition 
endotherm of DMPG. The HC50 values of F-15 and F-23 were 40 and 34-times greater than their 
MIC50 on M. tuberculosis while that of F-25 was 10-fold greater.  
 
Figure 22. Hemolytic activity of selected compounds on human erythrocytes. Different 
concentrations of test compounds were incubated with erythrocytes for 24 h 37 °C. Hemolysis was 
detected by the release of hemoglobin (measured at 570 nm) and calculated as a % of the release 
caused by 0.01% Triton-X which was set at 100%. Data was obtained from other lab members. 
4.6. Summary 
In Chapter 3, F-9, F-15, F-17, F-19, F-23 and F-25 were identified as promising hits in view of their low 
micromolar activities against M. bovis BCG and superior selective mycobacterial activities when 
compared to Hep G2 cells. In this chapter, investigations were carried out to confirm their status as 
validated hits for TB based on the criteria spelled out by Global Health Innovative Technology (GHIT) 
Fund. These are evidence of cellular potency (MIC50 M. tuberculosis H37Rv < 10 µM), selective activity (> 10-
fold difference between cytotoxicity against mammalian Vero cells and MIC50 M. tuberculosis), evidence of 
a preliminary SAR among analogs and tractability of the chemotype (no reactive or unstable 
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moieties, conformity to basic drug-like filters). The results showed that the compounds complied 
with some but not all of the stated criteria. They fulfilled the requirement for cellular potency but 
acceptable levels of selective toxicity against Vero cells were limited to F-15 and F-23 only. The 
presence of a dynamic SAR has already been established in Chapter 3. When assessed on two drug-
like filters, the compounds exceeded the lipophilicity cut-off in the rule of five and just met the 
rotatable bond count specified in Veber’s Rules. Both violations can be traced to the n-octyl side 
chain of the compounds but as noted earlier, this is an essential feature for activity.  In spite of the 
highly lipophilic nature of the compounds, solubility can be moderated by appropriate substitution 
at other positions on the indole ring. The 1,4-dioxapiperidin-1-ylmethyl side chain at position 3 is 
one such solubilizing group and when present together with methoxy at position 6 (F-23) improved 
solubility. As the methylindole fragment has been identified as a potential PAINS, a preliminary 
assessment of the thiol scavenging potential of the scaffold was conducted on some analogs but 
found to be absent. Thus, F-15 and F-23 may be deemed validated anti-TB hit compounds. Both 
compounds caused significant changes in the gel-fluid transition endotherm of DMPG vesicles 
(proxies of the bacterial membrane), thus lending support to the notion that membrane 
perturbation is involved in their antimycobacterial activities. These compounds may have the 
advantage of selective targeting of bacterial membranes as they induced minimal hemolysis at 





Chapter 5:  Conclusions and future work 
Tuberculosis continues to be a major global health problem today in spite of urgent and concerted 
world-wide efforts to contain the disease.  The main obstacles to TB eradication are resistance and 
persistence of mycobacteria to current TB chemotherapy. The emergence of highly resistant strains 
of mycobacteria can only be addressed by new anti-TB drugs, preferably acting on novel targets. 
Non-replicating mycobacteria (persisters) are a subpopulation of non-growing, phenotypically drug 
resistant bacteria, usually sequestered within tuberculous granulomas which are only partially 
accessible to current anti-TB drugs. Consequently they are difficult to eradicate and account for the 
long treatment period associated with the treatment of TB.  The problem of persisters, like that of 
genetically resistant mycobacteria, can only be addressed by new anti-TB drugs. 
Antibacterial agents generally act by targeting the biosynthesis of proteins, DNA, RNA, peptidoglycan 
or folic acid in rapidly growing bacteria.  These modes of action are ineffective against quiescent, 
non-replicating bacteria and explain why persistent infections which include staphylococcal biofilms, 
are so difficult to treat. New strategies are needed to break the vicious cycle of long treatment times, 
disease relapse and emergence of antibiotic resistance due to surviving bacteria.  Targeting bacterial 
membranes has been cited as an unexploited mechanism for treating persistent infections. As a 
therapeutic strategy against tuberculosis, it is conspicuously underexplored. The case for targeting 
the bacterial membrane rests on 3 factors: (i) The mandatory requirement of a functionally intact 
membrane for viability, regardless of whether organisms are actively replicating or quiescent; (ii) The 
lethal fallout from membrane damage because multiple critical proteins such as those for respiration 
and transport, reside within the membrane; (iii) The diminished potential for developing resistance 
because of the multitude of protein targets affected when the membrane breaks down. 
The investigations reported in this thesis were prompted by the promising antimycobacterial 
activity of 1-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-5-fluoro-3-[(piperidin-1-ylmethyl)]-5-fluoro-1H-
indole (114) against various mycobacterial strains (M. smegmatis, M. bovis BCG, M. tuberculosis) 
under replicating and media-deprived growth conditions. 114 is an amphiphilic molecule with a 
lipophilic geranyl side chain and a positively charged Mannich base.  As cationic amphiphilicity is a 
characteristic motif of membrane disrupting agents, it is hypothesized that membrane perturbation 
plays a significant role in the antimycobacterial activity of 114 and other similarly substituted 
indoles. To investigate this hypothesis, a detailed SAR investigation was carried out on indole 
analogs of 114. Cationic amphiphilicity as represented by the lipophilic n-octyl side chain and the 
54 
 
positively charged Mannich base were mandatory for activity. Figure 23 summarizes the main SAR 
findings. 
Figure 23. Summary of key SAR findings 
Six promising analogs were short listed for further characterization and of these, two analogs (F-15, 
F-23) met the criteria for a validated anti-TB hit, namely cellular potency (MIC50 M. tuberculosis < 10 µM), 
selectivity toxicity against mycobacteria as compared to mammalian cells (Vero E6), presence of a 
dynamic SAR and compliance to drug-like criteria.   
 
Figure 24. Top six analogs identified in this investigation. MIC50 refer to values obtained on M. 
tuberculosis and selective indices are derived from MIC50 Mtb/IC50 Vero cells. 
 F-15 and F-23 interacted with phospholipid vesicles prepared with negatively charged DMPG.  They 
induced changes in the melting transition endotherm of DMPG which were indicative of disruption 
of the phospholipid assembly at both the lipid-water interface as well as the hydrophobic core 
comprising the acyl chains of the lipid. To ensure that the membrane disrupting effects of F-
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15 and F-23 did not extend to mammalian cells, a hemolytic red blood assay was carried out.  No 
significant hemolytic activity was observed at the antimycobacterial concentrations of F-15 and F-23.  
Possibly, the positive charge on these analogs would preferentially direct interactions with bacterial 
membranes because of they are composed largely of negatively charged phospholipids. On the other 
hand, mammalian membranes like those found in erythrocytes are enriched with neutral 
phospholipids and would thus be less likely to attractive the cationic species. 
Future work will be directed towards confirming the membrane disrupting effects of F-15 and F-23. 
Several investigations are available to meet this objective. They include (i) monitoring changes in the 
membrane potential of mycobacteria treated with either F-15 or F-23. The membrane plays a critical 
role in maintaining proton motive force and its disruption will result in depolarization; (ii) Release of 
ATP from mycobacterial cells and (iii) Uptake of a membrane impermeable fluorescent dye such as 
SYTOX Green into mycobacteria. SYTOX Green is impermeable to intact cells but gains ready access 
to disrupted cells where it binds to DNA and fluoresces.  
Another direction for future work would be to carry out additional structural modifications to 
improve on the potency and selectivity of F-15 and F-23. Both compounds are validated hits but not 
early leads which have more stringent criteria.[2] These are in vitro potency of MIC50 M. tuberculosis < 1 
µM in the microplate Alamar Blue assay and MIC50 < 10 µM under non-replicating anaerobic 
conditions; in vitro activity against strains of M. tuberculosis that are resistant to a single TB drug (for 
example, isoniazid), evidence of in vitro bactericidal activity, oral bioavailability in rodents; oral 
efficacy in a mouse acute infection model; and safety indicators (such as absence of Herg inhibition). 





Chapter 6. Experimental details 
6.1. General details for chemical synthesis 
Reagents for organic synthesis were purchased from Sigma Aldrich Chemical Co., Alfa Aesar or Tokyo 
Chemical Industry Co. Ltd unless otherwise stated and used without further purification. Reactions 
were routinely monitored by thin-layer chromatography (TLC) on silica gel coated aluminium plates 
(Merck 60, F254) with visualization by UV light, and potassium permanganate solutions as 
developing stains. 1H, 13C and 19F NMR spectra were determined on a Bruker Avance 400 Ultrashield 
spectrometer. The spectra were analyzed with the ACD/Spectrus software (V11.02). Determination 
of nominal mass was performed on a AB SCIEX Qtrap 2000 mass spectrometer with electronspray 
ionization (ESI) run in positive mode. High-Resolution Mass Spectrometry (HRMS) for promising hits 
were completed using Bruker MicrOTOF-Q II with ESI-HR-MS run in positive mode. Reverse phase 
high performance liquid chromatography (HPLC) was employed to confirm compound purity 
(Appendix, part 6) and determinations were carried out on a Shimadzu Nexera SR HPLC system, 
Zorbax Eclipse SB-C18 -5 µM column (4.6 X 250 mm) at a UV detection wavelength of 254 nm and 230 
nm. Mobile phases employed were 95% acetonitrile-water (0.1% ammonia) or 95% methanol-water 
(0.1% v/vammonia) with a run time of 15 min and flow rate of 0.7 Ml/min. 
6.2. General procedure for the reaction of substituted indole, indazole or 7-azaindole with alkyl 
halide, 4-bromobut-1-yne or geranyl bromide 
To a stirred suspension of sodium hydride (NaH, 60% dispersion in mineral oil; 1.5 mmol) in 
anhydrous dimethylformamide (4 Ml) in an ice bath was added dropwise a solution of the 
substituted indole, indazole or 7-azaindole (1 mmol) dissolved in anhydrous dimethylformamide (10 
Ml) over a period of 10 min. The alkyl/alkynyl/geranyl halide (1 mmol) was then added dropwise 
over 5 min, the mixture warmed to room temperature (RT) and stirred 6 h-12 h. The reaction was 
quenched by addition of 10% ethanol-water, followed by extraction with dichloromethane (DCM, 20 
Ml x 3). The combined organic layers were washed with brine, dried (anhydrous Na2SO4), filtered and 
concentrated under reduced pressure to obtain the crude residue. The crude material was purified 
by flash column chromatography with ethyl acetate (EA): hexane (1:20) to give the product in yields 
ranging from 70-85%.  
6.3. General procedures for the Mannich reaction 
To a stirred solution of the N-substituted indole, indazole or 7-azaindole (0.5 mmol) in acetic acid (3 
Ml) was added formaldehyde (36% in aqueous, 0.55 mmol) and the amine (0.55 mmol). 
Alternatively, to a stirred solution of the N-substituted indole (0.5 mmol) in ethanol (5 Ml) was 
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added formaldehyde (36% in aqueous, 0.55 mmol), zinc chloride (0.6 mmol) and the amine (0.55 
mmol). The reaction mixture was stirred at RT for 3-12 h, after which DCM (20 Ml) and water (25 Ml) 
was added. The DCM layer was collected and the aqueous layer was extracted with DCM (2x 20 Ml). 
The combined organic layer was washed with brine, dried (anhydrous Na2SO4) and concentrated 
under reduced pressure to obtain the crude residue. The crude material was purified by column 
chromatography (DCM-MeOH 20:1) to give the product in yields ranging from 34-75%. 
6.4. Synthesis of 2-bromo-N-butylacetamide, 2-bromo-N-[2-(dimethylamino)ethyl]acetamide, 2-
bromo-N-cyclopropylacetamide and  2-bromo-N-(furan-2-ylmethyl)acetamide 
1-Bromoacetic acid (0.5 mmol) was dissolved in dry DCM (10 Ml) and the solution was maintained at 
0 °C. Hydroxybenzotriazole (HOBT, 0.4 mmol) and N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (EDC, 0.75 mmol) were added to the stirred solution. After stirring for 10 min, a 
solution of the amine (0.55 mmol) in dry DCM (5 Ml) was added and stirring was continued 
overnight. Thereafter, the solvent was removed under reduced pressure and the product was used 
directly in the next reaction step with the substituted indole as described in section 6.2.  
6.5. Synthesis of 1H-indazole-3-carboxylic acid and 5-chloro-1H-indazole-3-carboxylic acid 
In a dry single-neck 100 Ml flask was added isatin or 5-chloroisatin (25 mmol) to a solution of NaOH 
in water (6.3%, 16 Ml). The solution was heated at 50 °C for 10 min and then cooled to 0 °C. A 
solution of sodium nitrite (25 mmol) in 8 Ml of water was added followed by a cooled solution of 
H2SO4 (95%) (2.6 Ml) in 40 Ml of water. Both solutions were cooled to 0 °C before addition. The rate 
of addition was adjusted to ensure that the temperature did not exceed 4 °C. After addition was 
completed, the reaction mixture was stirred for 1 h. A cooled solution of tin chloride (SnCl2-2H2O, 60 
mmol) dissolved in HCl (20 Ml) was added, the mixture was stirred for 16 h and filtered. The 
resulting solid was washed with water to give the product as a yellow solid in good yield (> 95%). 5-
Chloro-1H-indazole-3-carboxylic acid was purified by column chromatography using EA-hexane (3:1). 
1H-indazole-3-carboxylic acid was not purified and used as such for the next reaction step. 
6.6. Synthesis of 5-fluoroindole-3-carboxylic acid 
The mixture of phosphorus oxychloride (10.8 mmol) and dry dimethylformamide (5 Ml) in a dry flask 
was stirred at 0 °C for half hour. In the next step, a solution of 5-fluoroindole (9 mmol) was added 
dropwise to the stirring mixture and the temperature increased to 70 °C for 3 h. Thereafter, a 
solution of NaOH (1 M, 50 Ml) was slowly added. A white precipitate (5-fluoro-1H-indole-3-
carbaldehyde) was formed and it was removed by filtration. The carbaldehyde (1.94 mmol) was 
dissolved in ethanol (5 Ml). After 10 min of stirring at 60 °C, potassium hydroxide (0.49 mmol) 
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dissolved in water (2 Ml) was added and stirring was continued for another 30 min after which a 
solution of potassium permanganate (2.04 mmol in 10 Ml ethanol). The mixture was stirred for 
another 6 h, Ph was adjusted to 6 with HCl (1M), water was added and the mixture extracted with 
DCM (3 × 20 Ml). The combined organic layer was washed with brine, dried with anhydrous 
Na2SO4, filtered and concentrated under reduced pressure. 5-Fluoro-1H-indole-3-carboxylic acid, was 
purified by column chromatography using EA-hexane (3:1) as eluting solvents. Yield was 85%.  
6.7. Determination of solubility by turbimetry 
A 10 Mm stock solution of the test compound was prepared in DMSO. Two-fold serial dilutions were 
carried out in the same solvent to give 9 concentrations ranging from 5 Mm to 0.0195 Mm which 
were dispensed in individual wells of a 96-well plate. Next, the contents in each well were diluted 
100-fold with PBS (0.01 M, Ph 7.4) and agitated (30 min, 2BOECO Microtitre Plate Shaker at 250 rpm, 
25 °C). Absorbance was then read at 620 nm on a Tecan GENios Microplate reader. Final DMSO 
concentration per well was maintained at 1% v/v. Each concentration was tested in triplicates and 
the experiments were repeated on three different occasions, using a freshly prepared stock solution 
of test compound. 
6.8. Cytotoxicity assay 
The cell lines used in this assay were human liver carcinoma cells Hep G2 (ATCC, Manassas, VA) and 
Vero E6 cells (gift from Dr Thomas Dick, Yong Loo Lin School of Medicine, NUS). Hep G2 and Vero E6 
were grown in DMEM as media supplemented with 1% penicillin and 10% fetal bovine serum 
(Hyclone Laboratories). Stock solutions of test compounds (20 Mm) were prepared in DMSO. The 
MTT solution was prepared at 5 mg/Ml in phosphate buffer, filtered through a 0.2 µM membrane 
filter, kept at 4 °C and protected from light. MTS solution was bought from Promega (Celltiter 96 
®Aqueous Non-Radioactive) and used directly. 
Test compounds were evaluated at the following concentrations (100 µM, 50 µM, 25 µM, 18.75 µM, 
12.5 µM, 6.25 µM, 3.125 µM, 1.56 µM). To each well in 96-well plate was seeded 20,000 Hep G2 
cells or 30,000 Vero E6 cells in a 100 µL suspension in media. The plate was incubated at 37 °C for 24 
h in 5% CO2 to allow adherence to the plate. The medium was removed by aspiration and test 
compounds were added. DMSO content of each well was kept at 0.5%. Cytotoxicity of test 
compounds on Hep G2 cells was evaluated by the tetrazolium dye MTT (Sigama) while on Vero cells, 
Celltitre 96 ®Aqueous One Solution was used. The latter uses a different tetrazolium compound [3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) in 
combination with an electron coupling reagent phenazine. Hep G2 cells were incubated with test 
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compound for 45 h (5% CO2, 37 °C) after which media was removed from each well and 100 µL of 
MTT was added. Incubation was continued for another 3h. After this time, the MTT solution was 
removed and 100 µL of DMSO was added to dissolve the purple formazan crystals (shaking for 3 min 
on shaker set at 600 rpm). Plates were read at 570 nm on a Tecan GENios Microplate reader. When 
the MTS assay was employed, the same procedure was followed except that 10 µL of MTS solution 
was added to each well (without removal of media) and incubated for 3 h. Thereafter, readings were 
made at 490 nm on the above mentioned plate reader. 
Cell viability was determined from the expression: 
Cell viability(%) =  
Absorbance cells + cpd − Absorbance cpd
Absorbance cells + vc − Absorbance vc
× 100% 
Where Absorbancecells + cpd = absorbance of wells containing cells and test compound in vehicle 
(media + 0.5% DMSO); Absorbancecells + vc = absorbance of wells containing cells in vehicle (vc) only; 
Absorbancevc = absorbance of wells containing vehicle; Absorbancecpd = absorbance of wells 
containing test compound. The % viability readings were plotted against log concentration on 
GraphPad Prism (Version 5.0, San Diego, CA) to give a sigmoidal curve from which IC50 
(concentration required to reduce viability by 50% compared to control/untreated cells) was 
obtained. The plot was constrained to ≥0 and ≤100%. At least 3 separate determinations of IC50 were 
determined. 
6.9. Differential Scanning Calorimetry 
1, 2-Dimyristolyl-sn-glycero-3-phosphoglycerol (DMPG) was purchased from Avanti Polar Lipids Inc. 
(Alabastar, AL). Tris buffer was purchased from Sigma-Aldrich Co. (Singapore). Chloroform (CHCl3, 
HPLC grade) was obtained from Fisher Scientific, Singapore. Tris-HCl buffer (0.05M, Ph 7.2; Ph 
adjusted with conc HCl) was prepared with ultrapure grade I water from a Millipore system. Phase 
transition temperatures, Tm, were recorded on a Shimadzu DSC-60 instrument, using aluminium 
hermetic pans (diameter 6 X 1.6), from Shimazdu (Singapore). 
20 Mm solution of DMPG was prepared in CHCl3. 5 Ml of the solution was transferred into a Quickfit 
round-bottom flask and the solvent removed under vacuum leaving behind a thin lipid film on the 
flask interior. The lipid film was further dried overnight under vacuum to remove traces of solvent. 
Liposomes were prepared the following day by the addition of 1 Ml of Tris-HCl buffer (0.05M, Ph 
7.2), followed by vortexing for 1 minute and subsequently rotating the flask with its contents on a 
rotary evaporator at 45 °C (above the Tm of the phospholipid, 23 °C) for 15 minutes. The milky lipid 
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suspension was then agitated at 150 rpm for 2 hours on a shaking incubator (Shel Lab S12 shaking 
incubator) at 29 °C, to obtain multilamellar vesicles (MLVs). 
Test compound was prepared at 2 Mm in CHCl3. 5 Ml of the CHCl3 solution and 5 Ml of the DMPG 
solution were added to a round-bottom flask and solvent was removed under vacuum on a rotary 
evaporator. The thin film thus obtained consisted of DMPG: test compound in a 10:1 molar ratio. 
This was dried overnight under vacuum and liposomes were prepared as described in the preceding 
paragraph for normal liposomes. 
Liposomes are freshly prepared for DSC determinations. 10 µL of the liposomal dispersion (1 Ml) was 
introduced into the aluminium pan. Lipid content in the pan was approximately 0.689 mg DMPG. 
The pan was hermatically sealed and placed in the sample compartment of the instrument, next to 
the reference pan which comprised an “empty” hermatically sealed pan. Liquid nitrogen was added 
to reduce temperature to 0 °C after which pans were heated at a rate of 2 °C per minute up to 30 °C. 
6.10. Determination of Michael acceptor reactivity by NMR 
The method described by Avontoet al[40] was followed with some modifications. The test compounds 
(56.8 mg, 0.158 mmol) were dissolved in 0.5 Ml DMSO-d6 and the 1H NMR spectra were recorded. 
The samples were retrieved and deuterated acetic acid (8.4 µL, 1% v/v) was added and the spectra 
were collected again. Thereafter, cysteamine (12.6 mg, 0.163 mmol; Sigma) was added to the 
samples, the mixture vortexed for 5 min and the spectra recorded immediately, 30 min, 24 h and 48 
h. NMR spectra were analyzed using ACD/Spectrus Software (V11.02). 
6.11. Strains, culture conditions and chemicals for antimycobacterial Assay 
M. tuberculosis H37Rv (ATCC 27294) and M. bovis BCG (ATCC 35734) liquid cultures were grown in 
Middle brook 7H9 broth (BD Difco) supplemented with 0.5% albumin, 0.2% glucose, 0.085% sodium 
chloride, 0.5% glycerol and 0.05% Tween 80.  
6.12. Growth inhibition assays 
Mininum Inhibitory Concentrations (MICs) were determined in broth as described previously by the 
broth dilution method[54-56] using turbidity (optical density) as a proxy for growth.[55] MIC50 and MIC90, 
the concentrations that inhibit 50% and 90% of growth respectively as compared to the untreated 
control, were determined.  
 
6.13. RBC hemolytic assay 
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Red blood cells were obtained from Interstate Blood Bank, Inc. Laboratory, USA. A previously 
reported method was followed,[57] with some modification. Briefly, various concentrations of test 
compound are incubated with 5 x 106 human red blood cells suspended in isotonic Ph 7.4 buffer at 
37 °C for 1 h in a 96 well plate. Hemolysis results in the release of hemoglobin (measured at 540 
nm). Compound-induced hemolysis is compared to that caused by the positive control Triton X (2%) 
and quantified by HC50 (concentration required to induce 50% hemolysis compared to the maximum 





1. Mdluli, K. T.; Kaneko, T.; Upton, A. Tuberculosis drug discovery and emerging targets. Ann. N. Y.   
Acad. Sci. 2014, 1323, 56-75. 
2. Katsuno, K.; Burrows, J. N.; Duncan, K.; Hooft, V. H. R.; Kaneko, T.; Kita, K.; Mowbray, C. E.; 
Schmatz, D.; Warner, P.; Slingsby, B. T. Hit and lead criteria in drug discovery for infectious diseases 
of the developing world. Nat. Rev. Drug Discov. 2015, 14, 751-758. 
3. Kim, P. S., Makhene, M.; Sizemore, C.; Hafner, R. Viewpoint: challenges and opportunities in 
tuberculosis research. J. Infect. Dis. 2012, 205, S347-S352. 
4.  Global Tuberculossi report 2015, WHO. http://www.who.int/tb/publications/global_report/en/ 
5. Global Tuberculossi report 2014, WHO. http://reliefweb.int/report/world/global-tuberculosis-
report-2014 
6. Pieroni, M., Machado, D.; Azzali, E.; Santos C. S.; Couto, I.; Costantino, G.; Viveiros, M. Rational 
Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy. J. Med. 
Chem. 2015, 58, 5842-5853. 
7. Dover, L.G.; Coxon, G.D. Current status and research strategies in tuberculosis drug development. 
J. Med. Chem. 2011, 54, 6157-6165. 
8. Dutta, N. K.; Karakousis, P. C. Latent tuberculosis infection: myths, models, and molecular 
mechanisms. Microbiol. Mol. Biol. Rev. 2014, 78, 343-371. 
9. Dartois, V. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nat. 
Rev. Microbiol. 2014, 12, 159-167. 
10. Goldman, R.C. Why are membrane targets discovered by phenotypic screens and genome 
sequencing in Mycobacterium tuberculosis? Tuberculosis. 2013, 93, 569-588. 
11. Neeraj, D.; Mckinney, J. D. Microbial phenotypic heterogeneity and antibiotic tolerance. Curr. 
Opin. Microbiol. 2007, 30-38.  
12. Hett, E. C.; Rubin, E. J. Bacterial growth and cell division: a mycobacterial perspective. Microbiol. 
Mol. Biol. Rev. 2008, 72, 126-156. 
13. Franzblau, S. G., DeGroote, M. A.; Cho, S. H.; Andries, K.; Nuermberger, E.; Orme, I. M.; Mdluli, K.; 
Angulo-Barturen, I.; Dick, T.; Dartois, V. Comprehensive analysis of methods used for the evaluation 
of compounds against Mycobacterium tuberculosis. Tuberculosis. 2012, 92, 453-488. 
14 Marrakchi, H.; Laneelle, M. A.; Daffe, M. Mycolic Acids: Structures, Biosynthesis, and Beyond. 
Chem. Biol. Rev. 2014, 21, 67-85. 
15. Minnikin, D. E. Lipids complex lipids, their chemistrt, biosynthesis and roles, The Biology of 
Mycobacteria. 1982, pp. 95-184. Academic Press, Ltd,. London, UK.  
63 
 
16. Hett, E. C.; Rubin, E. J. Bacterial Growth and Cell Division: a Mycobacterial Perspective. Microbiol. 
Mol. Biol. Rev. 2008, 72, 126–156. 
17. Verkleij, A. J., Zwaal, R. F. A., Roelofsen B., Comfurius P., Kastelijn D., Deenen L. L. M. The 
asymmetric distribution of phospholipids in the human red cell membrane- A combined study using 
phospholipases and freeze-etch electron microscopy.  Biochem. Biophys. Acta, 1973, 323, 178–193.  
18. Raquel, E.; Richard, E. Functional Consequences of the Lateral Organization of Biological 
Membranes. In The Structure of Biological Membranes, 3rd ed.; Yeagle, L. P., Ed.; CRC Press: New 
York, 2011; pp 133−152. 
19. Zou, H. X.; Koh, J. J.; Li, J. G.; Qiu, S. X.; Aung, T. T.; Lin, H. F.; Lakshminarayanan, R.; Dai, X. P.; 
Tang, C.; Lim, F. H.; Zhou, L.; Tan, A. L.; Verma, C.; Tan, D. T. H.; Chan, H. S. O.; Saraswathi, P.; Cao, Liu, 
D. R.; Beuerman, R. W. Design and Synthesis of Amphiphilic Xanthone-Based, Membrane Targeting 
Antimicrobials with Improved Membrane Selectivity, J. Med. Chem. 2013, 56, 2359−2373. 
20. Wimleym, W. C. Describing the Mechanism of Antimicrobial Peptide Action with the Interfacial 
Activity Model. ACS Chem. Biol. 2010, 5, 905-917. 
21. Michael, Z. Editorials: Antimicrobial peptides in health and disease. N. Engl. J. Med. 2002, 347, 
1199-200. 
22. Hurdle, J. G.; Yendapally, R.; Sun, D.; Lee, R. E. Evaluation of analogs of reutericyclin as 
prospective candidates for treatment of staphylococcal skin infections. Antimicrob. Agents 
Chemother. 2009, 53, 4028–4031. 
23. Darouiche, R. O.; Mansouri, M. D. Dalbavancin compared with vancomycin for prevention of 
Staphylococcus aureus colonization of devices in vivo. J. Infect. 2005, 50, 206–209. 
24. Epand, R. F.; Pollard, J. E.; Wright, J.; Savage, P. B.;  Epand, R. M. Depolarization, bacterial 
membranecomposition and the antimicrobial action of ceragenins. Antimicrob. Agents Chemother. 
2010, 54, 3708–3713. 
25. Coates, T.; Bax, R.; Coates, A. Nasal decolonization of Staphylococcus aureus with mupirocin: 
strengths, weaknesses and future prospects. J. Antimicrob. Chemother. 2009, 64, 9–15. 
26. Hurdle, J. G; O’Neill, A. J.; Chopra, I.; Lee, R. E. Targeting bacterial membrane function: an 
underexploited mechanism for treating persistent infections. Nat. Rev. 2011, 9, 62-74. 
27. Vooturi, S. K.; Dewal, M. B.; Firestine, S. M. Examination of a synthetic benzophenone 
membrane-targeted antibiotic. Org. Biomol. Chem. 2011, 9, 6367-6372. 
28. Koh, J.-J.; Zou, H. X.; Lin, S. M.; Lin, H. F.; Soh, Rui T.; Lim, F. H.; Koh, W. L.; Li, J. G.; 
Lakshminarayanan, R.; Verma, C. Nonpeptidic Amphiphilic Xanthone Derivatives: Structure–Activity 
Relationship and Membrane-Targeting Properties. J. Med. Chem. 2015, 59, 171-193. 
64 
 
29. 29. Roman, G.; Mannich bases in medicinal chemistry and drug design. Eur. J. Med. Chem. 2015, 
80, 743-816. 
30. Sinha, R., Joshi, Akshada, Joshi, Urmila J, Srivastava, Sudha, Govil, Girjesh. Localization and 
interaction of hydroxyflavones with lipid bilayer model membranes: A study using DSC and 
multinuclear NMR. Eur. J. Med. Chem. 2014, 80, 285-294. 
31. Pethe, K.; Sequeira, P. C.; Agarwalla, S.; Rhee, K.; Kuhen, K.; Phong, W.Y.; Patel, V.; Beer, D.; 
Walker, J. R.; Duraiswamy, J.; Jiricek, Keller, J.; Chatterjee, A.; Tan, M. P.; Ujjini, M.; Rao, S P.S.; 
Camacho, L.; Bifani, P.; Mak, P. A.; Ma, I.; Barnes, S. W.; Chen , Z.; Plouffe, D.; Thayalan, P.; Ng, S. H.; 
Au, M.; Lee, Tan, Ravindran, S.; Nanjundappa, M.; Lin , X. H.;  Goh, A.; Lakshminarayana, S. B.; Shoen, 
C.; Cynamon, M.; Kreiswirth, B.; Dartois, V.; Peters, E. C.; Glynne, R. Brenner, S.; Dick, T. A chemical 
genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors 
devoid of in vivo efficacy. Nat. Comm. 2010, 1-7. 
32. Hann, M. M. Molecular obesity, potency and other addictions in drug discovery. Med. Chem. 
Commun. 2011, 2, 349-355. 
33. Goldman, R. C. Why are membrane targets discovered by phenotypic screens and genome 
sequencing in Mycobacterium tuberculosis? Tuberculosis, 2013, 93, 569-588. 
34. Dover, L. G.; Coxon, G. D. Current Status and Research Strategies in Tuberculosis Drug 
Development. J. Med. Chem. 2011, 54, 6157-6165. 
35. Ballell, L; Bates, R.H.; Young, R.J.; Alvarez-Gomez, D.; Alvarez-Ruiz, E.; Barroso, V.; Blanco, D.; 
Crespo, B.; Escribano, J.; González, R.; Lozano, S.; Huss, S.; Santos-Villarejo, A.; Martín-Plaza, J. J.; 
Mendoza, A.; Rebollo-Lopez, M. J.; Remuiñan-Blanco, M.; Lavandera, J. L.; Pérez-Herran, E.; Gamo-
Benito, F. J.; García-Bustos, J. F.; Barros, D.; Castro, J. P.; Cammack, N. Fueling Open‐Source Drug 
Discovery: 177 Small‐Molecule Leads against Tuberculosis. Chem. Med. Chem. 2013, 8, 313-321. 
36. Fischbach, M. A.; Walsh, C. T. Antibiotics for emerging pathogens. Sci. 2009, 325, 1089-1093. 
37. Lipinski, C.A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational 
approaches to estimate solubility and permeability in drug discovery and development settings. Adv. 
Drug Deliv. Rev. 2012, 64, 4-17.  
38. Veber, D. F., Johnson, S. R.; Cheng, H. Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular 
properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 2002, 45, 2615-
2623. 
39. Kalgutkar, A. S.; Gardner, I.; Obach, R. S.; Shaffer, C. L.; Callegari, E.; Henne, K. R.; Mutlib, A. E.; 
Dalvie, D. K.; Lee, J. S.; Nakai, Y.; O’Donnell, J. P.; Boer J.; Harriman, S. P. A comprehensive listing of 
bioactivation pathways of organic functional group. Curr. Drug Metab. 2005, 6, 161-225.  
65 
 
40. Baell, J. B.; Holloway G. A. New substructure filters for removal of pan assay interference 
compounds (PAINS) from screening libraries and for their exclusion in bioassays. J. Med. Chem. 2010, 
53, 2719-2740. 
41. Avonto, C., Taglialatela‐Scafati, O.; Pollastro, F.; Minassi, A.; Di Marzo, V.; De Petrocellis, L.; 
Appendino, G. An NMR Spectroscopic Method to Identify and Classify Thiol‐Trapping Agents: Revival 
of Michael Acceptors for Drug Discovery? Angew. Chem. Int. Ed. 2011, 50, 467-471. 
42. Bevan, C. D.; Lloyd, R. S. A high-throughput screening method for the determination of aqueous 
drug solubility using laser nephelometry in microtiter plates. Anal. Chem. 2000, 72, 1781-1787. 
43. Sarpietro, M. G.; Giuffrida, M. C.; Ottimo, S.; Micieli, D.; Castelli, F. Evaluation of the interaction 
of coumarins with biomembrane models studied by differential scanning calorimetry and Langmuir-
Blodgett techniques. J. Nat. Prod. 2011. 74, 790-795. 
44. New, R. R. C., Characterization of liposomes. Liposomes: A practical approach. 1990, 105-161. 
45. Manrique-Moreno, M., Howe, J.; Suwalsky, M.; Garidel, P.; Brandenburg, K. Physicochemical 
interaction study of non-steroidal anti-inflammatory drugs with 
dimyristoylphosphatidylethanolamine liposomes. Lett. Drug Des. Discov. 2010, 7, 50-56. 
46. Mohr, K.; Struve, M. Differential influence of anionic and cationic charge on the ability of 
amphiphilic drugs to interact with DPPC-liposomes. Biochem. Pharmacol. 1991, 41, 961-965. 
47. Pinheiro, M.; Arede, M.; Nunes, C.; Caio, J. M.; Moiteiro, C.; Lucio, M.; Reis, S. Differential 
interactions of rifabutin with human and bacterial membranes: implication for its therapeutic and 
toxic effects. J. Med. Chem. 2013, 56, 417-426. 
48. Seydel, J. K. and M. Wiese, Drug-membrane interactions: analysis, drug distribution, modeling. 
John Wiley Sons. 15. 2009:  
49. Riske, K. A.; Barroso, R. P.; Vequi-Suplicy, C. C.; Germano, R.; Henriques, V. B.; Lamy, M. T. Lipid 
bilayer pre-transition as the beginning of the melting process. BBA-Biomembranes. 2009, 1788, 954-
963. 
50. Riske, K. A.; Fernandez, R. M.; Nascimento, O. R.; Bales, B. L.; Lamy-Freund, M. T. DMPG gel–fluid 
thermal transition monitored by a phospholipid spin labeled at the acyl chain end. Chem. Phys. Lipids. 
2003, 124, 69-80.  
51. Lin, B. F.; Missirlis, D.; Krogstad, D. V.; Tirrell, M. Structural effects and lipid membrane 
interactions of the Ph responsive GALA peptide with fatty acid acylation. Biochem. 2012, 51, 
4658−4668. 
52. Chu-Kung, A. F.; Nguyen, R.; Bozzelli, K. N.; Tirrell, M. Chain length dependence of antimicrobial 
peptide-fatty acid conjugate activity. J. Colloid Interf. Sci. 2010, 345, 160−167. 
66 
 
53. Radzishevsky, I. S.; Rotem, S.; Zaknoon, F.; Gaidukov, L.; Dagan, A.; Mor, A. Effects of acyl versus 
aminoacyl conjugation on the properties of antimicrobial peptides. Antimicrob. Agents Chemother. 
2005, 49, 2412−2420. 
54. Wee, X. K.; Yang, T. M.; and Go, M. L. Exploring the Anticancer Activity of Functionalized 
Isoindigos: Synthesis, Drug‐like Potential, Mode of Action and Effect on Tumor‐Induced Xenografts. 
Chem. Med. Chem. 2012, 7, 777-791. 
55. Lakshminarayana, S. B.; Huat, T. B.; Ho, P. C.; Manjunatha, U. H.; Dartois, V.; Dick, T.; Rao, S. P. S. 
Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents. J. 
Antimicrob. Chemoth. 2015, 70, 857-867. 
56. Murugasu-Oei, B.; Dick, T. Bactericidal activity of nitrofurans against growing and dormant 
Mycobacterium bovis BCG. J. Antimicrob Chemother. 2000, 46, 917-919 
57. Gopal, P.; Dick, T. The new tuberculosis drug Perchlozone® shows cross-resistance with 
thiacetazone.  Int. J. Antimicrob. Agents. 2015, 45, 430-433. 
58. Zou, H. X.; Koh, J. J.; Li, J. G.; Qiu, S. X.; Aung, T. T.; Lin, H. F.; Lakshminarayanan,R.;  Dai, X. P.; 
Tang, C.; Lim,F. H.; Zhou, L.; Tan, A. L.; Verma, C.; D. Tan, T. H.; Chan, H. S. O.; Saraswathi, P.; Cao, D. 
R.; Liu, S. P.; Beuerman, R. W. Design and Synthesis of Amphiphilic Xanthone-Based, Membrane 




















7. Characterization of intermediates and target compounds 
114: CAN-1-(3,7-dimethylocta-2,6-dienyl)-5-fluoro-3-(piperidin-1-ylmethyl)-1H-indole (C24H33FN2) 
Yellow oil; Yield: 14.7 %; 1H NMR (400 MHz, DMSO-d6) δ ppm 1.42 (br, 2 H), 1.59 (br, 7 H), 1.66 (s, 3 
H), 1.80 (s, 3 H), 2.08 (br, 4 H), 2.45 (br, 4 H), 3.64 (s, 2 H), 4.65 (d, J = 6.3 Hz, 2 H), 5.06 (br, 1 H), 5.36 
(t, J = 6.3 Hz, 1 H), 6.90-6.96 (m, 1 H), 7.11 (s, 1H), 7.17-7.21 (m, 1 H), 7.33-7.36 (m, 1H); 13C NMR δ 
ppm (101 MHz, CDCl3) δ ppm 16.4, 17.7, 24.3, 25.7, 25.9, 26.2, 39.4, 44.3, 53.9, 54.2, 104.2, 104.5, 
109.4, 109.8, 109.9, 110.1, 110.7, 119.6, 123.6, 128.9, 129.1, 129.3, 131.9, 132.8, 156.1, 159.2. 
 
 
Intermedate: 5-Fluoro-1H-indole-3-carboxylic acid 
White solid; 1H NMR (400 MHz, DMSO-d6) δ ppm 12.23 (s, 1 H), 9.91 (s, 1 H), 8.34 (d, J = 3.14 Hz, 1 
H), 7.75 (dd, J = 9.54, 2.26 Hz, 1 H), 7.53 (dd, J = 8.85, 4.58 Hz, 1 H), 7.12 (td, J = 9.16, 2.64 Hz, 1 H). 
 
 
A-1: 1-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-6-fluoro-1H-indole (C18H22FN) 
Yellow oil; Yield: 85%. 1H NMR (400 MHz, DMSO-d6) δ ppm 7.45-7.56 (m, 1H), 7.24-7.31 (m, 1H), 7.19 
(dd, J = 10.415, 1.882 Hz, 1H), 6.81-6.90 (m, 1H), 6.37-6.46 (m, 1H), 5.29 (t, J = 6.902 Hz, 1H), 4.96-




A-2: 5-Fluoro-3-(piperidin-1-ylmethyl)-1H-indole (C14H17FN2) 
While solid; 1H NMR (400 MHz, DMSO-d6) δ ppm 10.98 (s, 1H), 7.61 (dd, J = 8.658, 5.647Hz, 1H), 7.20 
(d, J = 2.008 Hz, 1H), 7.13 (dd, J = 10.164, 2.259 Hz, 1H), 6.84 (ddd, J = 9.788, 8.721, 2.321 Hz, 1H), 





A-3: 3-(Piperidin-1-ylmethyl)-1H-indole (C24H35N2) 
Yellow oil; Yield: 50.5%; 1H NMR (400MHz, CDCl3) δ ppm 7.69 (d, 1H, J = 8.0 Hz), 7.31 (d, 1H, J = 8.0 
Hz), 7.22-7.18(m, 1H), 7.14-7.10(m, 2H), 5.40-5.37(m, 1H), 5.09-5.06(m, 1H), 4.69 (d, 2H, J = 6.8 Hz), 
3.76(s, 2H), 2.53(br, 4H), 2.12-2.05(m, 4H), 1.81(s, 3H), 1.67(s, 3H), 1.64-1.62(m, 4H), 1.59(s, 3H), 
1.44-1.43(m, 2H); 13C NMR (101 MHz, CDCl3) δ ppm 139.56, 136.16, 131.80, 128.94, 127.74, 123.71, 
121.30, 119.84, 119.31, 119.04, 118.99, 109.55, 53.99, 53.64, 44.10, 39.43, 26.26, 25.65, 25.60, 
24.09, 17.67, 16.39. [M+H]+   351.3, found, 351.4. 
 
 
B-1: 1-(but-3-yn-1-yl)-5-fluoro-3-(piperidin-1-ylmethyl)-1H-indole C18H21FN2) 
Yellow oil; Yield: 46.7%; 1H NMR (400MHz, CDCl3) δ ppm 7.29 (dd, J = 9.60, 2.45 Hz, 1 H), 7.12-7.21 
(m, 1 H), 6.89 (td, J = 9.03, 2.51 Hz, 1 H), 4.17 (t, J = 6.40 Hz, 2 H), 3.59 (s, 2 H), 2.35-2.46 (m, 4 H), 
2.15-2.22 (m, 2 H), 2.07-2.14 (m, 2 H), 1.54 (q, J=5.65 Hz, 4 H), 1.32-1.41 (m, 2 H); 13C NMR (101 
MHz, CDCl3) δ ppm 158.96, 156.63, 132.65, 129.00, 118.59, 111.53, 110.46, 110.20, 109.69, 109.59, 
104.89, 104.65, 54.17, 53.66, 44.44, 25.97, 25.63, 24.11, 14.60. 
 
 
B-2: 1-butyl-5-fluoro-3-(piperidin-1-ylmethyl)-1H-indole C18H25FN2) 
Yellow oil; Yield: 65.6%; 1H NMR (400MHz, CDCl3) δ ppm 7.80 (d, 1H, J = 2.0 Hz), 7.27-7.25 (m, 1H), 
7.17 (d, 1H, J = 4.4 Hz),7.10(s, 1H), 4.04(t, 2H, J = 7.2 Hz), 3.66(s, 2H), 2.46 (br, 4H), 1.83-1.76 (m, 2H), 
1.63-1.58 (m, 4H), 1.44-1.42 (m, 2H), 1.28-1.24 (m, 10H), 0.87 (t, 3H, J = 7.2 Hz); 13C NMR (101 MHz, 
CDCl3) δ ppm 134.83, 130.39, 128.87, 124.11, 122.02, 112.34, 110.81, 110.10, 54.19, 53.62, 46.46, 





B-3/F-2: 5-Fluoro-1-octyl-3-(piperidin-1-ylmethyl)-1H-indole (C22H33FN2) 
Yellow oil; Yield: 75.8 %;  1H NMR (300 MHz, CDCl3): δ ppm 0.86 (t, J = 6.9 Hz, 3 H), 1.24-1.28 (m, 10 
H), 1.42 (d, J = 4.5 Hz, 2 H), 1.59 (t, J = 5.4 Hz, 4 H), 1.80 (br, 2 H), 2.45 (br, 4 H), 3.65 (s, 2 H), 4.04 (t, J 
= 7.2 Hz, 2 H), 6.93 (t, J = 8.1 Hz, 1 H), 7.11 (s, 1H), 7.17-7.22 (m, 1H), 7.35 (d, J = 1.5 Hz, 1 H); 13C 
NMR (75 MHz, CDCl3) δ ppm 11.7(2C), 14.0, 22.5, 24.2, 25.8 (2C), 26.9, 29.1 (2C), 30.1, 31.7, 46.5, 
53.8, 54.1 (2C), 104.4, 109.7, 109.9, 110.5, 129.0, 132.7, 155.9, 159.1. IT TOF-HRMS calculated for 




B-4: N-butyl-2-[5-fluoro-3-(piperidin-1-ylmethyl)-1H-indol-1-yl]acetamide C20H28FN3O) 
While solid; Yield: 26.7%; 1H NMR (400 MHz, DMSO-d6) δ ppm 7.29 (dd, J = 9.47, 2.45 Hz, 1 H), 7.08-
7.17 (m, 2 H), 6.91 (td, J = 9.03, 2.38 Hz, 1 H), 5.55 (br. S., 1 H), 5.21-5.27 (m, 1 H), 4.65 (s, 2 H) 3.66 
(s, 2 H), 3.05-3.13 (m, 2 H), 2.49 (br. S., 4 H), 1.59 (dt, J = 11.11, 5.49 Hz, 5 H), 1.40 (d, J = 5.14 Hz, 2 





While solid; Yield: 32.3%; 1H NMR (400 MHz, DMSO-d6) δ ppm 8.06 (t, J = 5.207 Hz, 1 H), 7.26-7.41 
(m, 3 H), 6.95 (td, J = 9.223, 2.510 Hz, 1 H), 6.42 (d, J = 3.012 Hz, 1 H), 4.80 (s, 2 H), 3.95 (s, 2 H), 3.28 
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(s, 4 H), 3.16 (q, J = 6.442 Hz, 2 H), 2.28 (t, J = 6.525 Hz, 2 H), 2.16 (d, J = 4.14 Hz, 2 H), 2.13 (s, 6 H) 
1.75-1.89 (m, 4 H); ECI, m/z 360.4 [M+H]. 
 
 
B-6: N-cyclopropyl-2-[5-fluoro-3-(piperidin-1-ylmethyl)-1H-indol-1-yl]acetamide (C19H24FN3O) 
While solid; Yield: 32.3%; 1H NMR (400 MHz, DMSO-d6) δ ppm 8.06 (t, J = 5.207 Hz, 1 H), 7.26-7.41 
(m, 3 H), 6.95 (td, J = 9.223, 2.510 Hz, 1 H), 6.42 (d, J = 3.012 Hz, 1 H), 4.80 (s, 2 H), 3.95 (s, 2 H), 3.28 
(s, 4 H),3.16 (q, J = 6.442 Hz, 2 H), 2.28 (t, J=6.525 Hz, 2 H), 2.16 (d, J = 4.14 Hz, 2 H), 2.13 (s, 6 H), 





 Yellow oil; Yield: 37.2 %; 1H NMR (300 MHz, CDCl3): δ ppm 1.59 (s, 3 H), 1.67 (s, 3 H), 1.80 (s, 3 H), 
2.09 (br, 4 H), 2.27 (s, 6 H), 3.56 (s, 2 H), 4.65 (d, J = 6.3 Hz, 2 H), 5.07 (br, 1 H), 5.36 (t, J = 6.3 Hz, 1 
H),6.90-6.96 (m, 1 H), 7.09 (s, 1H), 7.17-7.22 (m, 1 H), 7.31-7.34 (m, 1H); 13CNMR (75 MHz, CDCl3) δ 
ppm 16.3, 17.7, 25.6, 26.2, 39.4, 44.2, 45.2, 54.4, 104.0, 104.3, 109.5, 109.8, 109.9, 110.1, 111.6, 







Yellow oil; Yield: 43.4 %; 1H NMR (300 MHz, CDCl3) δ ppm 1.09 (t, J = 6.9 Hz, 6 H), 1.59 (s, 3 H), 1.67 
(s, 3 H), 1.80 (s, 3 H), 2.09 (br, 4 H), 2.55 (q, J = 6.9 Hz, 4 H), 3.72 (s, 2 H), 4.65 (d, J = 6.6 Hz, 2 H), 5.07 
(br, 1 H), 5.36 (t, J = 6.0 Hz, 1 H), 6.90-6.96 (m, 1 H), 7.08 (s, 1H), 7.17-7.21 (m, 1 H), 7.35-7.38 (m, 
1H); 13C NMR (75 MHz, CDCl3) δ ppm 11.8, 16.4, 17.7, 25.6, 26.2, 39.4, 44.3, 46.5, 48.0, 104.3, 104.6, 
109.4, 109.7, 109.9, 110.0, 111.8, 119.7, 123.6, 128.4, 128.9, 131.8, 132.9, 139.8, 156.0, 159.1; ECI, 





Yellow oil; Yield: 41.8 %; 1H NMR (300 MHz, CDCl3): δ 0.88 (t, J = 7.2 Hz, 6 H), 1.23-1.35 (m, 4 H), 
1.44-1.54 (m, 4 H), 1.67 (s, 3 H), 1.72 (s, 3 H), 1.80 (s, 3 H), 2.05-2.12 (m, 4 H), 2.43 (t, J = 7.5 Hz, 4 H), 
3.69 (s, 2 H), 4.65 (d, J = 6.6 Hz, 2 H), 5.07 (br, 1 H), 5.36 (t, J = 6.6 Hz, 1 H), 6.89-6.95 (m, 1 H), 7.04 (s, 
1H), 7.16-7.20 (m, 1 H), 7.34-7.38 (m, 1H); 13C NMR (75 MHz, CDCl3) δ ppm 14.1, 16.4, 17.7, 20.7, 
25.7, 26.2, 29.2, 39.4, 44.2, 49.4, 53.4, 104.4, 104.7, 109.3, 109.7, 109.8, 110.0, 112.4, 119.7, 123.7, 





Yellow oil; Yield: 58.6 %; 1H NMR (300 MHz, CDCl3): δ ppm 1.59 (s, 3 H), 1.67 (s, 3 H), 1.80 (s, 3 H), 
2.05-2.13 (m, 4 H), 2.49 (br, 4 H), 3.64 (s, 2 H), 3.70-3.73 (m, 4 H), 4.65 (d, J = 6.6 Hz, 2 H), 5.06 (d, J = 
6.0 Hz, 1 H), 5.36 (t, J = 6.0 Hz, 1 H), 6.90-6.97 (m, 1 H), 7.08 (s, 1H), 7.19-7.22 (m, 1 H), 7.36-7.40 (m, 
1H); 13C NMR (75 MHz, CDCl3) δ ppm 16.4, 17.7, 25.7, 26.2, 39.4, 44.3, 53.5, 54.0, 67.0, 104.3, 104.6, 
109.6, 109.9, 110.0, 110.2, 110.4, 119.5, 123.6, 128.6, 128.9, 131.9, 133.0, 140.0, 156.1, 159.2; ECI, 





C-5: CAN-4-((1-(3,7-dimethylocta-2,6-dienyl)-5-fluoro-1H-indol-3-yl)methyl) thiomorpholine 
(C23H31FN2OS) 
Yellow oil; Yield: 43.2 %; 1H NMR (300 MHz, CDCl3): δ ppm 1.59 (s, 3 H), 1.67 (s, 3 H), 1.80 (s, 3 H), 
2.09 (br, 4 H), 2.68-2.69 (m, 4 H), 2.73-2.75 (m, 4 H), 3.66 (s, 2 H), 4.65 (d, J = 6.6 Hz, 2 H), 5.06 (br, 1 
H), 5.36 (t, J = 6.6 Hz, 1 H), 6.90-6.97 (m, 1 H), 7.17 (s, 1H), 7.19-7.22 (m, 1 H), 7.34-7.38 (m, 1H). 13C 
NMR (75 MHz, CDCl3) δ ppm 16.4, 17.7, 25.7, 26.2, 28.0, 39.4, 44.3, 54.4, 54.7, 104.4, 104.7, 109.6, 





indole  (C23H31FN2O2S) 
Yellow oil; Yield: 36.5 %; 1H NMR (400 MHz, DMSO-d6) δ ppm 7.43 (dd, J = 10.038, 2.510 Hz, 1 H), 
7.31-7.39 (m, 2H), 6.97 (td, J = 9.192, 2.572 Hz, 1H), 5.26-5.34 (m, 1H), 4.97-5.06 (m, 1H), 4.74 (d, J = 
6.776 Hz, 2H), 3.77 (s, 2H), 3.04-3.13 (m, 4H), 2.82-2.92 (m, 4H), 1.95-2.11 (m, 4H), 1.75-1.82 (m, 3H), 





Yellow oil; Yield: 62.3 %; 1H NMR (400 MHz, CDCl3) δ ppm 7.28-7.32 (m, 1 H), 7.19-7.24 (m, 2 H), 
6.91-6.98 (m, 1 H), 5.33-5.39 (m, 1 H), 5.04-5.09 (m, 1 H), 4.67 (d, J = 6.776 Hz, 2 H), 3.82 (s, 2 H), 
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3.09 (d, J = 11.293 Hz, 2 H), 2.05-2.21 (m, 8 H), 1.81 (d, J = 0.878 Hz, 3 H), 1.67 (d, J = 0.753 Hz, 3 H), 
1.64 (d, J = 1.255 Hz, 1 H), 1.59 (s, 3 H), 1.32-1.47 (m, 3 H), 0.93 (d, J = 5.396 Hz, 3 H); 13C NMR (101 
MHz, CDCl3) δ ppm 159.03, 156.71, 140.12, 132.77, 131.88, 129.95, 129.13, 123.62, 119.39, 110.40, 
110.30, 109.95, 109.69, 104.11, 103.88, 52.80, 52.50, 44.46, 39.42, 33.19, 30.25, 26.24, 25.65, 21.63, 




[4.5]decane  (C26H35FN2O2) 
Yellow oil; Yield: 48.9%; 1H NMR (400 MHz, CDCl3) δ ppm 1.51-1.56 (m, 4 H), 1.56-1.63 (m, 6 H), 1.67 
(s, 3 H), 1.73 (q, J = 7.12 Hz, 2 H), 1.80 (s, 3 H), 2.01-2.13 (m, 4 H), 2.57-2.66 (m, 4 H), 3.72 (s, 2 H), 
3.97 (t, J = 7.15 Hz, 2 H), 5.00-5.07 (m, 1 H), 5.30 (t, J = 6.337 Hz, 1 H), 6.85 (td, J = 9.03, 2.51 Hz, 1 H) 
7.06 (s, 1 H), 7.10-7.15 (m, 1 H), 7.28 (dd, J = 9.85, 2.45 Hz, 1 H); ECI, m/z 426.5 [M+H]. 
 
 
C-9: 3-(Azepan-1-ylmethyl)-1-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-5-fluoro-1H-indole (C25H35FN2) 
Yellow oil; Yield: 61.5%; 1H NMR (400 MHz, CDCl3) δ ppm 7.55 (s, 1 H), 7.18-7.27 (m, 2 H), 6.96 (td, J 
= 8.941, 1.820 Hz, 1 H), 5.33 (t, J = 6.400 Hz, 1 H), 5.01-5.07 (m, 1 H), 4.70 (d, J = 6.776 Hz, 2 H), 4.23 
(s, 2 H), 3.10-3.16 (m, 4 H), 2.04-2.14 (m, 4 H), 1.87 (br. S., 4 H), 1.81 (s, 3 H), 1.63-1.70 (m, 7 H), 1.57 
(s, 3 H); 13C NMR (101 MHz, CDCl3) δ ppm 159.45, 157.10, 140.54, 132.57, 132.39, 131.86, 129.02, 
128.93, 118.93, 111.12, 111.02, 110.43, 110.17, 103.12, 102.89, 53.44, 51.56, 44.82, 39.36, 26.80, 







Yellow oil; Yield: 26.5%; 1H NMR (400 MHz, DMSO-d6) δ ppm 7.26-7.32 (m, 1H), 7.16-7.24 (m, 2H), 
6.89 (td, J = 9.160, 2.510 Hz, 1H), 5.21-5.28 (m, 1H), 4.94-5.02 (m, 1H), 4.66 (d, J = 6.651 Hz, 2H), 4.02 
(s, 1H), 3.45 (s, 6H), 1.95-2.05 (m, 7H), 1.71-1.76 (m, 3H), 1.51-1.56 (m, 3H), 1.46-1.51 (m, 3H); ECI, 
m/z 343.3 [M+H] 
 
 
C-11: N-({1-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-5-fluoro-1H-indol-3-yl}methyl)cyclopropan-amine  
(C22H29FN2).  
Yellow oil; Yield: 47.6%; 1H NMR (400 MHz, CDCl3) δ ppm 7.50 (s, 1 H), 7.35 (dd, J = 9.662, 2.384 Hz, 1 
H), 7.17 (dd, J = 8.909, 4.267 Hz, 1 H), 6.93 (td, J = 9.035, 2.259 Hz, 1 H), 5.30 (t, J = 6.337 Hz, 1 H), 
5.00-5.07 (m, 1 H), 4.65 (d, J = 6.525 Hz, 2 H), 4.09 (s, 2 H), 3.28 (m, 1 H), 2.01-2.13 (m, 4 H), 1.91-





Yellow oil; Yield: 71.5%; 1H NMR (400 MHz, CDCl3) δ ppm 7.50 (s, 1 H), 7.35 (dd, J = 9.662, 2.384 Hz, 1 
H), 7.17 (dd, J = 8.909, 4.267 Hz, 1 H), 6.93 (td, J = 9.035, 2.259 Hz, 1 H), 5.30 (t, J = 6.337 Hz, 1 H), 
5.00-5.07 (m, 1 H), 4.65 (d, J = 6.525 Hz, 2 H), 4.09 (s, 2 H), 3.28 (q, J = 6.870 Hz, 1 H), 2.01-2.13 (m, 4 
H), 1.91-1.99 (m, 3 H), 1.81-1.89 (m, 4 H), 1.57 (s, 3 H), 1.51 (br. S., 2 H); ECI, m/z 368.5 [M+H]. 
 
 
C-13: 3-(Azepan-1-ylmethyl)-1-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-5-fluoro-1H-indole (C25H35FN2) 
76 
 
Yellow oil; Yield: 68.4%; 1H NMR (400 MHz, CDCl3) δ ppm 8.17 (m, 1 H), 7.85 (m, 1 H), 7.17 (s, 1 H), 
7.28 (m, 1 H), 5.32 (td, J = 6.682, 0.941 Hz, 1 H), 4.99-5.06 (m, 1 H), 4.83 (d, J = 6.651 Hz, 2 H), 4.70 (s, 
2 H), 3.11-3.28 (m, 4 H), 2.06-2.12 (m, 4 H), 1.93 (s, 4 H), 1.84 (s, 3 H), 1.70 (s, 4 H), 1.63 (s, 3 H), 1.57 





Yellow oil; Yield: 43.6%; 1H NMR (400 MHz, DMSO-d6) δ ppm 7.67-7.76 (m, 1H), 7.36-7.43 (m, 1H), 
7.17-7.26 (m, 1H), 6.87-6.97 (m, 1H), 5.72 (s, 1H), 5.29 (t, J = 6.776 Hz, 1H), 4.95-5.03 (m, 1 H), 4.72 
(d, J = 6.776 Hz, 2H), 4.01 (d, J = 3.764 Hz, 2H), 2.87 (s, 2H), 2.77 (s, 4H), 2.72 (s, 2H), 1.98-2.09 (m, 
4H), 1.73-1.82 (m, 3H), 1.52-1.64 (m, 8H), 1.47-1.51 (m, 3H), 1.41 (s, 2H); ECI, m/z 434.6[M+H]. 
 
 
C-15: N-{[1-(3,7-dimethylocta-2,6-dien-1-yl)-5-fluoro-1H-indol-3 yl]methyl} 76 ricycle[3.3.1.13,7]-
decan-1-amine (C29H39FN2) 
Yellow oil; Yield: 38.9%; 1H NMR (400 MHz, DMSO-d6) δ ppm 7.28-7.35 (m, 1 H), 7.19-7.24 (m, 2 H), 
6.90 (td, J = 9.22, 2.51 Hz, 1 H), 5.20-5.30 (m, 1 H), 4.95-5.03 (m, 1 H), 4.68 (d, J = 6.78 Hz, 2 H), 4.32 
(d, J = 5.766 Hz, 2H),  4.03 (s, 1 H) 2.88 (s, 2H), 2.81 (s, 4H), 2.72 (s, 2H), 1.93-2.08 (m, 4 H), 1.75 (s, 3 







Yellow oil; Yield: 58.2%; 1H NMR (400 MHz, CDCl3) δ ppm 7.39 (s, 1H), 7.20-7.26 (m, 1H), 7.13 (dd, J = 
8.909, 4.266 Hz, 1H), 6.88 (td, J = 9.035, 2.384 Hz, 1H), 5.22-5.30 (m, 1H), 4.94-5.02 (m, 1H), 4.60 (d, J 
= 6.525 Hz, 2H), 4.06 (s, 2H), 3.15 (dd, J = 13.678, 7.404 Hz, 1H), 2.54 (d, J = 6.776 Hz, 2H), 1.96 – 2.06 
(m, 4H), 1.77 (d, J = 13.050 Hz, 2H), 1.73 (s, 3H), 1.59-1.67 (m, 3 H), 1.58 (d, J = 0.753 Hz, 4 H), 1.50 (s, 





Yellow oil; Yield: 64.2%; 1H NMR (400 MHz, CDCl3) δ ppm 7.31-7.19 (m, 9H), 5.29-5.26 (m, 1H), 5.04-
5.01 (m, 1H), 4.56 (d, 2H, J = 6.4 Hz), 3.78 (s, 2H), 3.64 (d, 2H, J = 6.4 Hz), 2.12-2.00 (m, 4H), 1.76 (s, 
3H), 1.63(s, 3H), 1.55(s, 3H); 13C NMR (101MHz, CDCl3) δ ppm 158.68, 140.16, 139.58, 138.39, 
132.97, 131.79, 129.03, 128.83, 128.16, 128.06, 126.94, 126.57, 123.65, 119.80, 111.69, 109.95, 






Yellow oil; Yield: 32.1%; 1H NMR (400 MHz, DMSO-d6) δ ppm 8.66 (t, J = 6.34 Hz, 1H), 8.28 (d, J = 8.17 
Hz, 1H), 7.35 (d, J = 7.532 Hz, 1H), 7.21 (m, 3H), 4.43-4.54 (m, 4H), 1.82-1.91 (m, 2H), 1.16-1.28 (m, 
10H), 0.78-0.84 (m, 3H); ECI, m/z 407.4 [M+H]. 
 
 




While solid; Yield: 72.6%; 1H NMR (400 MHz, DMSO-d6) δ ppm 7.82 (d, J = 1.882 Hz, 1H), 7.70 (s, 1 H), 
7.43 (d, J = 8.658 Hz, 1H), 7.29-7.35 (m, 1H), 5.33 (t, J = 6.651 Hz, 1H), 4.97-5.03 (m, 1 H), 4.82 (d, J = 
6.902 Hz, 2H), 3.55-3.61 (m, 4H), 1.98-2.09 (m, 4H), 1.80 (s, 3H), 1.61-1.68 (m, 2H), 1.47-1.58 (m, 
10H); 13C NMR (101 MHz, DMSO-d6) δ ppm 164.79, 140.37, 134.59, 131.82, 131.52, 129.04, 124.84, 






Yellow oil; Yield: 71.2%; 1H NMR (400MHz, CDCl3) δ ppm 7.64 (d, 1H, J = 1.6 Hz), 7.20 (d, 1H, J = 8.4 
Hz), 7.14-7.11(m, 2H), 5.36-5.32(m, 1H), 5.07-5.03(m, 1H), 4.65 (d, 2H, J = 6.8 Hz), 3.66(s, 2H), 2.48 
(br, 4H), 2.11-2.04 (m, 4H), 1.79 (s, 3H), 1.66(s, 3H), 1.63-1.58 (m, 7H), 1.45-1.43 (m, 2H); 13C NMR 
(100MHz, CDCl3) δ ppm 140.04, 134.59, 131.87, 129.92, 128.84, 124.90, 123.62, 121.58, 119.42, 
118.84, 110.56, 109.99, 54.14, 53.62, 44.28, 39.39, 26.21, 25.64, 24.15, 17.66, 16.39; [M+H]+   





Yellow oil; Yield: 76.3%; 1H NMR (400MHz, CDCl3) δ 7.76 (d, 1H, J = 1.6 Hz), 7.28-7.23 (m, 2H), 7.16 
(d, 1H, J = 8.8 Hz), 5.35-5.31 (m, 1H), 5.06-5.03 (m, 1H), 4.65 (d, 2H, J = 6.8 Hz), 3.76 (s, 2H), 2.57 (br, 
4H), 2.09-2.03 (m, 4H), 1.79 (s, 3H), 1.71-1.66 (m, 7H), 1.58 (s, 3H), 1.46 (br, 2H); 13C NMR (100MHz, 
CDCl3) δ ppm 140.20, 134.81, 131.88, 130.52, 129.48, 124.28, 123.59, 121.63, 119.25, 112.74, 
111.20, 108.38, 53.81, 44.40, 39.38, 29.66, 26.20, 25.64, 25.16, 23.81, 17.67, 16.42; [M+H]+  






Yellow oil; Yield: 72.6%; 1H NMR (400 MHz, CDCl3) δ ppm 7.30 (s, 1 H), 7.08-7.11 (m, 2H), 6.74-6.80 
(m, 1H), 5.35 (td, J = 6.713, 1.129 Hz, 1H), 5.06 (ddd, J = 7.435, 4.674, 1.317 Hz, 1H), 4.66-4.72 (m, 
2H), 4.08 (s, 2H), 2.76 (s, 4H), 2.05-2.11 (m, 4H), 1.81 (s, 3H), 1.71-1.77 (m, 4 H), 1.66 (d, J = 0.878 Hz, 




Yellow oil; Yield: 71.0%; 1H NMR (400 MHz, DMSO-d6) δ ppm 7.70-7.79 (m, 1H), 7.39-7.46 (m, 1H), 
7.20-7.29 (m, 1H), 6.90-7.00 (m, 1H), 5.75 (s, 1H), 5.32 (t, J = 6.776 Hz, 1H), 4.98-5.06 (m, 1 H), 4.75 
(d, J = 6.776 Hz, 2H), 4.04 (d, J = 3.764 Hz, 2H), 2.80 (s, 4H), 2.01-2.12 (m, 4 H), 1.76-1.85 (m, 3H), 
1.60-1.67 (m, 4H), 1.58 (s, 3H), 1.50-1.54 (m, 3H), 1.44 (s, 2H); ECI, m/z 368.5[M+H] 
 
 
D-5: 1-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-7-fluoro-3-(piperidin-1-ylmethyl)-1H-indole (C24H33FN2) 
Yellow oil; Yield: 71.5%; 1H NMR (400 MHz, CDCl3) δ ppm 7.29-7.38 (m, 2H), 7.01-7.09 (m, 1H), 6.86-
6.94 (m, 1H), 5.40 (t, J = 6.839 Hz, 1H), 5.01 – 5.09 (m, 1H), 4.88-4.96 (m, 2H), 4.29 (s, 2H), 2.80-3.18 
(m, 4H), 2.05 (s, 4H), 1.81-1.91 (m, 4H), 1.79 (s, 3H), 1.61-1.66 (m, 3H), 1.57 (s, 3H), 1.41-1.54 (m, 





D-6: 3-(Azepan-1-ylmethyl)-1-[(2E)-7-methylocta-2,6-dien-1-yl]-4-nitro-1H-indole (C24H33N3O2) 
1H NMR (400 MHz, CDCl3) δ ppm 8.37 (s, 1 H), 8.04 (d, J=7.906 Hz, 1 H), 7.67 (dd, J=8.219, 0.690 Hz, 1 
H), 7.28 – 7.32 (m, 1 H), 5.32 (td, J = 6.682, 0.941 Hz, 1 H), 4.99-5.06 (m, 1 H), 4.83 (d, J = 6.651 Hz, 2 
H), 4.70 (s, 2 H), 3.11-3.28 (m, 4 H), 2.06-2.12 (m, 4 H), 1.93 (s, 4 H), 1.84 (s, 3 H), 1.70 (s, 4 H), 1.63 
(s, 3 H), 1.57 (s, 3 H); 13C NMR (101 MHz, CDCl3) δ ppm 141.92, 141.54, 138.88, 131.91, 123.47, 
120.60, 119.44, 117.27, 102.66, 53.30, 52.64, 45.44, 39.32, 26.86, 26.14, 25.62, 23.39, 17.67, 16.59; 
ECI, m/z 395.5 [M+H]. 
 
 
D-7: E-1: 1-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-3-(piperidin-1-ylmethyl)-1H-pyrrolo[2,3-b]pyridine 
(C23H33N3) 
Yellow oil; Yield: 46.2%; 1H NMR (400 MHz, CDCl3) δ ppm 8.33 (dd, J = 4.705, 1.443 Hz, 1H), 7.98 (dd, 
J = 7.843, 1.568 Hz, 1H), 7.27 (s, 1H), 7.05-7.10 (m, 1H), 5.41-5.46 (m, 1H), 5.04-5.10 (m, 1H), 4.89 (d, 
J = 6.776 Hz, 2H), 3.85 (s, 2H), 2.62 (s, 4H), 2.04-2.17 (m, 6H), 1.80-1.83 (m, 3H), 1.67 (s, 5H), 1.58 (s, 
3H), 1.45 (s, 2H); ECI, m/z 352.2 [M+H]. 
 
 
E-1:  1-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-3-(piperidin-1-ylmethyl)-1H-pyrrolo[2,3-b]pyridine 
(C23H33N3) 
1H NMR (400 MHz, CDCl3) δ ppm 8.33 (dd, J = 4.705, 1.443 Hz, 1H), 7.98 (dd, J = 7.843, 1.568 Hz, 1H), 
7.27 (s, 1H), 7.05-7.10 (m, 1H), 5.41-5.46 (m, 1H), 5.04-5.10 (m, 1H), 4.89 (d, J = 6.776 Hz, 2H), 3.85 
(s, 2H), 2.62 (s, 4H), 2.04-2.17 (m, 6H), 1.80-1.83 (m, 3H), 1.67 (s, 5H), 1.58 (s, 3H), 1.45 (s, 2H); ECI, 





E3: N-benzyl-1H-indazole-3-carboxamide (C15H14N3O) 
1H NMR (400 MHz, DMSO-d6) δ ppm 13.59 (s, 1H), 8.93 (t, J = 6.149 Hz, 1H), 8.17 (d, J = 8.156 Hz, 
1H), 7.61 (d, J = 8.533 Hz, 1H), 7.41 (t, J = 7.278 Hz, 1H), 7.27-7.38 (m, 4H), 7.19-7.27 (m, 2H), 4.51 (d, 
J = 6.274 Hz, 2H); 13C NMR (101 MHz, DMSO-d6) δ ppm 162.84, 141.59, 140.41, 138.70, 128.70, 




White solid; mp: 176.5-176.9; 1H NMR (400 MHz, DMSO-d6) δ ppm 13.62 (s, 1H), 9.02 (t, J = 6.337 Hz, 
1H), 8.16 (d, J = 8.156 Hz, 1H), 7.62 (d, J = 8.407 Hz, 1H), 7.32-7.46 (m, 2H), 7.11-7.28 (m, 3H), 7.01-
7.09 (m, 1H), 4.50 (d, J = 6.274 Hz, 2H); 13C NMR (101 MHz, DMSO-d6) δ ppm 163.47, 162.54, 161.05, 
143.09, 143.01, 141.18, 138.13, 130.30, 130.21, 126.63, 123.36, 123.34, 122.19, 121.56, 113.73, 
110.77, 41.52;ECI, m/z 270.3 [M+H]. 
 
 
E-5: N-benzyl-1-[(2E)-7-methylocta-2,6-dien-1-yl]-1H-indazole-3-carboxamide (C24H26ClN3O) 
1H NMR (400 MHz, DMSO-d6) δ ppm 8.83 (s, J = 5.337 Hz, 1H), 8.18 (d, J = 8.156 Hz, 1H), 7.76 (d, J = 
8.658 Hz, 1H), 7.21-7.39 (m, 6H), 4.43-4.54 (m, 4H), 1.82-1.91 (m, 2H), 1.16-1.28 (m, 10H), 0.78-0.84 





E-6: 5-chloro-N-(cyclohexylmethyl)-1H-indazole-3-carboxamide (C15H18ClN3O) 
1H NMR (400 MHz, DMSO-d6) δ ppm 8.83 (s, J = 5.337 Hz, 1H), 8.18 (d, J = 8.156 Hz, 1H), 7.76 (d, J = 
8.658 Hz, 1H), 7.21-7.39 (m, 1H), 3.18 (dd, J = 13.678, 7.404 Hz, 1H), 2.57 (d, J = 6.776 Hz, 2H), 1.98-
2.11 (m, 4H), 1.82-1.91 (m, 2H), 1.59 (s, 4 H); ECI, m/z 291.6 [M+H]. 
 
 
E-8: N-benzyl-1-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-1H-indazole-3-carboxamide (C24H27N3O) 
White solid; 1H NMR (400 MHz, DMSO-d6) δ ppm 8.86 (t, J = 6.337 Hz, 1H), 8.18 (d, J = 8.156 Hz, 1H), 
7.76 (d, J = 8.658 Hz, 1H), 7.45 (ddd, J = 8.376, 7.058, 1.004 Hz, 1H), 7.21-7.39 (m, 6H), 4.43-4.54 (m, 
4H), 1.82-1.91 (m, 2H), 1.16-1.28 (m, 10H), 0.78-0.84 (m, 3H); 13C NMR (101 MHz, DMSO-d6) δ ppm 
162.46, 141.01, 140.35, 137.31, 128.69, 127.86, 127.18, 127.00, 122.77, 122.61, 122.25, 110.78, 





White solid; 1H NMR (400 MHz, DMSO-d6) δ ppm 8.78 (s, J = 5.327 Hz, 1H), 8.28 (d, J = 8.257 Hz, 1H), 
7.86(d, J = 8.248 Hz, 1H), 7.28-7.42 (m, 6H), 4.43-4.56 (m, 4H), 1.82-1.93 (m, 2H), 1.13-1.29 (m, 10H), 
0.78-0.85 (m, 3H); ECI, m/z 430.1 [M+H]. 
 
 
F-1: 4-Fluoro-1-octyl-3-(piperidin-1-ylmethyl)-1H-indole (C22H33FN2) 
Yellow oil; Yield: 78.6%; 1H NMR (400 MHz, CDCl3) δ ppm 7.16-7.22 (m, 2 H), 7.09 (dd, J = 8.91, 4.27 
Hz, 1 H), 6.84 (td, J = 9.07, 2.45 Hz, 1 H), 3.93 (t, J = 7.22 Hz, 2 H), 3.86 (s, 2 H), 2.00-2.08 (m, 3 H), 
1.75-1.82 (m, 6 H), 1.71 (d, J  = 7.15 Hz, 2 H), 1.55-1.65 (m, 6 H), 1.15-1.24 (m, 10 H), 0.77-0.82 (m, 3 
H); 13C NMR (101 MHz, CDCl3) δ ppm 158.81, 156.49, 132.90, 128.98, 127.68, 127.59, 110.18, 110.09, 
83 
 
109.97, 109.71, 103.79, 103.56, 52.73, 46.60, 41.60, 36.50, 35.25, 31.78, 30.27, 29.52, 29.21, 29.16, 
27.00, 22.62, 14.07; ECI, m/z 410.2 [M+H]. 
 
 
F-4: 7-Fluoro-1-octyl-3-(piperidin-1-ylmethyl)-1H-indole (C22H33FN2) 
Yellow oil; Yield: 65.3%; 1H NMR (400 MHz, CDCl3) δ ppm 0.84-0.91 (m, 3 H), 1.24-1.33 (m, 10 H), 
1.40-1.49 (m, 2 H), 1.64 (q, J = 5.68 Hz, 4 H), 1.77-1.89 (m, 2 H), 2.52 (s, 4 H), 3.73 (s, 2 H), 4.24 (t, J = 
7.15 Hz, 2 H), 6.82-6.90 (m, 1 H), 6.98 (td, J = 7.84, 4.52 Hz, 1 H), 7.10 (s, 1 H), 7.42 (d, J = 8.03 Hz, 1 
H); 13C NMR (101 MHz, CDCl3) δ ppm 151.32, 148.90, 132.87, 129.87, 129.72, 124.02, 119.17, 115.06, 
110.51, 107.09, 54.03, 53.58, 48.97, 31.73, 29.14, 26.70, 25.60, 24.11, 22.58, 14.02; 19F NMR (101 
MHz, CDCl3) δ ppm -135.66; ECI, m/z 410.7 [M+H]. 
 
 
F-5: 4-Methoxy-1-octyl-3-(piperidin-1-ylmethyl)-1H-indole (C24H38N2O) 
Yellow oil; Yield: 64.2%; 1H NMR (400 MHz, CDCl3) δ ppm 0.81-0.89 (m, 3 H), 1.17-1.34 (m, 12 H), 
1.75-1.89 (m, 4 H), 2.16 (d, J = 4.14 Hz, 2 H), 2.44-2.91 (m, 2 H), 3.28-3.70 (m, 2 H), 3.94 (s, 3 H), 4.09 
(t, J = 7.34 Hz, 2 H), 4.61 (s, 2 H), 6.55 (d, J = 7.78 Hz, 1 H), 6.98 (d, J = 8.28 Hz, 1 H), 7.11-7.17 (m, 1 
H), 7.69 (s, 1 H); 13C NMR (101 MHz, CDCl3) δ ppm 154.24, 131.47, 128.97, 111.69, 110.47, 101.01, 




F-6: 5-Methoxy-1-octyl-3-(piperidin-1-ylmethyl)-1H-indole (C23H36N2O) 
Yellow oil; Yield: 54.2%; 1H NMR (400 MHz, CDCl3) δ ppm 0.85-0.90 (m, 3 H), 1.26 (d, J = 6.02, 3.76 
Hz, 6 H), 1.30 (d, J = 2.76 Hz, 4 H), 1.50 (s, 2 H), 1.73-1.89 (m, 6 H), 2.74 (s, 4 H), 3.86-3.89 (m, 3 H), 
84 
 
3.95 (s, 2 H), 4.04-4.10 (m, 2 H), 6.89 (dd, J = 8.91, 2.38 Hz, 1 H), 7.09 (d, J = 2.38 Hz, 1 H), 7.21-7.26 
(m, 1 H), 7.31 (s, 1 H); 13C NMR (101 MHz, CDCl3) δ ppm 154.24, 131.47, 130.14, 128.97, 111.69, 
110.47, 110.01, 56.05, 53.14, 52.96, 46.69, 31.73, 30.21, 29.15, 26.97, 24.50, 23.30, 22.58, 14.02; 




Yellow oil; Yield: 49.2%; 1H NMR (400 MHz, CDCl3) δ ppm 0.81-0.90 (m, 3 H), 1.17-1.35 (m, 10 H), 
1.55 (s, 2 H), 1.78-1.87 (m, 2 H), 1.97 (s, 4 H), 2.99 (s, 4 H), 3.88 (s, 3 H), 4.06 (t, J = 7.28 Hz, 2 H), 4.23 
(s, 2 H), 6.81 (d, J = 2.13 Hz, 1 H), 6.85 (dd, J = 8.66, 2.13 Hz, 1 H), 7.41-7.45 (m, 1 H), 7.50 (s, 1 H); 13C 
NMR (101 MHz, CDCl3) δ ppm 156.56, 136.84, 130.58, 122.70, 118.72, 110.17, 93.9, 55.77, 52.07, 
51.88, 46.64, 31.70, 29.88, 29.12, 26.93, 23.07, 22.55, 22.25, 14.00; ECI, m/z 356.6 [M+H]. 
 
 
F-8: 7-Methoxy-1-octyl-3-(piperidin-1-ylmethyl)-1H-indole (C24H38N2O) 
Yellow oil; Yield: 62.1%; 1H NMR (400 MHz, CDCl3) δ ppm 0.77-0.83 (m, 3 H), 1.15-1.24 (m, 10 H), 
1.30-1.39 (m, 2 H), 1.54 (q, J = 5.62 Hz, 4 H), 1.67-1.76 (m, 2 H), 2.43 (s, 4 H), 3.65 (s, 2 H), 3.84 (s, 3 
H), 4.21-4.28 (m, 2 H), 6.53 (d, J = 7.65 Hz, 1 H), 6.88-6.95 (m, 2 H), 7.17 (d, J = 8.03 Hz, 1 H); 13C NMR 
(101 MHz, CDCl3) δ ppm 147.50, 131.12, 129.38, 125.68, 119.36, 112.02, 102.20, 55.25, 53.90, 53.57, 
49.30, 32.14, 31.78, 29.22, 26.74, 25.59, 24.10, 22.61, 14.04;  ECI, m/z 356.6 [M+H]. 
 
 
F-9: 4-Fluoro-3-[(4-methylpiperidin-1-yl)methyl]-1-octyl-1H-indole (C23H35FN2) 
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Yellow oil; Yield: 49.8%; 1H NMR (400 MHz, CDCl3) δ ppm 7.05-7.13 (m, 3 H), 6.68-6.79 (m, 1 H), 4.06 
(t, J = 7.22 Hz, 2 H), 3.88 (s, 2 H), 3.02 (d, J = 11.80 Hz, 2 H), 2.11 (t, J = 11.23 Hz, 2 H), 1.77-1.88 (m, 2 
H), 1.57-1.68 (m, 2 H), 1.20-1.37 (m, 13 H), 0.85-0.94 (m, 6 H); 13C NMR (101 MHz, CDCl3) δ ppm 
158.49, 156.04, 138.87, 128.14, 121.58, 11709, 108.81, 105.56, 104.39, 104.19, 53.71, 53.19, 46.64, 
34.07, 31.70, 30.60, 30.06, 29.13, 26.92, 22.58, 21.79, 14.02; ECI, m/z 358.4 [M+H]. HRMS (EI+) calcd 
C23H35FN2 (M+) 359.2857, found 359.2854. 
 
 
F-10: 5-Fluoro-3-[(4-methylpiperidin-1-yl)methyl]-1-octyl-1H-indole (C23H35FN2) 
Yellow oil; Yield: 72.5%; 1H NMR (400 MHz, CDCl3) δ ppm 0.75-0.81 (m, 3 H), 0.87-0.94 (m, 3 H), 1.11-
1.25 (m, 11 H), 1.68-1.82 (m, 6 H), 2.66 (s, 2 H), 3.42 (d, J = 10.92 Hz, 2 H), 4.04 (t, J = 7.34 Hz, 2 H), 
4.29 (s, 2 H), 6.90 (td, J = 9.03, 2.38 Hz, 1 H), 7.13-7.24 (m, 2 H), 7.77 (s, 1 H); 13C NMR (101 MHz, 
CDCl3) δ ppm 159.46, 157.12, 133.85, 132.56, 128.80, 111.01, 110.49, 110.23, 103.11, 101.62, 51.75, 
46.96, 31.65, 30.08, 29.07, 26.86, 22.51, 20.67, 13.96. 19F NMR (101 MHz, DMSO-d6) δ ppm -123.38; 
ECI, m/z 358.5 [M+H]. 
 
 
F-11: 6-Fluoro-3-[(4-methylpiperidin-1-yl)methyl]-1-octyl-1H-indole (C23H35FN2) 
Yellow oil; Yield: 49.8%; 1H NMR (400 MHz, CDCl3) δ ppm 0.84-0.89 (m, 3 H), 0.98 (d, J = 6.53 Hz, 3 
H), 1.21-1.32 (m, 10 H), 1.54 (s, 1 H), 1.72-1.89 (m, 6 H), 2.63 (s, 2 H), 3.37-3.47 (m, 2 H), 4.06 (t, J = 
7.28 Hz, 2 H), 4.28 (s, 2 H), 6.93 (td, J = 9.07, 2.20 Hz, 1 H), 7.03 (dd, J = 9.66, 2.26 Hz, 1 H), 7.48 (dd, J 
= 8.72, 5.08 Hz, 1 H), 7.67 (s, 1 H); 13C NMR (101 MHz, CDCl3) δ ppm 136.19, 132.21, 124.82, 118.95, 
109.19, 96.68, 51.51, 46.88, 31.68, 31.06, 29.94, 29.10, 26.89, 22.55, 20.75, 14.00; 19F NMR (101 






F-12: 7-Fluoro-3-[(4-methylpiperidin-1-yl)methyl]-1-octyl-1H-indole (C23H35FN2) 
Yellow oil; Yield: 68.6%; 1H NMR (400 MHz, CDCl3) δ ppm 0.84-0.89 (m, 3 H), 0.96 (d, J = 6.53 Hz, 3 
H), 1.19-1.32 (m, 11 H), 1.43-1.55 (m, 1 H), 1.65-1.78 (m, 4 H), 1.83 (t, J = 6.71 Hz, 2 H), 2.41-2.52 (m, 
2 H), 3.27 (d, J = 11.80 Hz, 2 H), 4.11 (s, 2 H), 4.26 (t, J = 7.28 Hz, 2 H), 6.89 (dd, J = 12.67, 7.78 Hz, 1 
H), 7.03 (td, J = 7.91, 4.39 Hz, 1 H), 7.32 (d, J = 7.91 Hz, 1 H), 7.50 (s, 1 H); 13C NMR (101 MHz, CDCl3) 
δ ppm 151.42, 148.99, 132.53, 124.00, 120.20, 114.06, 107.62, 52.19, 51.89, 49.30, 31.81, 31.68, 
31.50, 29.56, 29.10, 26.64, 22.55, 20.99, 14.00; 19F NMR (101 MHz, DMSO-d6) δ ppm -134.77; ECI, 
m/z 358.5 [M+H]. 
 
 
F-13: 4-Methoxy-3-[(4-methylpiperidin-1-yl)methyl]-1-octyl-1H-indole (C24H38N2O) 
Yellow oil; Yield: 48.2%; 1H NMR (400 MHz, CDCl3) δ ppm 0.81-0.90 (m, 3 H), 0.98 (d, J = 6.40 Hz, 3 
H), 1.18-1.33 (m, 10 H), 1.54 (s, 1 H), 1.73 (d, J = 13.43 Hz, 2 H), 1.77-2.02 (m, 4 H), 2.59-2.79 (m, 2), 
3.51-3.64 (m, 2 H), 3.94 (s, 3 H), 4.10 (t, J = 7.34 Hz, 2 H), 4.66 (s, 2 H), 6.55 (d, J = 7.78 Hz, 1 H), 6.98 
(d, J = 8.28 Hz, 1 H), 7.14 (t, J = 8.03 Hz, 1 H), 7.74 (s, 1 H); 13C NMR (101 MHz, CDCl3) δ ppm 153.73, 
137.55, 131.75, 122.61, 117.88, 103.66, 101.11, 100.15, 55.04, 52.50, 51.60, 31.68,  31.06, 30.09, 
29.48, 29.11, 29.09, 26.88, 22.53, 20.91, 13.98; ECI, m/z 371.0 [M+H]. 
 
 
F-14: 5-Methoxy-3-[(4-methylpiperidin-1-yl)methyl]-1-octyl-1H-indole (C24H38N2O) 
Yellow oil; Yield: 42.9%; 1H NMR (400 MHz, CDCl3) δ ppm 0.85-0.91 (m, 3 H), 0.93 (d, J = 5.52 Hz, 3 
H), 1.20-1.33 (m, 10 H), 1.34-1.44 (m, 3 H), 1.64 (d, J = 9.41 Hz, 2 H), 1.75-1.87 (m, 2 H), 2.13 (t, J = 
10.42 Hz, 2 H), 3.04 (d, J = 11.04 Hz, 2 H), 3.78 (s, 2 H), 3.86-3.90 (m, 3 H), 4.05 (t, J = 7.15 Hz, 2 H), 
6.88 (dd, J = 8.91, 2.38 Hz, 1 H), 7.11-7.17 (m, 2 H), 7.19-7.23 (m, 1 H); 13C NMR (101 MHz, CDCl3) δ 
ppm 153.89, 131.52, 129.02, 128.92, 111.45, 110.16, 101.40, 56.02, 53.28, 53.22, 46.52, 33.72, 





F-15: 6-Methoxy-3-[(4-methylpiperidin-1-yl)methyl]-1-octyl-1H-indole (C24H38N2O) 
Yellow oil; Yield: 54.2%; 1H NMR (400 MHz, CDCl3) δ ppm 7.58 (d, J = 8.41 Hz, 1 H), 6.97 (s, 1 H), 6.76-
6.82 (m, 2 H), 4.02 (t, J = 7.22 Hz, 2 H), 3.89 (s, 3 H), 3.69 (s, 2 H), 2.96 (d, J = 11.80 Hz, 2 H), 1.95-2.06 
(m, 2 H), 1.83 (q, J = 7.06 Hz, 2 H), 1.61 (d, J = 10.29 Hz, 2 H), 1.21-1.40 (m, 14 H), 0.86-0.96 (m, 6 H); 
13C NMR (101 MHz, CDCl3) δ ppm 156.04, 136.77, 126.43, 123.27, 120.15, 110.80, 108.49, 93.12, 
55.73, 53.68, 53.57, 46.16, 34.32, 31.73, 30.73, 29.98, 29.17, 26.97, 22.58, 21.85, 14.02; ECI, m/z 
371.2 [M+H]. HRMS (EI+) calcd C24H38N2O (M+) 371.3057, found 371.3059. 
 
 
F-16: 7-Methoxy-3-[(4-methylpiperidin-1-yl)methyl]-1-octyl-1H-indole (C24H38N2O) 
Yellow oil; Yield: 58.3%; 1H NMR (400 MHz, CDCl3) δ ppm 0.84-0.90 (m, 3 H), 0.96 (d, J = 6.53 Hz, 3 
H), 1.22-1.32 (m, 10 H), 1.43-1.55 (m, 1 H), 1.65-1.77 (m, 4 H), 1.83 (t, J = 6.65 Hz, 2 H), 2.40-2.53 (m, 
2 H), 3.27 (d, J = 11.80 Hz, 2 H), 4.11 (s, 2 H), 4.26 (t, J = 7.28 Hz, 2 H), 6.89 (dd, J = 12.67, 7.40 Hz, 1 
H), 7.03 (d, J = 7.91, 4.52 Hz, 1 H), 7.32 (d, J=7.91 Hz, 1 H), 7.50 (s, 1 H); 13C NMR (101 MHz, CDCl3) δ 
ppm 147.52, 131.09, 129.47, 125.69, 119.42, 111.97, 102.24, 55.25, 53.30, 53.18, 49.31, 33.83, 
32.13, 31.77, 30.50, 29.20, 26.73, 22.61, 21.67, 14.03; ECI, m/z 371.3 [M+H]. 
 
 
F-17: 8-[(4-Fluoro-1-octyl-1H-indol-3-yl)methyl]-1,4-dioxa-8-azaspiro[4.5]decane (C24H35FN2O2) 
Yellow oil; Yield: 71.4%; 1H NMR (400 MHz, CDCl3) δ ppm 7.67 (s, 1 H), 7.09-7.15 (m, 2 H), 6.74-6.81 
(m, 1 H), 4.32 (s, 2 H), 4.10 (t, J = 7.28 Hz, 2 H), 3.93 (d, J = 1.00 Hz, 4 H), 3.11 (br. S., 4 H), 2.01 (br. S., 
4 H), 1.83 (t, J = 6.84 Hz, 2 H), 1.21 – 1.32 (m, 10 H), 0.85 (t, J = 6.84 Hz, 3 H); 13C NMR (101 MHz, 
88 
 
CDCl3) δ ppm 157.80, 155.37, 138.74, 138.63, 131.80, 122.14, 122.06, 116.94, 116.75, 106.23, 
105.32, 105.10, 104.91, 102.33, 64.47, 52.28, 49.93, 46.96, 32.89, 31.65, 30.00, 29.06, 26.84, 22.51, 
13.98;  ECI, m/z 402.1 [M+H]. HRMS (EI+) calcd C24H36FN2O2 (M+) 3740.2755, found 403.2759. 
 
 
F-18: 8-[(5-Fluoro-1-octyl-1H-indol-3-yl)methyl]-1,4-dioxa-8-azaspiro[4.5]decane (C24H35FN2O2) 
Yellow oil; Yield: 71.5%; 1H NMR (400 MHz, CDCl3) δ ppm 7.82 (dd, J = 8.42, 5.40 Hz, 1 H), 7.01-7.04 
(m, 3 H), 4.00 (t, J = 7.15 Hz, 2 H), 3.84 (s, 3 H), 3.72 (s, 2 H), 2.69 (s, 4 H), 1.69-1.78 (m, 4 H), 1.76 (t, J 
= 5.65 Hz, 4 H), 1.25-1.39 (m, 10 H), 0.86-0.90 (m, 3 H); 19F NMR (101 MHz, DMSO-d6) δ ppm -129.64;  
ECI, m/z 402.3 [M+H]. 
 
 
F-19: 8-[(6-Fluoro-1-octyl-1H-indol-3-yl)methyl]-1,4-dioxa-8-azaspiro[4.5]decane (C24H35FN2O2) 
Yellow oil; Yield: 58.3%; 1H NMR (400 MHz, CDCl3) δ ppm 7.62 (dd, J = 8.78, 5.40 Hz, 1 H), 7.01-7.04 
(m, 1 H), 6.97 (dd, J = 9.91, 2.26 Hz, 1 H), 6.86 (ddd, J = 9.57, 8.69, 2.32 Hz, 1 H), 4.00 (t, J = 7.15 Hz, 2 
H) 3.94 (s, 3 H), 3.71 (s, 2 H) 2.79 (t, J = 6.09 Hz, 1 H), 2.59 (s, 2 H) 1.78 – 1.88 (m, 4 H), 1.76 (t, J = 
5.65 Hz, 4 H), 1.19 – 1.36 (m, 10 H), 0.86 – 0.91 (m, 3 H); 13C NMR (101 MHz, CDCl3) δ ppm 160.97, 
158.61, 136.34, 127.63, 125.03, 120.44, 107.70, 95.77, 64.18, 53.02, 51.20, 46.44, 41.37, 34.83, 
31.73, 30.02, 29.16, 26.96, 22.58, 14.02; 19F NMR (101 MHz, DMSO-d6) δ ppm -121.47; ECI, m/z 
402.5 [M+H]. HRMS (EI+) calcd C24H36FN2O2 (M+) 403.2755, found 403.2753. 
 
 
F-20: 8-[(7-Fluoro-1-octyl-1H-indol-3-yl)methyl]-1,4-dioxa-8-azaspiro[4.5]decane (C24H35FN2O2) 
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Yellow oil; Yield: 56.3%; 1H NMR (400 MHz, CDCl3) δ ppm 7.46 (d, J = 7.91 Hz, 1 H), 6.93 – 7.02 (m, 2 
H), 6.81-6.89 (m, 1 H), 4.23 (t, J = 7.09 Hz, 2 H), 3.93-3.96 (m, 3 H), 3.71 (s, 1 H), 2.79 (t, J = 6.09 Hz, 1 
H), 2.59 (br. S., 3 H), 2.46 (t, J = 6.09 Hz, 1 H), 1.79-1.88 (m, 4 H), 1.76 (t, J = 5.65 Hz, 3 H), 1.22-1.35 




F-21: (8-[(4-Methoxy-1-octyl-1H-indol-3-yl)methyl]-1,4-dioxa-8-azaspiro[4.5]decane) (C25H38N2O)  
Yellow oil; Yield: 48.3%; 1H NMR (400 MHz, CDCl3) δ ppm 7.46-7.52 (m, 1 H), 6.90-7.10 (m, 3 H), 4.01 
(t, J = 7.09 Hz, 2 H), 3.82-3.96 (s, 3 H), 3.71 (s, 2 H), 2.61 (s, 4 H), 1.79-1.88 (s, 2 H), 1.76 (s, 4 H), 1.22-
1.38 (m, 12 H), 0.89 (t, J = 6.84 Hz, 3 H); ECI, m/z 415.4 [M+H]. 
 
 
F-22: (8-[(5-Methoxy-1-octyl-1H-indol-3-yl)methyl]-1,4-dioxa-8-azaspiro[4.5]decane) (C25H38N2O) 
1H NMR (400 MHz, CDCl3) δ ppm 7.56-7.62 (m, 1 H), 6.90-7.00 (m, 1 H), 6.71-6.81 (m, 2 H), 4.01 (t, J = 
7.09 Hz, 2 H), 3.92-3.96 (m, 3 H), 3.71 (s, 2 H), 2.61 (s, 4 H), 1.79-1.88 (s, 2 H), 1.76 (s, 4 H), 1.22-1.38 
(m, 12 H), 0.89 (t, J = 6.84 Hz, 3 H); ECI, m/z 415.4 [M+H]. 
 
 
F-23: (8-[(6-Methoxy-1-octyl-1H-indol-3-yl)methyl]-1,4-dioxa-8-azaspiro[4.5]decane) (C25H38N2O) 
Yellow oil; Yield: 75.6%; 1H NMR (400 MHz, CDCl3) δ ppm 7.51-7.55 (m, 1 H), 7.15 (s, 1 H), 6.77-6.82 
(m, 2 H), 4.02 (t, J = 7.22 Hz, 2 H), 3.93 (s, 4 H), 3.87-3.90 (m, 5 H), 2.79 (br. S., 4 H), 1.78-1.91 (m, 6 
H), 1.24-1.35 (m, 10 H), 1.24-1.35 (m, 10 H), 0.84-0.90 (m, 3 H); 13C NMR (101 MHz, CDCl3) δ ppm 
156.23, 136.83, 127.79, 122.88, 119.63, 109.08, 106.49, 93.31, 64.29, 55.74, 52.45, 50.66, 46.33, 
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33.96, 31.71, 29.93, 29.15, 29.11, 26.94, 22.55, 14.01; ECI, m/z 415.6 [M+H]. HRMS (EI+) calcd 




Yellow oil; Yield: 45.3%; 1H NMR (400 MHz, CDCl3) δ ppm 7.86-7.92 (m, 1 H), 6.90-7.07 (m, 2 H), 
6.75(s, 1 H), 4.09 (t, J = 7.09 Hz, 2 H), 3.91-3.99 (m, 3 H), 3.71 (s, 2 H), 2.61 (s, 4 H), 1.78-1.88 (s, 2 H), 
1.76 (s, 4 H), 1.24-1.38 (m, 12 H), 0.88 (t, J = 6.84 Hz, 3 H); ECI, m/z 415.4 [M+H]. 
 
 
F-25: 3-(Azepan-1-ylmethyl)-4-fluoro-1-octyl-1H-indole (C23H35FN2) 
Yellow oil; Yield: 58.2%; 1H NMR (400 MHz, CDCl3) δ ppm 7.04-7.13 (m, 3 H), 6.68-6.78 (m, 1 H), 4.07 
(t, J = 7.09 Hz, 2 H), 3.98 (s, 2 H), 2.73-2.82 (m, 4 H), 1.82 (t, J = 6.53 Hz, 2 H), 1.59-1.75 (m, 8 H), 1.23-
1.36 (m, 10 H), 0.88 (t, J = 6.59 Hz, 3 H); 13C NMR (101 MHz, CDCl3) δ ppm 158.46, 156.01, 138.93, 
127.98, 121.62, 121.54, 117.00, 116.80, 105.59, 104.35, 104.15, 55.11, 53.58, 46.66, 31.72, 30.08, 
29.13, 27.36, 26.99, 26.92, 22.58, 14.02; ECI, m/z 359.2 [M+H]. HRMS (EI+) calcd C23H35FN2 (M+) 
359.2857, found 359.2857. 
 
 
F-26: 3-(Azepan-1-ylmethyl)-5-fluoro-1-octyl-1H-indole (C23H35FN2) 
Yellow oil; Yield: 65.3%; 1H NMR (400 MHz, CDCl3) δ ppm 0.76-0.83 (m, 3 H), 1.15-1.25 (m, 10 H), 
1.51-1.56 (m, 4 H), 1.56-1.63 (m, 4 H), 1.73 (q, J = 7.12 Hz, 2 H), 2.57-2.66 (m, 4 H), 3.72 (s, 2 H) 3.97 
(t, J = 7.15 Hz, 2 H), 6.85 (td, J = 9.03, 2.51 Hz, 1 H), 7.06 (s, 1 H), 7.10-7.15 (m, 1 H), 7.28 (dd, J = 9.85, 
2.45 Hz, 1 H); 13C NMR (101 MHz, CDCl3) δ ppm 158.72, 156.39, 132.91, 129.01, 128.79, 128.70. 
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109.90, 109.77, 109.51, 104.59, 104.35, 55.30, 53.49, 46.54, 31.72, 30.17, 29.13, 27.72, 26.95, 22.58, 
14.01; 19F NMR (101 MHz, DMSO-d6) δ ppm -125.55; ECI, m/z 359.3 [M+H]. 
 
 
F-27: 3-(Azepan-1-ylmethyl)-6-fluoro-1-octyl-1H-indole (C23H35FN2) 
Yellow oil; Yield: 68.2%; 1H NMR (400 MHz, CDCl3) δ ppm 0.85-0.92 (m, 3 H), 1.21-1.35 (m, 10 H), 
1.62 (dd, J = 5.90, 3.14 Hz, 4 H), 1.68 (d, J=5.40 Hz, 4 H), 1.81 (q, J = 7.12 Hz, 2 H), 2.66-2.78 (m, 4 H), 
3.85 (s, 2 H), 4.01 (t, J = 7.15 Hz, 2 H), 6.86 (t, J = 9.13 Hz, 1 H), 6.97 (dd, J = 10.04, 2.13 Hz, 1 H), 7.10 
(s, 1 H), 7.63 (dd, J=8.66, 5.40 Hz, 1 H); 13C NMR (101 MHz, CDCl3) δ ppm 160.95, 158.60, 136.34, 
127.76, 124.97, 120.42, 120.32, 107.66, 107.41, 95.79, 95.53, 55.27, 53.47, 46.44, 31.72, 30.01, 




F-28: 3-(Azepan-1-ylmethyl)-7-fluoro-1-octyl-1H-indole (C23H35FN2) 
Yellow oil; Yield: 54.2%; 1H NMR (400 MHz, CDCl3) δ ppm 0.84 – 0.91 (m, 3 H) 1.21 – 1.35 (m, 10 H) 
1.58 – 1.66 (m, 4 H) 1.68 (d, J=5.40 Hz, 4 H) 1.77 – 1.88 (m, 2 H) 2.67 – 2.79 (m, 4 H) 3.85 (s, 2 H) 4.24 
(t, J=7.15 Hz, 2 H) 6.82 – 6.90 (m, 1 H) 6.98 (td, J=7.84, 4.52 Hz, 1 H) 7.09 (s, 1 H) 7.45 (d, J=7.91 Hz, 1 
H);13C NMR (101 MHz, CDCl3) δ ppm 102.42, 101.60, 96.05, 94.88, 91.38, 90.09, 87.29, 69.57, 68.91, 
67.40, 61.52, 61.45, 60.63, 60.12, 59.88, 59.80, 58.39, 55.46; 19F NMR (101 MHz, DMSO-d6) δ ppm -
135.72; ECI, m/z 359.2 [M+H]. 
 
 
F-29: 3-(Azepan-1-ylmethyl)-4-methoxy-1-octyl-1H-indole (C24H38N2O) 
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Yellow oil; Yield: 54.2%; 1H NMR (400 MHz, CDCl3) δ ppm 0.85-0.90 (m, 3 H), 1.19-1.33 (m, 12 H), 
1.71 (s, 4 H), 1.78-1.86 (m, 4 H), 1.88 – 2.14 (m, 4 H), 3.95 (s, 3 H), 4.09 (t, J = 7.34 Hz, 2 H), 4.60 (s, 2 
H), 6.56 (d, J = 7.78 Hz, 1 H), 6.99 (d, J = 8.28 Hz, 1 H), 7.12-7.18 (m, 1 H), 7.77 (s, 1 H); 13C NMR (101 
MHz, CDCl3) δ ppm 153.77, 137.47, 131.53, 122.66 177.80, 103.71, 102.15, 100.13, 55.07, 52.94, 
52.52, 46.95, 31.70, 30.09, 29.12, 27.15, 26.89, 23.36, 22.55, 14.00; ECI, m/z 370.7 [M+H]. 
 
 
F-30: 3-(Azepan-1-ylmethyl)-5-methoxy-1-octyl-1H-indole (C24H38N2O) 
Yellow oil; Yield: 49.2%; 1H NMR (400 MHz, CDCl3) δ ppm 0.80-0.89 (m, 3 H), 1.16-1.33 (m, 12 H), 
1.47-2.25 (m, 12 H), 3.87 (s, 3 H), 4.09 (t, J = 7.28 Hz, 2 H), 4.47 (s, 2 H), 6.90 (dd, J = 8.91, 2.38 Hz, 1 
H), 7.05 (d, J = 2.26 Hz, 1 H), 7.25 (d, J = 9.03 Hz, 1 H), 7.74 (s, 1 H); 13C NMR (101 MHz, CDCl3) δ ppm 
154.54, 132.36, 130.93, 128.52, 111.64, 110.64, 100.83, 99.85, 55.79, 53.40, 52.22, 46.57, 31.37, 




Yellow oil; Yield: 57.3%; 1H NMR (400 MHz, CDCl3) δ ppm 7.58 (d, J = 8.56 Hz, 1 H), 7.02 (s, 1 H), 6.76-
6.82 (m, 2 H), 4.02 (t, J = 7.15 Hz, 2 H), 3.87-3.90 (m, 3 H), 3.83-3.87 (m, 2 H), 2.71-2.78 (m, 4 H), 
1.77-1.88 (m, 2 H) 1.69 (br. S., 4 H), 1.58-1.65 (m, 4 H), 1.22-1.33 (m, 10 H), 0.85-0.92 (m, 3 H); 13C 
NMR (101 MHz, CDCl3) δ ppm 156.09, 136.87, 126.58, 123.00, 120.14, 108.58, 93.17, 55.75, 55.20, 
53.50, 46.21, 31.74, 29.98, 29.15, 27.53, 26.93, 22.59, 14.03; ECI, m/z 370.9 [M+H]. 
 
 
F-32: 3-(Azepan-1-ylmethyl)-7-methoxy-1-octyl-1H-indole (C24H38N2O) 
Yellow oil; Yield: 57.6%; 1H NMR (400 MHz, CDCl3) δ ppm 0.86-0.91 (m, 3 H) 1.24-1.32 (m, 10 H), 
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1.59-1.66 (m, 4 H), 1.70 (s, 4 H) 1.74-1.85 (m, 2 H), 2.72-2.78 (m, 4 H), 3.87 (s, 2 H), 3.93 (s, 3 H), 
4.30-4.37 (m, 2 H), 6.62 (d, J = 7.53 Hz, 1 H), 7.00 (t, J = 7.79 Hz, 1 H), 7.04 (s, 1 H) 7.27 (d, J = 8.03 Hz, 
1 H); 13C NMR (101 MHz, CDCl3) δ ppm 147.50, 130.90, 129.11, 125.74, 119.31, 112.10, 102.23, 
55.24, 53.34, 49.30, 32.15, 31.78, 29.23, 27.43, 26.93, 26.74, 22.62, 14.05; ECI, m/z 370.6 [M+H]. 
 
 
F-33: N-[(4-Fluoro-1-octyl-1H-indol-3-yl)methyl]93ricycle[3.3.1.13,7]decan-1-amine (C27H39FN2) 
Yellow oil; Yield: 64.3%; 1H NMR (400 MHz, CDCl3) δ ppm 7.13 (s, 1 H), 7.03-7.11 (m, 2 H), 6.74 (ddd, 
J = 11.11, 6.90, 1.57 Hz, 1 H), 4.05 (s, 2 H), 4.02 (t, J = 7.28 Hz, 2 H), 2.12 (br. S., 3 H), 1.75-1.88 (m, 8 
H), 1.62-1.74 (m, 6 H), 1.20-1.36 (m, 10 H), 0.84-0.92 (m, 3 H); 13C NMR (101 MHz, CDCl3) δ ppm 
158.20, 155.77, 139.35, 139.22, 127.09, 121.84, 121.76, 116.04, 115.84, 111.40, 105.68, 104.07, 




F-34: N-[(5-fluoro-1-octyl-1H-indol-3-yl)methyl]93ricycle[3.3.1.13,7]decan-1-amine (C27H39FN2) 
Yellow oil; Yield: 54.6%; 1H NMR (400 MHz, CDCl3) δ ppm 0.92-0.99 (m, 3 H), 1.31-1.44 (m, 10 H), 
1.70-1.83 (m, 6 H), 1.83-1.95 (m, 8 H), 2.20 (s, 3 H), 2.31 (s, 1 H), 4.00 (s, 2 H), 4.10 (t, J = 7.22 Hz, 2 
H), 7.01 (td, J = 9.10, 2.51 Hz, 1 H), 7.23-7.30 (m, 2 H), 7.33-7.39 (m, 1 H); 19F NMR (101 MHz, DMSO-
d6) δ ppm -126.75; ECI, m/z 411.2 [M+H]. 
 
 
F-35: N-[(6-fluoro-1-octyl-1H-indol-3-yl)methyl]93ricycle[3.3.1.13,7]decan-1-amine (C27H39FN2) 
Yellow oil; Yield: 68.9%; 1H NMR (400 MHz, CDCl3) δ ppm 0.85-0.90 (m, 3 H), 1.21-1.38 (m, 10 H), 
1.65-1.78 (m, 6 H), 1.82 (d, J = 2.51 Hz, 8 H), 2.15 (s, 3 H), 2.18 (d, J = 2.51 Hz, 1 H), 3.98 (s, 2 H), 4.21 
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(t, J = 7.28 Hz, 2 H), 6.86 (dd, J = 12.92, 7.65 Hz, 1 H), 6.98 (m, 1 H), 7.17 (s, 1 H), 7.38 (d, J = 7.97 Hz, 
1 H); 13C NMR (101 MHz, CDCl3) δ ppm 162.47, 160.99, 158.63, 136.44, 126.94, 123.93, 119.65, 
107.62, 107.38. 95.88, 95.62, 51.78, 46.39, 42.16, 36.63, 36.39, 35.47, 31.72, 31.38, 30.07, 29.58, 
29.16, 26.94, 22.55, 14.00; 19F NMR (101 MHz, DMSO-d6) δ ppm -126.67; ECI, m/z 411.3 [M+H]. 
 
 
F-36: N-[(7-fluoro-1-octyl-1H-indol-3-yl)methyl]94ricycle[3.3.1.13,7]decan-1-amine (C27H39FN2) 
Yellow oil; Yield: 68.4%; 1H NMR (400 MHz, CDCl3) δ ppm 0.85-0.91 (m, 3 H), 1.20-1.36 (m, 10 H), 
1.63-1.76 (m, 6 H), 1.81 (d, J = 2.51 Hz, 8 H), 2.13 (s, 3 H), 2.18 (d, J = 2.51 Hz, 1 H), 3.95 (s, 2 H), 4.20 
(t, J = 7.28 Hz, 2 H), 6.85 (dd, J = 12.92, 7.65 Hz, 1 H), 6.98 (td, J = 7.84, 4.52 Hz, 1 H), 7.09 (s, 1 H), 
7.38 (d, J = 7.91 Hz, 1 H); 13C NMR (101 MHz, CDCl3) δ ppm 151.36, 148.94, 131.63, 128.16, 124.21, 
124.12, 119.04, 114.56, 114.06, 107.18, 106.99, 51.45, 48.86, 42.36, 36.69, 35.55, 31.76, 31.60, 




F-37: N-[(4-methoxy-1-octyl-1H-indol-3-yl)methyl]94ricycle[3.3.1.13,7]decan-1-amine (C28H42N2O)  
Yellow oil; Yield: 64.8%; 1H NMR (400 MHz, CDCl3) δ ppm 0.84-0.91 (m, 3 H), 1.24-1.36 (m, 10 H), 
1.66-1.73 (m, 6 H), 1.81 (d, J = 7.03 Hz, 2 H), 1.83-1.88 (m, 6 H), 2.08 (s, 1 H), 2.13 (s, 3 H), 3.95 (s, 3 
H), 3.99 (t, J = 6.65 Hz, 2 H), 4.04 (s, 2 H), 6.50 (d, J = 7.65 Hz, 1 H), 6.91-6.95 (m, 1 H), 7.01 (s, 1 H), 
7.08-7.13 (m, 1 H); 13C NMR (101 MHz, CDCl3) δ ppm 153.92, 138.36, 125.93, 122.16, 117.27, 103.19, 








F-38: N-[(5-methoxy-1-octyl-1H-indol-3-yl)methyl]95ricycle[3.3.1.13,7]decan-1-amine (C28H42N2O)  
Yellow oil; Yield: 58.4%; 1H NMR (400 MHz, CDCl3) δ ppm 0.84-0.89 (m, 3 H), 1.23 (s, 10 H), 1.57-1.67 
(m, 6 H), 1.70-1.79 (m, 2 H), 1.99 (s, 6 H), 2.05 (s, 3 H), 3.90-3.96 (m, 5 H), 4.00 (s, 2 H), 6.81 (dd, J = 
8.91, 2.26 Hz, 1 H), 7.07 (d, J = 8.91 Hz, 1 H), 7.19 (d, J = 2.26 Hz, 1 H), 7.42 (s, 1 H); 13C NMR (101 
MHz, CDCl3) δ ppm 154.17, 131.08, 130.54, 127.57, 112.07, 110.29, 100.83, 56.11, 46.55, 39.07, 
35.69, 35.20, 31.74, 30.22, 29.16, 26.90, 22.58, 14.01; ECI, m/z 422.6 [M+H]. 
 
 
F-39: N-[(6-methoxy-1-octyl-1H-indol-3-yl)methyl]95ricycle[3.3.1.13,7]decan-1-amine (C28H42N2O)  
Yellow oil; Yield: 57.3%; 1H NMR (400 MHz, CDCl3) δ ppm 0.86-0.90 (m, 3 H), 1.25-1.33 (m, 12 H), 
1.63-1.74 (m, 6 H), 1.83 (d, J = 2.51 Hz, 6 H), 2.12 (s, 4 H), 3.87 (s, 3 H), 3.94-4.00 (m, 4 H), 6.74-6.81 
(m, 2 H), 7.05 (s, 1 H), 7.50 (d, J = 8.53 Hz, 1 H); 13C NMR (101 MHz, CDCl3) δ ppm 156.24, 137.07, 
125.69, 121.88, 119.36, 108.62, 93.38, 55.79, 46.21, 42.12, 36.65, 35.60, 31.78, 30.08, 29.60, 29.23, 
29.15, 27.02, 22.60, 14.04; ECI, m/z 422.6 [M+H]. 
 
 
F-40: N-[(7-methoxy-1-octyl-1H-indol-3-yl)methyl]95ricycle[3.3.1.13,7]decan-1-amine (C28H42N2O)  
Yellow oil; Yield: 57.9%; 1H NMR (400 MHz, CDCl3) δ ppm 0.87-0.91 (m, 3 H), 1.25-1.34 (m, 10 H), 
1.62-1.72 (m, 6 H), 1.73-1.80 (m, 2 H), 1.82 (d, J = 2.64 Hz, 6 H), 2.07 (s, 1 H), 2.12 (s, 3 H), 3.92 (s, 3 
H), 3.93-3.97 (m, 2 H), 4.27-4.33 (m, 2 H), 6.59-6.65 (m, 1 H), 6.97-7.03 (m, 1 H), 7.03-7.07 (m, 1 H), 
7.19-7.23 (m, 1 H); 13C NMR (101 MHz, CDCl3) δ ppm 147.64, 129.76, 127.91, 125.98, 119.33, 111.45, 
102.41, 55.28, 51.65, 49.24, 42.30, 36.74, 35.64, 32.23, 31.86, 29.66, 29.29, 26.80, 22.66, 14.10; ECI, 





G-1: 3-(Azepan-1-ylmethyl)-4-fluoro-1H-indole (C15H17FN2) 
Yellow oil; Yield: 83.2%; 1H NMR (400 MHz, CDCl3) δ ppm 10.93 (br. S., 1 H), 7.97 (d, J = 2.64 Hz, 1 H), 
7.34 (d, J = 8.28 Hz, 1 H), 7.00 (td, J = 8.03, 5.14 Hz, 1 H), 6.70 (dd, J = 11.67, 7.78 Hz, 1 H), 4.50 (s, 2 
H), 2.96 (d, J = 14.81 Hz, 2 H), 2.64 (br. S., 2 H), 1.73-2.11 (m, 4 H), 1.46-1.72 (m, 5 H); 13C NMR (101 
MHz, CDCl3) δ ppm 157.27, 154.86, 138.68, 130.33, 122.35, 116.20, 109.20, 105.18, 100.42, 53.62, 
53.08, 26.67, 23.18; ECI, m/z  247.2[M+H]. 
 
 
G-2: 3-(Azepan-1-ylmethyl)-1-ethyl-4-fluoro-1H-indole (C17H23FN2) 
Yellow oil; Yield: 48.3%; 1H NMR (400 MHz, CDCl3) δ ppm 7.19 (s, 1 H), 7.06-7.11 (m, 2 H), 6.70-6.78 
(m, 1 H), 4.14 (q, J = 7.28 Hz, 2 H), 4.02 (s, 2 H), 2.79-2.84 (m, 4 H), 1.71 (d, J = 5.02 Hz, 4 H), 1.61-
1.66 (m, 4 H), 1.46 (t, J=7.28 Hz, 3 H); 13C NMR (101 MHz, CDCl3) δ ppm 158.46, 156.01, 138.70, 
127.14, 121.66, 117.03, 110.00, 105.40, 104.19, 55.14, 53.60, 41.21, 27.34, 26.99, 15.26. 19F NMR 
(101 MHz, DMSO-d6) δ ppm -121.98; ECI, m/z 275.2[M+H]. 
 
 
G-3: 3-(azepan-1-ylmethyl)-1-butyl-4-fluoro-1H-indole (C19H27FN2) 
Yellow oil; Yield: 64.5%; 1H NMR (400 MHz, CDCl3) δ ppm 7.15 (s, 1 H), 7.08 (br. S., 2 H), 6.70-6.77 
(m, 1 H), 4.08 (t, J = 7.09 Hz, 2 H), 4.01 (s, 2 H), 2.79 (d, J = 5.02 Hz, 4 H), 1.81 (q, J = 7.28 Hz, 2 H), 
1.71 (br. S., 4 H), 1.63 (br. S., 4 H), 1.30-1.40 (m, 2 H), 0.95 (t, J = 7.34 Hz, 3 H); 13C NMR (101 MHz, 
CDCl3) δ ppm 158.45, 156.00, 138.96, 127.77, 121.56, 116.75, 110.00, 105.48, 104.27, 55.11, 53.57, 
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G-4: 3-(azepan-1-ylmethyl)-1-decyl-4-fluoro-1H-indole (C25H39FN2) 
Yellow oil; Yield: 58.3%; 1H NMR (400 MHz, CDCl3) δ ppm 7.10-7.16 (m, 1 H), 7.07 (br. S., 2 H), 6.73 
(dd, J = 10.54, 4.02 Hz, 1 H), 4.06 (t, J = 7.09 Hz, 2 H), 4.01 (s, 2 H), 2.79 (d, J = 5.02 Hz, 4 H), 1.75-1.88 
(m, 2 H), 1.70 (br. S., 4 H), 1.63 (br. S., 4 H), 1.23-1.34 (m, 14 H), 0.89 (t, J = 6.53 Hz, 3 H); 13C NMR 
(101 MHz, CDCl3) δ ppm 158.45, 156.00, 138.81, 127.73, 121.46, 116.75, 110.00, 105.47, 104.05, 
55.11, 53.60, 46.56, 31.77, 30.01, 29.41, 29.12, 27.48, 26.95, 26.86, 22.57, 14.00; 19F NMR (101 MHz, 















































































































































































































Figure S1. Solubility ranges of 114, F-25 and F-9 using turbimetric method (2nd and 3rd times) 
 
 













4. Melting endotherms of DSPG vesicles in the 




 Figure S3. 
Melting endotherms of DMPG vesicles in the presence of series F compounds. Compound to Lipid 







5. Purity of target compounds 
Purity was determined on a reverse-phase HPLC on a Shimadzu Nexera SR HPLC system (Shimadzu 
Scientific Instruments, Columbia, MD, USA) with a Zorbax Eclipse SB-C18 column (Agilent Tech. Inc., 
Loveland, CO) at two wavelengths: 230 nm and 254 nm. Two isocratic solvent systems were 
employed: 95% acetonitrile-5% water and 95% methanol-5% water. Flow rate was adjusted to 0.7 
Ml/min and run time was fixed at 15 min. 
Table S1:  Determination of purity (%P) of target compounds by reverse phase HPLC. Retention 
times (RT) are indicated in min.  
 
Cpd 
ACN:H2O = 95: 5 MeOH : H2O= 95: 5 
254Nm 230Nm 254Nm 230nM 
P (%) R.T(min) P (%) R.T(min) P (%) R.T(min) P (%) R.T(min) 
A-1 98.00 8.56 98.90 8.56 95.20 16.26 95.06 7.26 
A-2 99.00 3.03 98.05 3.02 97.92 2.99 96.58 2.99 
B-1 98.42 5.88 97.12 5.88 95.12 5.92 95.67 5.93 
B-4 98.24 6.12 97.46 6.13 98.34 6.13 97.26 6.13 
B-5 99.03 7.85 98.43 7.84 99.31 7.22 98.36 7.22 
B-6 98.65 5.93 98.79 5.91 99.03 6.20 99.54 6.10 
B-7 97.21 6.25 95.03 6.29 96.41 6.30 97.54 6.27 
C-6 96.85 76.11 96.00 6.11 99.55 4.07 95.77 4.07 
C-7 95.92 7.08 96.48 7.10 99.79 6.62 98.74 6.57 
C-8 99.51 7.50 97.59 7.53 99.85 7.25 100.00 7.22 
C-9 96.51 6.66 98.72 6.66 100.00 6.71 100.00 6.71 
C-10 96.87 5.68 90.03 5.67 94.31 5.74 96.84 5.75 
C-11 98.34 6.47 100.00 6.47 100.00 6.68 97.56 6.76 
C-12 100.00 6.76 98.49 6.76 100.00 6.49 100.00 6.58 
C-13 95.52 5.68 96.89 5.67 98.48 5.74 97.46 5.75 
C-14 98.68 7.89 96.41 7.89 97.94 6.82 97.51 6.82 
C-15 100.00 5.44 97.90 5.47 95.20 5.64 95.06 5.63 
C-16 99.54 6.49 97.31 6.48 100.00 6.40 100.00 6.40 
C-17 99.83 7.03 98.57 7.00 95.12 6.98 94.09 6.86 
C-19 96.49 6.90 96.79 6.93 100.00 6.68 98.46 6.71 
C-20 100.00 13.09 96.88 13.10 96.66 12.97 96.76 12.97 
D-3 100.00 6.85 97.05 6.85 99.92 6.57 96.48 6.657 
D-4 99.33 10.14 98.31 10.14 98.74 11.26 97.56 11.26 
D-5 98.68 6.84 96.41 6.84 97.94 6.82 97.51 6.82 
D-6 99.57 6.96 98.49 6.79 99.47 6.34 99.89 6.38 
D-7 96.54 6.46 99.40 6.46 97.56 6.50 98.62 6.50 
E-1 98.68 6.84 96.41 6.84 97.94 6.82 97.51 6.82 
E-3 99.90 6.20 99.71 6.20 99.51 6.12 99.20 6.12 
E-4 96.53 7.89 97.89 7.81 95.43 7.68 98.64 7.73 
E-5 98.56 11.98 100.00 11.82 100.00 11.12 100.00 11.20 
E-6 97.53 10.32 99.34 10.29 98.27 10.21 98.39 10.17 
E-8 96.63 12.10 98.12 12.10 99.54 8.47 95.99 8.47 
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E-9 97.48 11.98 98.76 12.14 96.52 10.79 98.34 10.88 
F-1 98.68 6.84 96.41 6.84 97.94 6.82 97.51 6.82 
F-3 98.99 7.11 97.26 7.11 99.86 6.63 95.49 6.47 
F-4 98.87 7.47 96.60 7.47 98.09 8.38 97.33 8.39 
F-5 99.58 7.29 98.95 7.29 99.89 6.84 99.69 6.84 
F-6 95.51 7.06 98.73 7.04 99.15 6.87 99.02 6.87 
F-7 95.97 6.93 97.62 6.93 100.00 6.71 99.65 6.71 
F-7 98.84 7.32 99.56 7.32 97.51 7.07 98.56 7.07 
F-10 97.42 7.27 99.03 7.27 97.18 7.89 98.49 7.89 
F-11 98.54 7.33 97.58 7.33 95.04 7.00 98.46 7.00 
F-12 96.48 7.87 97.68 7.87 100.00 7.51 97.03 7.51 
F-13 99.18 7.54 95.29 7.55 99.52 6.93 98.94 6.94 
F-14 99.17 7.25 98.61 7.25 100.00 7.02 99.94 7.02 
F-16 100.00 7.72 97.34 7.71 99.23 7.17 98.41 7.17 
F-18 94.98 6.13 98.21 76.13 97.23 5.96 95.01 5.96 
F-19 96.41 5.98 96.87 5.98 98.54 7.58 97.51 7.58 
F-20 96.34 7.18 97.89 7.15 99.98 8.93 97.41 8.79 
F-21 99.75 7.19 99.94 7.20 98.03 6.96 95.78 6.69 
F-22 98.84 6.89 98.80 6.89 100.00 7.31 98.24 7.31 
F-24 98.01 6.44 97.05 6.45 100.00 6.24 95.34 6.25 
F-26 96.32 7.38 94.99 7.38 97.09 7.24 98.34 7.24 
F-27 97.31 7.35 96.12 7.35 100.00 6.94 95.64 6.94 
F-28 97.56 7.70 98.57 7.69 96.32 7.35 97.58 7.35 
F-29 97.46 7.67 98.68 7.67 95.32 7.08 98.06 7.13 
F-30 97.11 7.68 98.13 7.67 97.25 7.01 98.33 7.01 
F-31 96.34 7.65 98.35 7.64 96.42 7.03 96.39 7.03 
F-35 96.78 8.11 98.34 8.11 97.84 8.12 97.88 8.12 
F-36 98.54 8.50 96.35 8.50 98.57 7.59 97.51 7.59 
F-37 96.49 6.25 98.79 6.25 97.54 5.86 98.46 5.86 
F-38 100.00 8.25 100.00 8.25 100.00 5.83 100.00 5.83 
F-39 96.43 6.76 98.21 6.75 97.26 6.68 98.12 6.60 
F-40 100.00 8.87 95.52 8.87 99.03 6.57 100.00 6.49 
G-1 98.98 5.89 97.86 5.87 96.54 5.88 95.00 5.88 
G-2 96.59 6.02 97.85 6.02 99.02 6.07 95.03 6.08 
G-3 96.31 6.20 95.78 6.21 98.89 6.24 99.05 6.31 




















6. HRMS of six promising hits  
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